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ABSTRACT 
This work details the development of bioanalytical tools for use in rapid diagnostics (Chapters 2-4) 
and in the study of physiology (Chapters 5-6). This research harness the power of real-time, single-
molecule microfluidics to study loop-mediated isothermal amplification in urinary tract infections 
(Chapter 2), chlamydia (Chapter 3), and gonorrhea (Chapter 4). In Chapter 5, non-reactive beads are 
designed and optimized to study the impact of polymers on murine gastrointestinal mucosa. Chapter 
6 details the implementation of a mass spectrometry method to quantify bile acids and investigate 
their interaction with the microbiota in the murine gastro-intestinal tract.    
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C h a p t e r  1  
AN OVERVIEW 
How much?  
It’s quite obvious to us when we feel ill. Maybe it’s sniffling or a cough. Swelling. An itch. A 
headache. But how much are you not well?  
Society has a broad need for diagnostics that define and quantify illness. Medicine currently attempts 
to quantify people relative to the “standard person”—a theoretical person with no interesting features 
whatsoever other than being completely normal in every way. This standard person is established 
from averages of the general population and defines a “reference range” of wellness. Of course this 
person does not exist, and as real humans (not “standard” humans) we have the unfortunate situation 
of being unique.  
That uniqueness starts all the way down at your DNA. Even identical twins sharing identical DNA 
have unique fingerprints. An old man has roughly the same genome as on the day he was born, yet 
he appears very different from his youthful self. Fluctuations in physiology are expected as phenotype 
arises through myriad gene and protein expression networks. In the end, knowing your blueprint 
(genotype) doesn’t tell us what state of health you’ll be in at a given time. Your uniqueness is shaped 
by environmental factors, epigenetics (what your ancestors did), and hysteresis (what you’ve done 
until now).  
The answer to the question “how much” is determined by how and what is measured, and even what 
we measure against. Consider the vast variation in concentrations of cortisol and the thyroid hormones 
as they pass through a diurnal cycle. (When you measure matters!) Or how a sudden arrhythmia in a 
professional athlete takes heartrate from 40 bpm to an ‘abnormally normal’ 90 bpm, matching that of 
the general population. Despite having a ‘low’ heartrate, that athlete is unhealthy when their 
measurement agrees with the population average. (Your personal variation matters!) The levels of 
our individual hormones vary greatly—some measurements vary within a day, others by the day of 
the month (e.g., female reproductive hormones), others by the time of the year, and others change 
from year to year. Your individual levels may vary dramatically between you and your friends. Given 
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these wide fluctuations, it’s worth questioning whether we should use the reference of a single 
“standard” person at all.   
My research at Caltech has focused on improving the process of analyzing biology with chemical 
tools and the understanding of “how much” with regard to diseases that impact human biology and 
physiology.  
This thesis details the development of bioanalytical tools for use in rapid diagnostics (Chapters 2-4).  
In my research, I found great use in “digital” microfluidics: a process in which individual molecules 
can be placed in a small compartment, a reaction run, and the total number of molecules counted by 
the presence or absence of the reaction product in each compartment. The field calls this “digital” 
because of the binary (presence or absence) of a molecule within the compartment. By running several 
thousand compartments in parallel, we can begin to quantify “how much.” 
These studies also employ a DNA amplification technique that can be run at a single temperature, 
thus simplifying amplification from the standard process which requires multiple heating and cooling 
steps. This technique is known as Loop-mediated Amplification (LAMP).  
Chapter 2 discusses a process to make the best aspects of digital microfluidics, namely the ability to 
monitor thousands of single template reactions in parallel with real-time kinetics (measuring “how 
fast”!) available to anyone with relatively standard laboratory equipment. We demonstrate how the 
technique can be used to study the impact different conditions have on a LAMP reaction. Finally, we 
apply the system to an Antibiotic Susceptibility Test (AST) of E. coli from clinical Urinary Tract 
Infections to ask: Which antibiotics will be effective?   
Chapter 3 extends the digital LAMP method to incorporate melting temperature—a means to 
discriminate between true and false amplification based on the underlying DNA product. This 
additional refinement allows us to know if we are counting the right thing. We use digital LAMP with 
melting temperature to study the impact of enzyme selection on true and false amplifications, and the 
implications those choice have on determining the fewest number of molecules that can be counted. 
We call this version of “how much” the Limit of Detection (LOD). Additionally, we study the impact 
that a patient’s DNA (likely to be present in urine samples and clinical swabs) may have on the 
detection of the sexually transmitted bacterial infection chlamydia.  
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Chapter 4 applies the digital LAMP method to quantify the response of gonorrhea to a common 
class of antibiotics known as β-lactams, and it demonstrates a sum-of-steps for the assay in 30 
minutes—demonstrating the potential for using these methods to develop a diagnostic that can be 
used directly at the point of care.   
This thesis also details the development of tools to for the study of physiology (Chapters 5-6), in 
particular within the murine gastrointestinal tract.  
In Chapter 5, I designed and optimized non-reactive beads to study the impact of polymers on murine 
gastrointestinal mucosa. These beads could be loaded onto murine intestinal mucosa, and the 
thickness of the mucosa quantified in response to the introduction of different sized polymers, some 
which occur naturally in the diet. The challenge in developing these beads was that they needed to be 
chemically inert so that only the physics of the system could be monitored. I developed a process to 
covalently attach non-reactive PEG polymers to the surface of small polystyrene beads and quantify 
the amount of non-reactive polymer attached. Because the polymers were non-reactive, I could not 
run additional reactions to quantify the extent of the polymer attached to the surface and instead 
selected Nuclear Magnetic Resonance (NMR) to quantify the extent of polymer attached to the 
surface. Those familiar with NMR will note that magnetic susceptibility changes in the presence of a 
solid surface like a bead, and can find a solution to this problem in the Materials and Methods section 
on page 159. In general, we found that a combination of introducing a linear, high-molecular-weight 
polymer, “backfilled” by a second low-molecular-weight polymer resulted in the least surface charge 
(a measurement of possible bead reactivity). These beads have great utility for many additional 
applications; at the time of the publication of this thesis, the beads have been used in two additional 
studies that are not detailed in this thesis.  
Chapter 6 details the implementation of a mass spectrometry method to quantify bile acids and 
investigate their interaction with the microbiota in the murine gastrointestinal tract. Bacteria within 
the gastrointestinal tract are known to chemically modify the natural soaps (bile acids) that our body 
produces to help digest and absorb food. In the process, the chemical transformation of some of these 
molecules turns bile acids into signaling molecules, which may impact host physiology. I developed 
a method using chromatography (a technique to separate molecules by their propensity to partition 
into oil-like and water-like materials) coupled with their mass to simultaneously quantify how much 
of these 35 different bile acids exist within a given section of the gastrointestinal tract.  
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In the long term, my hope is that the studies detailed in this thesis, and other studies like them, will 
enable an improved understanding of human health. Scientifically, we still must understand the 
variation in genotype and phenotype at the single-cell level and between tissues, and then scale up to 
see variation among individuals at the organism level. My hope is that longitudinal studies of human 
health will allow us to begin to define health, instead of malady, and usher in a new era of personalized 
medicine—medicine that accounts for your uniqueness, and not for the standard person. Finally, as 
devices and the hardware to operate them continue to miniaturize, my hope is that we can improve 
access to healthcare for all people, regardless of their healthcare system. To me, this is providing 
access to quality diagnostics, regardless of the location. It’s access for a mother at her daughter’s 
gymnastics event, for military personal in the theater of war, for communities in rural Nepal where 
resources may be limited, to a patient at the doctor’s office with an urgent medical question. You will 
find these concepts echoed throughout the following chapters when I talk about diagnostics for 
Limited Resources Settings (LRS) and at the Point of Care (POC).  
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C h a p t e r  2  
REAL-TIME, DIGITAL LAMP WITH COMMERCIAL MICROFLUIDIC 
CHIPS REVEALS THE INTERPLAY OF EFFICIENCY, SPEED, AND 
BACKGROUND AMPLIFICATION AS A FUNCTION OF REACTION 
TEMPERATURE AND TIME 
Justin C. Rolando, Erik Jue, Nathan G. Schoepp, and Rustem F. Ismagilov. Analytical 
Chemistry. 2018. 91(1):1034–1042. DOI: 10.1021/acs.analchem.8b04324 
 
ABSTRACT 
Real-time, isothermal, digital nucleic acid amplification is emerging as an attractive 
approach for a multitude of applications including diagnostics, mechanistic studies, and 
assay optimization. Unfortunately, there is no commercially available and affordable real-
time, digital instrument validated for isothermal amplification; thus, most researchers have 
not been able to apply digital, real-time approaches to isothermal amplification. Here, we 
generate an approach to real-time digital loop-mediated isothermal amplification (LAMP) 
using commercially available microfluidic chips and reagents, and open-source 
components. We demonstrate this approach by testing variables that influence LAMP 
reaction speed and the probability of detection. By analyzing the interplay of amplification 
efficiency, background, and speed of amplification, this real-time digital method enabled 
us to test enzymatic performance over a range of temperatures, generating high-precision 
kinetic and endpoint measurements. We were able to identify the unique optimal 
temperature for two polymerase enzymes, while accounting for amplification efficiency, 
non-specific background, and time to threshold. We validated this digital LAMP assay and 
pipeline by performing a phenotypic antibiotic susceptibility test on 17 archived clinical 
urine samples from patients diagnosed with urinary tract infections. We provide all the 
necessary workflows to perform digital LAMP using standard laboratory equipment and 
commercially available materials. This real-time digital approach will be useful to others 
in the future to understand the fundamentals of isothermal chemistries—including which 
components determine amplification fate, reaction speed, and enzymatic performance. 
Researchers can also adapt this pipeline, which uses only standard equipment and 
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commercial components, to quickly study and optimize assays using precise, real-time 
digital quantification—accelerating development of critically needed diagnostics. 
INTRODUCTION 
In this paper, we describe a methodology to use commercially available chips, reagents, 
and microscopes to perform real-time digital LAMP. We use this methodology to perform a 
mechanistic study of digital isothermal amplification; and apply the lessons learned to 
perform a phenotypic antibiotic susceptibility test (AST). 
Microfluidics-based diagnostics for infectious diseases are advancing as a result of using 
nucleic acid testing—making them amenable to the point of care (POC) and limited-resource 
settings where they will have clinical impact. Isothermal amplification methods in particular 
show promise for simplifying nucleic-acid-based POC diagnostics by circumventing the 
stringent thermal cycling requirements of PCR.1 One isothermal method that is being actively 
pursued in bioanalytical chemistry and the field of diagnostics is loop-mediated isothermal 
amplification (LAMP).2-6 
LAMP and other isothermal technologies are fast and sensitive, but when performed in a 
bulk format in microliter volumes (e.g. in a tube) they provide only semi-quantitative (log-
scale) resolution or presence/absence measurements.7-15 As a result, when optimizing an 
assay, it is difficult to quantify how small changes in assay conditions (e.g. in primers, 
reagents, or temperature) impact the reaction’s speed and analytical sensitivity. To reliably 
understand these effects with high precision would require hundreds of bulk experiments per 
condition.16 For the field to be able to take full advantage of the capabilities of LAMP, 
researchers need to be able to optimize reaction conditions by understanding and testing the 
variables that may influence reaction speed and probability of detection. Furthermore, the 
semi-quantitative measurements yielded by bulk isothermal methods are insufficient for 
analyses requiring precise quantification, such as phenotypic antibiotic susceptibility 
testing.17,18 
These problems can be solved using “digital” approaches, which partition single target 
molecules in large numbers of compartments and give a binary (presence/absence) readout 
for each compartment. These “digital” approaches thus allow determination of the efficiency 
of the amplification reaction19 and provide absolute quantification with high resolution. 
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Digital isothermal measurements have been used to quantify viral load for HCV,16,20,21 
HIV,19,20 and influenza,22 perform bacterial enumeration,23-25 optimize primers,16 and test for 
phenotypic antibiotic susceptibility18 using LAMP18-28 and RPA.29 
Real-time digital formats are especially valuable for examining the variables that most 
affect non-specific amplification and the speed of amplification. Many excellent approaches 
for end-point19,20,22-28 and real-time16,18,21 digital LAMP (dLAMP) have been published. 
Despite the value that real-time dLAMP can bring to diagnostics, this method is difficult to 
implement—especially for those without a background in micro-electro-mechanical systems 
or microfluidics—because there is no commercial system for real-time, digital isothermal 
amplification. To achieve statistical significance, a meaningful study might require dozens 
of experiments; such studies are difficult to perform without a commercial source of chips. 
Consequently, the few LAMP mechanistic studies that have been performed were not done 
with high precision. Further, those who would most benefit from optimized digital isothermal 
reactions (e.g. those working on POC diagnostics) cannot efficiently improve them. 
Here, we demonstrate how to generate high-precision kinetic and endpoint measurements 
using a real-time dLAMP assay that is performed completely with commercially available 
and open-source components (Figure 2.2.1). We use this real-time information to investigate 
dLAMP reactions mechanistically, including the interplay of efficiency, speed, and 
background amplification as a function of reaction temperature and time on two enzymes. 
To illustrate one application of using real-time dLAMP to improve a clinically relevant assay, 
we optimized the assay conditions for a phenotypic AST using the real-time dLAMP pipeline 
and used the optimized protocol to compare our AST of 17 clinical urine samples to the gold-
standard method. 
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Figure 2.1. A schematic of the pipeline for performing multiplexed, real-
time, digital loop-mediated isothermal amplification (LAMP) using only 
commercially available and/or open source components. Microfluidic chips 
and reagents (e.g. primers, enzymes, buffer composition) can be purchased 
commercially. Multiple instrument configurations can be used to capture 
results. e.g. a customized real-time instrument (instructions for building 
publicly available30) or any commercial microscope. Data analysis is 
automated using a MATLAB script (Supporting Information, S-I).  
 
 
EXPERIMENTAL SECTION 
Microfluidic chips used in this paper were sourced from Applied Biosystems, Foster City, 
CA, USA) Ref A26316, "QuantStudio 3D Digital PCR 20k Chip Kit V2." 
LAMP reagents 
Our amplification target was the E. coli 23S ribosomal gene, which we used previously as 
a target to perform rapid AST on clinical samples.18 Primers were purchased through 
Integrated DNA Technologies (San Diego, CA, USA) and were described previously.18 Final 
primer concentrations were identical for all experiments: 1.6 µM FIP/BIP, 0.2 µM 
FOP/BOP, and 0.4 µM LoopF/LoopB. 
LAMP experiments using Bst 3.0 (Figure 2.2.2; Figure 2.2.3b d, e, f, h-j; Figure 2.2.4) 
contained the following final concentrations, optimized previously18: 1x Isothermal 
Amplification Buffer II (New England BioLabs (NEB), Ipswich, MA, USA; Ref. B0374S; 
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containing 20 mM Tris-HCl 10 mM (NH4)2SO4 150 mM KCl, 2 mM MgSO4, 0.1% Tween 
20 pH 8.8 at 25 °C), 4 mM additional MgSO4 (beyond 2 mM from buffer), 1.4 mM 
Deoxynucleotide Solution Mix, primers: 1.6 µM FIP/BIP, 0.2 µM FOP/BOP, and 0.4 µM 
LoopF/LoopB, 1 mg/mL BSA (New England BioLabs, Ref B90005), 320 U/mL Bst 3.0, 
Ambion RNAse cocktail (ThermoFisher, Waltham, MA, USA; Ref AM2286, 5 U/mL RNase 
A, 400 U/mL TNase T1), 2 µM SYTO 9 (ThermoFisher, Reference S34854), and 
approximately 660 copies/µL template in Ambion nuclease-free water (ThermoFisher, Ref 
AM9932). 
LAMP experiments using Bst 2.0 (Figure 2.2.3a, c, e, g) contained the following final 
concentrations, optimized as shown in Figure 2.2.S3: 1x Isothermal Amplification Buffer 
(New England BioLabs, Ref. B0537S; containing 20 mM Tris-HCl 10 mM (NH4)2SO4, 50 
mM KCl 2 mM MgSO4 0.1% Tween 20 pH 8.8 at 25 °C), additional 6 mM MgSO4 (New 
England BioLabs, Ref. B1003S), 1.4 mM Deoxynucleotide Solution Mix (New England 
BioLabs, Ref N0447S), primers: 1.6 µM FIP/BIP, 0.2 µM FOP/BOP, and 0.4 µM 
LoopF/LoopB, 1 mg/mL BSA (New England BioLabs, Ref B90005), 320 U/mL Bst 2.0 
(New England BioLabs, Ref M0537S), Ambion RNAse cocktail (ThermoFisher, Ref 
AM2286, 5 U/mL RNase A, 400 U/mL TNase T1), 2 µM SYTO 9 (ThermoFisher, Ref 
S34854), and approximately 660 copies/µL template in Ambion nuclease-free water 
(ThermoFisher, Ref AM9932). 
Template E. coli DNA was extracted from exponential-phase cultures grown in BBL 
Brain-Heart Infusion media (BD, Franklin Lakes, NJ, USA; Ref. 221813) using 
QuickExtract DNA Extraction Solution (Lucigen, Middleton, WI, USA; Ref. QE09050) as 
described previously.18 Serial 10-fold dilutions were prepared in Tris-EDTA buffer (5 mM 
Tris-HCl, 0.5 mM EDTA, pH 8.0) containing 2 U/mL RNase A and 80 U/mL RNase T1 
(ThermoFisher, Ref AM2286). DNA dilutions were quantified as described previously18 
using the QX200 Droplet Digital PCR (ddPCR) system (Bio-Rad Laboratories, Hercules, 
CA, USA). 
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Phenotypic antibiotic susceptibility testing (AST) 
on clinical samples 
For the phenotypic AST, we adopted a workflow described previously,17,18 and used 
archived nucleic-acid extractions from a previous study.18 Briefly, clinical urine samples 
from patients with urinary tract infections (UTI) were split and diluted into equal volumes of 
media with or without the presence of an antibiotic. Samples were incubated for 15 min at 
37 °C, a nucleic-acid extraction was performed, and these samples were archived at -80 °C 
until use. LAMP was performed on the archived samples to quantify the number of copies 
of the E. coli 23S ribosomal gene. 
We tested our optimized assay on 17 archived clinical UTI samples containing ≥5 × 104 
CFU/ml E. coli that had been categorized previously using the gold-standard broth 
microdilution AST (5 ciprofloxacin-susceptible, 5 ciprofloxacin-resistant, 4 nitrofurantoin-
susceptible, and 3 nitrofurantoin-resistant). 
We assessed samples as phenotypically “resistant” or “susceptible” by calculating the ratio 
of the concentration of 23S in the control and antibiotic-treated sample, which we call the 
control:treated (C:T) ratio. The C:T ratio was calculated 10 min after beginning to heat the 
LAMP reaction. A threshold of 1.1 was established previously,17,18 so samples with C:T 
ratios >1.1 indicated that there was DNA replication in the untreated (control) group but not 
in the antibiotic-treated samples; these samples were identified as susceptible to the 
antibiotic. Samples with C:T ratios of <1.1 indicated that DNA replication occurred in both 
the control and antibiotic-treated samples; these samples were identified as resistant to the 
antibiotic. 
 
RESULTS AND DISCUSSION 
Workflow summary of real-time digital LAMP 
To evaluate a pipeline for real-time dLAMP experiments, we chose commercially sourced 
microfluidic chips sold for endpoint digital PCR applications. The chips consist of an array 
of 20,000 uniform partitions (Figure 2.2.1), each 60 µm in diameter and an estimated 0.75 
nL internal volume, which is similar to the volumes typically used in dLAMP.16,18,20-23,25,26,28 
These chips are loaded by pipetting the sample mixture (in our case containing the LAMP 
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reagents: buffer components, enzymes, template, and primers) into the plastic “blade” 
provided with the chips, and dragging the blade at a 70–80° angle to the chip to load the 
sample mixture by capillarity. This is followed by drying and evaporation of the surface layer 
for 20 sec at 40 °C, and application of the immersion fluid. Manual loading requires some 
skill, though a machine can be purchased to perform the task; typically, we were able to load 
~18,000 out of the 20,000 partitions. We performed our evaluation using two different 
enzyme mixtures, Bst 2.0 and Bst 3.0 . Our amplification target (Figure 2.2.1) was the E. 
coli 23S ribosomal gene that we previously used as a target to perform rapid AST on clinical 
samples.18 
The instrumentation requirements for real-time isothermal capabilities include a heater that 
can hold a stable temperature, and optical components with high spatial resolution that are 
capable of imaging the fluorescence intensity of the 20,000 individual partitions of the chip 
over time (Figure 2.2.2a). Here, we investigated two approaches: using a standard laboratory 
microscope (Leicia DMI-6000B), and using the RTAI,30 which is composed of a 
thermocycler, optical components, a camera, and a light source. 
We generated a custom MATLAB script to analyze the digital real-time data (details in 
Supporting Information, S-I). The software follows the change in fluorescence in 
individual partitions over time. From these data, we extract each partition’s time to a 
fluorescence intensity threshold and calculate the bulk template concentration. In our 
demonstration, we loaded the acquired images into FIJI31 as a time-stack series and manually 
separated the images of the individual chips to be analyzed separately. To process each chip’s 
image stack, we used the custom MATLAB script that tracks the mean intensity of each 
partition over the course of each experiment. This script could be run with only minor 
modifications with images obtained from different instruments. 
To calculate the bulk template concentration over time, we (1) identified the partitions that 
did or did not contain reaction solution, (2) tracked the partitions that met a minimum 
fluorescence intensity and (3) used the previous information to calculate the concentration of 
template in the bulk solution. 
A summary of the script is as follows: (i) load the images into memory, (ii) count the total 
number of partitions before heating (iii) identify positive partitions after the conclusion of 
the experiment, (iv) track the intensity of positive partitions for each image frame, (v) apply 
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Gaussian smoothing and baseline subtraction, (vi) save the data, and (vii) repeat for each 
image stack. The output of the script contains: the raw traces of individual partitions over 
time, baseline corrected traces of individual partitions over time (Figure 2.2.2b), the number 
of partitions exceeding the manually defined minimum fluorescence intensity threshold with 
time (Figure 2.2.2f), and the maximum relative rate in RFU per 30 sec for individual 
partitions (Figure 2.2.2d). These data provide all the necessary information to conduct the 
analyses detailed in Figure 2.2.2. 
 
Figure 2.2. Experimental demonstration of the real-time digital LAMP 
(dLAMP) approach using the commercially available enzyme Bst 3.0. 
Experiments were run at 70 C and imaged using a commercial microscope. 
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(a) A time course of fluorescence images from a subset of 350 partitions out 
of 20,000 partitions undergoing dLAMP reactions. (Intensity range 920-1705 
RFU). (b) Fluorescence intensity for a subset of partitions over time.  Blue 
traces indicate partitions containing template; red traces indicate fluorescence 
in the absence of template (i.e. non-specific amplification). Partitions turn 
“on” at the time point when the curve passes the threshold at 250 RFU. 
Vertical traces correspond to time points illustrated in panel (a) and generate 
endpoint measurements. (c) An “endpoint” measurement taken on a subset of 
partitions at 25 min. Bin width is 100 RFU. Fluorescence threshold is 250 
RFU. (d) A histogram of the maximum observed change in fluorescence of 
individual partitions using the full chip. Rate threshold is 45 RFU/30 sec. (e) 
Change in observed bulk concentration over time from the full chip using 
fluorescence intensity as threshold (solid lines) and rate (dashed lines). (f) 
Time at which individual partitions in panel (b) cross the fluorescence 
intensity threshold. (g) Maximum rate per partition plotted by time to 
fluorescence intensity threshold. 
Digital, real-time experiments to quantify LAMP performance 
We next sought to experimentally evaluate this pipeline (Figure 2.2.1). First, we 
established whether the fluorescence from LAMP reactions could be reliably measured from 
individual partitions over time (Figure 2.2.2a). We used LAMP reagents for Bst 3.0, 
commercial chips, a resistive heater held at 70 °C, and a commercial microscope. Although 
the microscope is capable of collecting all 20,000 partitions on one chip in a single image, 
for simplicity, in Figure 2.2.2a, we cropped the image to include only 350 of the 20,000 
partitions. Before turning on the heater (t = 0), we measured the autofluorescence from SYTO 
9 to quantify the total number of partitions loaded with reaction solution. (To calculate 
template concentration using the Poisson distribution32,33, we must know the total number of 
partitions containing the reaction mixture.) Autofluorescence from SYTO 9 decreases as the 
chip is heated and is completely eliminated within 3 min. The heater used on the microscope 
reaches reaction temperature within 120 sec. In less than 10 min, an increase in fluorescence 
was observed within some of the individual partitions, indicating amplification of individual 
template molecules inside those partitions. Due to the stochastic nature of amplification 
initiation, some of the partitions fluoresced later. 
In the negative-control (no template) partitions, fluorescence was not observed for the first 
45 min. However, we began to observe non-specific amplification after ~60 min. In these 
experiments, the negative control contains only 0.05x Tris-EDTA buffer in place of template 
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and represents a best-case scenario. We attribute amplification in the absence of template to 
primer dimers and other non-specific LAMP products. 
Second, we asked if the signal from non-specific amplification was sufficiently delayed to 
differentiate it from the signal arising from specific amplification in the presence of template. 
To answer this question, we generated real-time fluorescence curves by plotting the change 
in fluorescence of individual partitions as a function of time (Figure 2.2.2b). We observed 
specific amplification (blue curves) beginning to initiate at ~7 min and non-specific 
amplification beginning to initiate at ~50 min (red curves) and concluded that we could 
discriminate specific and non-specific amplification by time. 
Third, we asked whether enzymatic heterogeneity16,21,34 of specific amplification can be 
quantified to differentiate specific from non-specific amplification. We plotted the maximum 
change of fluorescence achieved by each partition of the full chip per 30-sec interval (Figure 
2.2d). For the negative-control sample (red bars), we observed non-specific amplification 
following a bimodal distribution of rates, with a first peak with little to no rate of fluorescence 
increase and a second peak at ~25 RFU per 30 sec. For the sample containing template (blue 
bars), rates for specific amplification were heterogeneous and centered around a rate of 70 
RFU/30 sec. We note that in PCR, which is gated by temperature cycling, there is no 
equivalent concept of “rate” as long as replication of DNA occurs faster that the duration of 
each elongation step. We found in our dLAMP experiments that the rate of specific 
amplification was greater than non-specific amplification. Hence, tracking amplification in 
real-time made it possible to distinguish true positives from false positives (non-specific 
amplification). 
Fourth, we asked if the distribution in time to fluorescence threshold is sufficiently narrow 
to discriminate specific and non-specific amplification. By plotting the number of “on” 
partitions (i.e. partitions that crossed the fluorescence intensity threshold defined in Figure 
2.2b) against time, we generated a distribution curve (Figure 2.2f) that illustrates the number 
of partitions that turn on per time point. This is related to the derivative of the change in 
concentration over time. This plot contains the time to threshold of all partitions within the 
entire chip, rather than a subset, to minimize sampling bias. In the sample containing template 
(blue curve), most partitions reached the threshold in 7–20 min, whereas the negative-control 
sample (red curve) had little non-specific amplification until approximately 60 min. 
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Graphing time to threshold illustrates the overall reaction’s speed (defined as the location of 
the peak or mode time to threshold) and efficiency (proportional to the area under the curve 
and illustrated in Figure 2.2f as the calculated concentration). In our experiment, the peak of 
the sample containing template was narrow and well separated from the non-specific 
amplification of the negative control (Figure 2.2f), indicating sufficiently low heterogeneity 
in amplification rate and time to initiation of the reaction. 
Fifth, we asked how the calculated bulk concentration changes over time. To answer this 
question, we generated endpoint-style measurements for each 30-sec time point, and 
calculated how the concentration changed over time. To demonstrate how to generate a single 
endpoint-style measurement, we selected one time point (25 min) and plotted RFU as a factor 
of the number of partitions (Figure 2.2c). Partitions were classified as either “on” (>250 
RFU threshold) or “off” (<250 RFU threshold). Partitions that are defined as having turned 
“on” contain a template molecule that amplified, whereas partitions that are ”off” either lack 
a template molecule or have not yet begun amplification. The sum of the partitions passing 
the threshold out of the total number of partitions with solution was used to determine a 
precise bulk concentration of template in the sample using the Poisson equation, as has been 
documented elsewhere.32,33 We plotted the calculated concentration as it changed over time 
in Figure 2.2e (solid lines). 
When the aim is to determine a precise concentration, we need to determine the best time 
at which to stop the assay. Deciding the best time to end the assay is complicated because 
each reaction initiates stochastically,16,21 causing the calculated concentration to 
asymptotically approach the true concentration (Figure 2.2e). It would be ideal for the 
calculated concentration to rapidly rise to the true bulk concentration and plateau near the 
true concentration; however, the reaction should be stopped before the rise in non-specific 
amplification (observed in our example starting at 60 min; red curves, Figure 2.2e–f). We 
tested whether there is heterogeneity in amplification rate (i.e. whether partitions with slow 
amplification rates take longer to reach the fluorescence intensity threshold than partitions 
with fast amplification rates) and found that initiation time was stochastic, but the reaction 
rates for true and false positives were consistent (Figure 2.2g). Hence, two molecules could 
have the same TTP, yet initiate at different moments, resulting in variable amplification rates.  
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Combining information about the concentration of template (Figure 2.2e) and the time it 
takes for partitions to turn “on” (Figure 2.2f) can be used to inform the choice of an optimal 
assay length for endpoint measurements, for situations where real-time quantification is not 
feasible. For example, in Figure 2.2, the optimal assay length for an endpoint readout would 
be ~45 min. This approach allows one to balance stochastic initiation of amplification, 
overcome enzymatic heterogeneity, and reduce the incidence of false positives caused by 
non-specific amplification. 
However, in cases where real-time measurements are desirable, thresholding by rate may 
be used to separate specific and non-specific amplification. For example, to correct for the 
observed increase in non-specific amplification (after 45 min), we implemented a threshold 
(Figure 2.2d) on the maximum rate per partition, thus eliminating some of the non-specific 
amplification in both the presence and absence of template (compare solid and dashed lines 
in Figure 2.2e). For example, the measured value at 60 min is 280 copies per µL (solid line), 
and the corrected value is 258 copies per µL (dashed line). In the no-template control, at 60 
min, the measured value is 16 copies per µL (solid line), whereas the corrected value is 3 
copies per µL (dashed line). The correction is more pronounced at 80 min where non-specific 
amplification is greater.  At 80 min, the measured value in the presence of template is 325 
copies per µL and the corrected value 266 copies per µL—indicating that almost 20% of the 
signal could arise from non-specific amplification. In the absence of template, the 
uncorrected value at 80 min is 187 copies per µL, however if rate is accounted for, then the 
value can be corrected to 16 copies per µL, thus eliminating the majority of the false 
positives. 
Finally, we note that although we calculated template concentration, the value is precise 
but could be inaccurate if not all target molecules loaded into the chip undergo amplification 
(in other words, if efficiency of amplification is not 100%). Thus, we next sought to measure 
the absolute likelihood of detecting a molecule as a function of reaction condition. 
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Evaluation of the effect of temperature on dLAMP with two different enzymes to 
analyze the interplay of amplification efficiency, background, and speed of 
amplification 
After establishing a protocol for generating real-time, digital measurements, we evaluated 
the absolute amplification efficiency of LAMP as a function of temperature for two different 
enzymes. We selected two commercial polymerases that worked well for us previously. Both 
enzymes are in silico homologues on the Bacillus stearothermophilus DNA Polymerase I 
and Large Fragment. NEB describes Bst 3.0 as an improvement of Bst 2.0 by adding reverse 
transcriptase activity, increased amplification speed, and increased thermostability. We 
sought to understand the differences in performance between these two enzymes at the single 
template level.  For this experiment, we used the previously described RTAI.30 The field of 
view for this instrument is larger than a microscope, allowing up to six samples to be 
observed concurrently. Hence, both the positive and negative controls could be collected in 
triplicate simultaneously. We expect some differences in measurements made on different 
instruments as a result of differing camera sensitivities and differences in the heating 
mechanism. Indeed, when we ran a single-concentration amplification reaction under 
identical conditions and compared measurements from the microscope and the RTAI, we 
found that there was significant difference (P = 0.03) in amplification efficiency between the 
two instruments (Figure 2.S2), with the RTAI generating higher amplification efficiency. 
Hence, we performed all enzyme-performance comparisons on a single instrument. 
 
Amplification efficiency 
First, we sought to establish the amplification efficiency of dLAMP, i.e. the fraction of 
template copies loaded that are detected (Figure 2.3a-b). We calculated the bulk 
concentration of template molecules from the digital measurement and plotted the observed 
template concentration as a fraction of template molecules loaded. To calculate the 
amplification efficiency, we determined template concentration using ddPCR and assumed 
all template molecules amplified. Using the real-time component of our measurements, we 
plotted the percent of copies detected over time compared with ddPCR. 
  
18 
We next asked how temperature impacts amplification efficiency. In general, we observed 
greater amplification efficiency at longer amplification times, which aligned with our 
previous observation (Figure 2.2d–e). Second, when observing at a fixed time, increasing 
temperature increased amplification efficiency to an optimum (green box in Figure 2.3a-b) 
before activity decreased. 
 
 
Figure 2.3. Evaluation of reaction conditions (enzymes and temperature) 
using real-time digital LAMP. (a-b) Amplification efficiency (percent 
template copies detected out of copies loaded) of Bst 2.0 (a) and Bst 3.0 (b) 
as a function of temperature. Green boxes indicate the optimal temperature 
range for the greatest probability of template detection. (c-d) Non-specific 
amplification in template-free buffer samples using Bst 2.0 (c) and Bst 3.0 
(d) for conditions matching panels a-b. (e-f) Distribution of time to 
fluorescence threshold using Bst 2.0 (e) and Bst 3.0 (f). (g) The fractional 
cumulative distribution function (CDF) compares the enzymes at their 
optimal temperatures (68 °C). (h) Fractional CDF plots of Bst 3.0 rate at 
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three temperatures. Error bars are S.D. For all datasets, N = 3 chips 
(technical replicates). CDF plots are the sum of 3 technical replicates.  
Several observations can be made by comparing the results from Bst 2.0 and Bst 3.0 
(Figure 2.3a-b). Although Bst 2.0 and Bst 3.0 have an identical reported optimal incubation 
temperature in bulk (65°C), we observed they had different optimal temperature ranges for 
amplification efficiency (Bst 2.0 at 66–68 °C; Bst 3.0 at 68–70 °C). We detected lower 
amplification efficiency at higher temperatures with Bst 2.0 compared with Bst 3.0. Bst 2.0 
failed to amplify at 72 °C, whereas Bst 3.0 continued amplifying until 76 oC. At short 
amplification times, (such as 10 min), Bst 3.0 had greater amplification efficiency than Bst 
2.0 (42.8% vs 20.8%, respectively). In contrast, at longer amplification times, such as 30 or 
45 min, efficiency for the enzymes was similar (77.6% vs 71.5% at 45 min, respectively), 
though Bst 2.0 had slightly greater amplification efficiency than Bst 3.0. 
We hypothesize that increased temperature improved amplification efficiency (presumably 
by increasing the breathing of dsDNA and facilitating primer annealing) until, at higher 
temperatures, a combination of enzyme denaturation or failure of the primers to anneal 
occurred. Our primers had melting temperatures ranging from 56–61 °C, when excluding the 
secondary FIP and BIP anealing regions, as calculated using OligoCalc.35 We found that 
chip-to-chip variability was extremely low. Relative error for Bst 2.0 at optimal temperature 
(68 °C) and 45 min of amplification was ~2% (Figure 2.2a), whereas the predicted Poisson 
noise for a single chip is 0.7%. Achieving such high precision using bulk measurements 
would require hundreds of experiments. The low variability among these measurements 
indicates that we were correctly determining whether a partition contained solution and 
whether it amplified. 
 
Non-specific background amplification 
Next, we quantified the amount of non-specific amplification (Figure 2.3 c-d) as a function 
of time and temperature. We plotted the number of wells that turned “on” in the absence of 
template relative to the total number of wells filled with LAMP solution. As previously 
stated, these non-specific amplification reactions included buffer in place of template and 
represent a best-case scenario. We concluded that at least for these idealized conditions, non-
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specific amplification in dLAMP was extremely low. For example, a fraction of 0.001 could 
correspond to 20 partitions turning on from among a total of 20,000 possible partitions. For 
both enzymes, we found the maximum fraction of non-specific amplification per total 
partitions was 0.0012 for times 20 min or less. The highest fraction of non-specific 
amplification observed was 0.017 at 45 min, corresponding to fewer than 350 non-specific 
partitions of the 20,000 total (Figure 2.3c-d). Furthermore, we observed higher temperatures 
resulted in lower non-specific amplification (Figure 2.3c-d). Finally, at extremely long 
amplification times (e.g. 60 min amplification, data not shown) Bst 2.0 had lower background 
than Bst 3.0. 
Variations in speed and amplification efficiency 
Third, we quantified the variation in speed and amplification efficiency across partitions in 
the time to reach fluorescence intensity threshold (Figure 2.3e-f). We first plotted the percent 
copies detected as a function of time for each temperature. As described previously, these 
curves represent the distribution in the time to threshold across all partitions and thus 
illustrate the interplay of (i) detecting a molecule (area under the curve from zero to a given 
time corresponding to the values plotted in Figure 2.3a-b), (ii) the speed of the reaction (the 
time at which the peak reaches a maxima) and (iii) several parameters of peak width 
summarized in Table S1. We hypothesize peak width is related to both the enzyme 
amplification rate, overall amplification efficiency, and the time at which the reaction 
initiates. Next, we plotted the peak time to threshold (Figure 2.S1). Images were collected 
in 30-sec intervals and we report the average of three trials. In some cases, the difference in 
time to threshold was less than the imaging time interval. For each time point, if fewer than 
15 partitions (0.075% of total partitions) were “on,” that time point was not included in the 
calculation of the mode. For these measurements, at the start of the reaction, the heat block 
was at 25 °C and the time to threshold included the time for the heat block to come to reaction 
temperature (~70 sec). Hence, there will be minor differences (seconds) in the time for each 
reaction to reach the fixed temperature. We do not see evidence that this difference manifests 
in the mode time to positive (TTP) measurements. 
In reactions with Bst 2.0, below 68 °C, mode TTP was narrowly clustered around 9.5 min. 
At 70 °C, mode TTP increased, and the reaction failed to amplify beyond 72 °C. In reactions 
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with Bst 3.0, the mode TTP decreased from 8.2 ± 0.3 (mode ± S.D.) min at 64 °C to 6.6 ± 
0.3 min at 70 °C, then increased with increasing temperature until amplification failed for all 
partitions at temperatures ≥76 °C. In the negative controls for both enzymes (Figure 2.S1), 
amplification either failed or started after 75 min. 
Several observations can be made by comparing the results from Figure 2.3e-f. We found 
that the optimal temperature for time to threshold corresponded with the optimal temperature 
for amplification efficiency (Figure 2.3a-b), and that the optimal temperatures also had the 
smallest tailing factors, Full Width at Half Maximum (FWHM) and asymmetric factor (i.e. 
narrowest peak widths) (Figure 2.3e-f; Table S1). At optimal efficiency, Bst 3.0 was 
approximately 2 min faster in mode TTP, had much narrower FWHM, smaller tailing factor, 
and lower asymmetry than Bst 2.0. Finally, as efficiency decreases, measurements of peak 
shape and width increase. To the best of our knowledge, this is the first published 
quantification that explicitly tests and quantifies the time dependence of LAMP efficiency 
using these enzymes. Real-time digital enables us to identify the time point at which the 
observed concentration most closely approximates the true concentration thus optimizing the 
assay duration. 
 
Rates of amplification (specific and non-specific) 
Fourth, we compared the rates of specific and non-specific amplification between Bst 2.0 
and Bst 3.0. The data shown represent the combined rates of three separate trials. We found 
that non-specific amplification rates were similar for the two enzymes (Figure 2.3g, dashed 
lines), whereas in the presence of template, amplification rates were faster for Bst 2.0 than 
Bst 3.0 (Figure 2.3g, solid lines), despite lower efficiency at short times. Differences in 
camera sensitivity between the microscope (used for real-time images in Figure 2.2) and the 
RTAI (used for Figure 2.3) result in different apparent amplification rates. 
We also examined the relationship between temperature, efficiency, and maximum rate. In 
the case of Bst 3.0, maximum reaction amplification rate does not correspond with optimal 
efficiency (Figure 2.3h). 64 °C had the fastest amplification rates, but suboptimal efficiency 
(57.3% at 45 min). Optimal amplification efficiency occurs at 68 °C (71.5% at 45 min), but 
slightly slower amplification rate than 64 C. At 74 °C, we observed both poor efficiency 
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(32.7% at 45 min) and slowest reaction rate. We attribute this to a combination of decreased 
enzymatic velocity and decreased primer annealing. Additionally, we note that different 
thresholds for amplification rate would be needed for each temperature. This is expected 
given changes in enzymatic velocity. 
 
Application of the pipeline to a phenotypic antibiotic susceptibility test (AST) using 
clinical samples 
We next asked whether we could apply the output of this digital real-time pipeline to perform 
a rapid phenotypic AST. Specifically, we aimed to categorically sort clinical samples as 
phenotypically “susceptible” or “resistant” to an antibiotic in agreement with the gold-
standard reference method. This study was constructed as a demonstration of the capability 
of the microfluidic chips and the value gained from using this digital real-time pipeline to 
optimize reaction conditions—it was not an assessment of the digital AST (dAST) 
methodology established previously.17,18 We selected the optimal dLAMP conditions for Bst 
3.0 based on the measurements of mode TTP and amplification efficiency established in the 
previous experiments (Figure 2.3b)—70 °C and a reaction time of 10 min. We used archived 
clinical urine samples from patients diagnosed with urinary tract infections (UTI) containing 
E. coli. These samples had been categorized as phenotypically susceptible or resistant to the 
antibiotics ciprofloxacin or nitrofurantoin using the gold-standard (broth microdilution) 
method.18 We tested exactly 17 samples and observed 100% categorical agreement with the 
gold-standard method (0 major errors; 0 minor errors). We conclude that the pipeline 
presented in this paper performs well and could be used, among other applications, to 
optimize reaction conditions for speed and sensitivity and apply those conditions to a 
determination of phenotypic antibiotic susceptibility in clinical samples. 
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Figure 2.4. Phenotypic antibiotic susceptibility tests of 17 clinical urine 
samples from patients infected with a urinary tract infection containing E. 
coli. Susceptibility to the antibiotics nitrofurantoin and ciprofloxacin were 
tested using dLAMP conditions optimized using digital real-time 
experiments (Figure 2.3). Urine samples were exposed to media without 
antibiotic (control) or media with an antibiotic (treated) for 15 min and then 
concentrations of nucleic acids were quantified to calculate a control:treated 
(C:T) ratio. Samples were categorized by dLAMP as susceptible (above the 
susceptibility threshold) or resistant (below the threshold). All samples were 
categorized in agreement with the clinical gold-standard method. 
CONCLUSION 
We have presented a pipeline to generate real-time, digital isothermal amplification 
measurements using only commercial and open-source components. We used this pipeline 
to examine how small changes in reaction conditions influence the interplay of LAMP 
efficiency, speed, and background by performing 124 real-time dLAMP experiments. As one 
practical application of this approach, we determined the optimal reaction conditions for a 
phenotypic test of antibiotic susceptibility using 17 clinical urine samples from patients 
diagnosed with urinary tract infections. In all cases, the results of the optimized dLAMP 
assays were in agreement with the clinical gold-standard AST. 
These experiments validate that real-time digital measurements enable tests of enzymatic 
performance in dLAMP. Generally, we found that each enzyme had a unique optimal 
temperature for amplification efficiency (probability of detecting a target molecule) and for 
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eliminating non-specific amplification. This “optimal” temperature produced the fastest 
mode TTP and the narrowest, most symmetrical distribution curves; interestingly, the 
optimal temperature did not necessarily yield the fastest amplification rate. Together, these 
data suggest that amplification efficiency is an interplay of enzymatic rate, diffusive 
transport, and DNA breathing. When reactions are performed away from optimal 
temperature, the distribution curves broaden and decrease in total area, resulting in reduced 
overall amplification efficiency and slower mode TTP; whereas amplification rate decreases 
with increasing temperature. With regard to the specific enzymes in this study, although 
efficiency was similar at long amplification times (> 20 min), Bst 3.0 had a faster mode TTP 
than Bst 2.0 by approximately 2 min, and more narrow and symmetrical distribution curves. 
However, Bst 2.0 had faster amplification rates than Bst 3.0, so reactions with Bst 2.0 took 
longer to initiate, but proceeded more rapidly. For both polymerases, non-specific 
amplification in buffer was extremely low. 
In the future, this pipeline can be used to understand the fundamental pieces of LAMP. The 
field of diagnostics would benefit from a thorough mechanistic study of LAMP asking which 
components determine amplification fate, and how components, such as primers and heating 
rate (Figure 2.S2), impact reaction and enzymatic speed. This pipeline makes such a 
mechanistic study possible. For example, in this study we corrected the observed 
concentration by separating true positives from background amplification using rate and 
fluorescence, but we did not explore the origins of non-specific amplicons—which deserves 
its own study and development of more precise tools for studies of non-specific 
amplification. Finally, this pipeline can be extended to optimize other isothermal 
amplification chemistries that could be suited to other types of diagnostic assays. 
Ultimately, this pipeline will make digital real-time measurements more accessible to 
researchers, even those who lack microfluidic expertise or specialized equipment. The 
commercially available chips and reagents used here could be coupled with many 
combinations of standard laboratory or field equipment, such as a hot plate and a fluorescent 
stereoscope, or a chemical heater and a cell phone camera. While we believe the general 
trends found in this manuscript will extend to other primer sets, we hope this pipeline will 
enable others to study other primer sets and conditions of interest to them.  
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S-I  Summary of MATLAB script functions  
In order to quantify the reactions on chips using the Poisson distribution, we needed to know 
the number of partitions that contained solution and the number of partitions that were empty.  
(It would be naïve to assume that all 20,000 partitions were loaded with solution; visual 
inspection shows that was rare.) We counted the total number of partitions with solution 
using the image of the autofluorescence of SYTO 9 dye before heating at time 0 (Figure 
2.2a).   SYTO 9 had uniform autofluorescence independent of template presence, making it 
easy to count all partitions loaded with solution.   
To track the mean fluorescence intensity of each partition over time, we solved two 
challenges.  First, when the microfluidic chip was heated (especially during the first 2 min) 
the chip moved.  As the chip heated, it lost the initial autofluorescence from SYTO 9.  
Consequently, it was not possible to track this movement with the fluorescence of a single 
fluorophore.  We solved this challenge by creating a mask (using image segmentation) that 
outlined each detectable partition at the chip’s final position using a frame at the end of 
amplification.  An advantage to using only the detectable partitions that met a minimum 
fluorescence intensity (out of a total of 20,000 partitions per chip) was reduced overall 
computation time because only a fraction of the total partitions were tracked in real-time. 
A second challenge when tracking mean fluorescence intensity of each partition over time 
using only the detectable partitions is that partitions can appear to be different sizes because 
of differences in fluorescence intensity (dark partitions can appear artificially smaller and 
bright partitions can appear artificially larger).  To counteract the effect of each partition 
having a different average intensity, we performed multi-level thresholding with tight 
restrictions for the area and major axis filters.  We set a minimum fluorescence intensity 
(threshold) for each pixel at a given time and used this information to segment (define the 
perimeter) each individual partition.  This threshold was combined with selection criteria for 
the area and major axis.  The area filter defined the smallest and largest partitions while the 
major axis filter ensured that detected regions were circular. We repeated this for different 
threshold values and merged the resulting partitions.  This technique restricted partitions to 
a specific size and shape while enabling detection over many intensity values. 
Finally, we used the information from quantifying the number of partitions containing 
solution and tracking mean fluorescence of each partition over time to calculate the 
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concentration of template in the bulk solution.  To smooth the traces and reduce the noise, 
we first applied a Gaussian-weighted moving average filter with window length 10 frames 
to each intensity curve.  To ensure all partitions start at zero intensity, we determined the 
baseline intensity by calculating the average partition intensity for selected frames after 
heating but prior to detectable amplification (between 2.5 min and 5 min).  The baseline 
intensity was subtracted from all frames.  Finally, we manually defined a threshold to 
determine whether a partition would be counted as a “positive” or “negative.”  Using the 
adjusted traces, threshold, and the total number of partitions, we determined the fraction of 
partitions that were “on” for any given time.  Using the fraction of partitions that were “off,” 
we calculated via the Poisson distribution the concentration of template detected in the bulk 
solution for any given time point. From this measurement of concentration, we can calculate 
the amplification efficiency by dividing the measured concentration by the known (true) 
concentration. 
The MATLAB script described here has been deposited in the open-access online 
repository GitHub and may be accessed using the following direct link: 
https://github.com/IsmagilovLab/Digital_NAAT_Analyzer  
 
 
S-II Real-time data acquisition parameters  
 
Acquiring real-time data using microscopy   
Images were acquired in 30-sec intervals on a Leica DMI-6000B (Leica, Buffalo Grove, IL, 
USA) with a 1.25x 0.04NA HCX PL FLUOTAR Objective (506215) and 0.55x coupler 
(Leica C-mount 11541544) using a 1-sec exposure through the L5 (GFP) Nomarski prism 
and a Hamamatsu ORCA-ER CCD camera (Hamamatsu Photonics K.K., Hamamatsu City, 
Shizuoka, Japan; Ref. C4742-80-12AG).  Heating was performed using an integrated circuit 
(IC) board prototype for temperature control developed by Green Domain Design (San 
Diego, CA, USA).  The IC board was connected to a DC power supply (Model 3670; Electro 
Industries, Monticello, MN, USA), a Nichrome wire (12 ohm) attached to a 5 x 25 x 25 mm 
aluminum block. A thermistor was mounted within the block to measure the temperature of 
the heating block.  When the temperature of the heating block was lower than the set-point 
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temperature, the IC board supplied current to the Nichrome wire resistive heater.  With this 
setup, heating was achieved to 70.0 ± 2 °C within 2 min.  Images obtained on the microscope 
were processed with our MATLAB script (Supporting Information, S-I) using the 
following parameters: Area Bound [5 40] pixels, Major Axis [2 9] pixels, Threshold [250] 
Relative Fluorescence Units (RFU), Baseline Smoothing Frames [6 11], Masking Image 
Frame [175]. 
Acquiring data using a custom large-format real-time amplification instrument 
(RTAI)  
Images were acquired in 30-sec intervals on a custom-built, public-domain real-time 
amplification instrument (RTAI), described previously,30 using the FAM channel with a 15-
sec exposure at f/5.6.  Heating was achieved using the built-in PCT-200 thermocycler, which 
heats to 70.0 ± 0.3 °C within 70 sec.  The temperature of the thermocycler block was held at 
25 °C to start all reactions, with the exception of an experiment where the block was 
preheated to the optimal temperature (Figure 2.S2b).  We equipped the thermocycler with 
an aluminum block with two sloped planes (each set at 11°—an angle defined by the 
microfluidic chip manufacturer’s requirements), to segregate bubbles formed during the 
reaction to a specifically designed bubble trap.  It was advantageous to use this instrument to 
analyze up to six chips in parallel in a single field of view and under a uniform temperature.  
By running multiple chips on a real-time instrument we achieved “multiplexed” assays 
(wherein multiple measurements are made simultaneously). Images obtained on the RTAI 
were processed through our MATLAB script (Supporting Information, S-I) using the 
following parameters: Area Bound [4 12] pixels, Major Axis [2 5] pixels, Threshold [100] 
RFU, Baseline Smoothing frames [6 11], Masking Image Frame [175]. 
 
S-III Limitations of chips used  
A limitation of chips that discretize by capillary action is that solution can spread among the 
partitions. For example, during dLAMP quantification of extractions for three of the clinical 
samples, we observed spreading of one positive partition to its adjacent partitions. We 
attribute this spreading to liquid bridges forming among adjacent wells, resulting in transfer 
of the amplicon among compartments. These bridges could arise from defects in surface 
coatings of commercial chips or from an excess of surface active molecules present in some 
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clinical samples. To test whether spreading was due to surface active impurities in the 
samples, samples were diluted in Tris-EDTA (TE) buffer and in the subsequent test, 
spreading was eliminated for one sample.  For the remaining samples, dilution reduced the 
spreading enough that quantification at 10 min was not hindered, although some spreading 
was observed at later times. Quantification of the C:T ratio remained consistent (and the 
susceptibility call the same) because we use a ratiometric calculation.  
S-IV Calculation of Peak width metrics  
 
The average distribution curve (averaged over three trials) was calculated for each 
temperature and all values normalized to the peak prominence. Time resolution was 
estimated to the nearest 15 second interval. Calculations were based on: John V. Hinshaw. 
“How Do Your Peaks Measure Up?” Oct 01, 2013, LCGC Europe, Volume 26, Issue 10, pg 
575–582. 
Full Width at Half Maximum was calculated at the time difference between the leading at 
tailing edges at 50% peak prominence.  
Asymmetric factor was calculated by dividing the time between the peak prominence and 
the tailing edge (“b0.1“) by the time between the peak prominence and the leading edge at 
10% peak height (“f0.1“).  
 
(Eq. S1) 
𝐴𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐 𝐹𝑎𝑐𝑡𝑜𝑟 =
𝑏0.1
𝑓0.1
 
 
Tailing factor was calculated as the total peak width at 5% of the prominence (or the distance 
from the leading edge to the time of peak prominence (“f0.05”) plus the distance from the time 
of peak prominence to the tailing edge (“b0.05”)) divided by twice the distance from the 
leading edge to the time of peak prominence.  
(Eq. S2) 
𝑇𝑎𝑖𝑙𝑖𝑛𝑔 𝐹𝑎𝑐𝑡𝑜𝑟 =  
𝑓0.05 +  𝑏0.05
2𝑓0.05
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Table 2.S1. Tabular quantification of the time to threshold distribution curves. 
Bst 2.0 Bst 3.0 
Temp 
(ºC) 
Efficiency at  
45 min (%) 
Mode 
TTP 
(min) 
FWHM 
(min) 
Asymmetric 
Factor 
Tailing 
Factor 
Temp 
(ºC) 
Efficiency at  
45 min (%) 
Mode 
TTP 
(min) 
FWHM  
(min) 
Asymmetric 
Factor 
Tailing 
Factor 
64.0 64±8 9.5±0.0 2.5 10.2 14.8 64.0 57±2 8.2±0.3 3.0 8.0 14.2 
66.0 78±2 9.3±0.3 2.3 7.6 11.7 66.0 61±2 7.3±0.3 2.3 5.6 11.4 
68.0 78±2 9.8±0.3 2.3 7.2 14.3 68.0 71±6 7.6±0.3 2.3 6.0 9.2 
70.0 66±1 11.0±0.0 2.8 8.8 9.1 70.0 69±3 6.7±0.3 1.5 7.3 3.7 
      72.0 51±3 7.2±0.3 2.0 8.3 4.3 
      74.0 33±9 10.2±0.6 2.8 5.7 13.1 
 
S-V  Time to Mode Positive 
 
 
Figure 2.S1. Bar graphs of the time location of the peak of the distribution curve (time 
to mode positive) using Bst 2.0 (a) and Bst 3.0 (b). We required 15 or greater partitions 
turn on at a given time (0.075% of total partitions), to include the time point for the 
mode. Data are summarized in Table S1 in S-III. 
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S-VI Hardware and pre-heating considerations 
We asked if multiple instrumentation formats could be used to collect the data and if 
hardware format impacted the amplification efficiency. We used the optimal conditions for 
Bst 3.0. First, we compared the performance of the large-format real-time amplification 
instrument (RTAI) to a wide-field microscope fitted with a heat block—a set-up that would 
be accessible to most laboratories. We found that the heater ramp rate was slower on the 
microscope than the RTAI (120 sec versus 70 sec) resulting in 9.0 ±1.0 min time to mode 
positive (Figure 2.S2a).   
Next, we looked at the effect of pre-heating using the RTAI. We compared the optimal 
conditions using Bst 3.0 and starting from 25 °C (green curve) with the same instrument and 
heating block already at the optimal reaction temperature of 70 °C (orange curve).  When the 
block is preheated, we observed the mode time to threshold reduced from 6.7 ±0.3 min to 6.0 
±0.0 min (Figure 2.S2a).  
Next, we asked if differences in hardware configuration and the heating rates between the 
instruments would also correspond to differences in probability of detection. We observed 
significant variation in amplification efficiency (RTAI vs RTAI with preheating P = 0.002; 
RTAI vs microscope with heater P = 0.031, RTAI with preheating vs microscope with heater 
P < 0.001) and concluded that heating rate may impact probability of amplification (Figure 
2.S2b). Hence, all comparisons made in this study were instrument specific. Though it 
remains to be tested, we suspect more precise hardware, with improved heating control, could 
improve device performance.  
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Figure 2.S2. Effect of hardware and heating on (a) 
the distribution in time to fluorescence threshold 
and (b) quantification of amplification efficiency 
(mean percentage copies detected ± S.D.) at 40 
min.  
 
 
 
S-VII  Optimization of Bst 2.0 buffer composition 
Following the protocol described previously18, buffer conditions for Bst 2.0 were optimized 
in bulk at 713 copies/µL (e.g.  ~4,280 or 0 copies per 6 µL reaction). Optimal buffer 
composition was selected based on fastest bulk time to positive.  
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Figure 2.S3. Magnesium optimization for Bst 2.0. 
A value of 0.25 indicates that no amplification was 
observed. Amplification was performed at 67.5° 
C. N=1 for all TTP values. 
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C h a p t e r  3  
REAL-TIME KINETICS AND MELT CURVES IN SINGLE-
MOLECULE DIGITAL LAMP DIFFERENTIATE SPECIFIC AND 
NONSPECIFIC AMPLIFICATION EVENTS TO IMPROVE THE 
LIMIT OF DETECTION  
Justin C. Rolando, Erik Jue, Jacob Barlow, and Rustem F. Ismagilov 
ABSTRACT  
Isothermal amplification assays, such as LAMP, are showing great utility for the 
development of rapid diagnostics for infectious diseases because they have high 
sensitivity, pathogen-specificity, and robustness to high levels of host DNA. 
However, assay optimization remains constrained by a limited understanding of how 
assay parameters affect specific and nonspecific amplification.  Here, using 
chlamydia DNA as a clinically relevant target, we develop a real-time digital LAMP 
(dLAMP) approach to investigate patterns in specific and nonspecific amplification. 
By incorporating melting temperature (Tm) as a tool to evaluate the impact of 
thresholds, we show that the digital single-molecule approach can reveal the origins 
of nonspecific amplification, the role of human DNA, differences among enzymes, 
and the impact of assay parameters (time, temperature, etc.). By differentiating true 
and false positives, Tm enables determination of the combination of assay parameters 
that lead to the lowest limit of detection (LOD) in a digital assay.  We predict that 
this approach of combining melting temperature with real-time dLAMP will be 
valuable for a wide variety of applications, particularly in the optimization of clinical 
assays that contain high levels of background DNA and require optimization for low 
LOD. 
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INTRODUCTION   
Isothermal methods, such as loop-mediated isothermal amplification (LAMP), are 
attractive for nucleic acid amplification tests (NAATs) in point of care (POC) and 
limited-resource settings. LAMP in particular shows promise as a less expensive 
NAAT with fewer hardware requirements compared with PCR. However, despite 
advancements, optimization of individual LAMP NAATs for a specific target 
sequence and primer set remains constrained by a limited understanding of how 
amplification is affected by myriad factors, including temperature, time, and ion 
concentrations. In particular, nonspecific amplification can be problematic and 
constrains an assay’s limit of detection (LOD). In reactions containing template target 
molecules, both specific and nonspecific amplification reactions may occur. Unlike 
PCR, LAMP lacks a temperature-gating mechanism, so nonspecific reactions 
consume reagents and compete with specific amplification. The presence of 
nonspecific amplicons therefore adversely impacts both the assay’s analytical 
sensitivity (the fewest template molecules which can be detected) and its analytical 
specificity (ability to detect the target template in the presence of competing 
reactions). Separating specific and non-specific amplification would therefore be 
invaluable both during assay optimization and assay deployment for use in clinical 
diagnostics.  
Substantial research is focused on using isothermal amplification chemistries for 
diagnosis of infectious disease.  For example, chlamydia (caused by the pathogen 
Chlamydia trachomatis, CT) is the most common sexually transmitted infection 
(STI) worldwide, with more than 110 million cases reported annually (1). Diagnosis 
of CT infections is challenged by a lack of standard symptoms (many infections are 
asymptomatic) (2) and the presence of mixed flora (particularly in the female 
reproductive tract) (3). Thus, rapid NAATs with high sensitivity and specificity are 
critically needed, especially NAATs that can deal with the high levels of host DNA 
likely to be present in clinical samples such as urine samples and swabs.  
To optimize LAMP for CT and other infectious pathogens, a method of separating 
nonspecific reactions from specific amplification is needed. Reactions run in bulk 
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(i.e., in a tube) in the absence of template, can be informative to provide 
information on performance of non-specific amplification. However, in the presence 
of template, though specific and nonspecific reactions occur simultaneously, they 
cannot be monitored simultaneously. Thus, bulk reactions have three important 
limitations with regard to assay optimization: (i) differences in the kinetics of specific 
and nonspecific reactions cannot be separated, (ii) rare but significant events, such as 
early but infrequent nonspecific amplification events, cannot be easily characterized; 
and (iii) bulk cannot provide valuable statistical probabilities without running 
hundreds of replicate experiments.  
To improve analytical specificity and sensitivity, one strategy is to eliminate the 
detection of non-specific amplification. In bulk LAMP experiments, this has been 
done by using probes or beacons that show only specific amplification of the target 
(Cite Meagher, Tilley, others). Although this method improves the assay, this 
approach doesn’t capture nonspecific reactions and thus cannot give insights into the 
origin of nonspecific amplification or the impact of conditions. Moreover, because 
the use of probes or beacons does not eliminate nonspecific amplification, it merely 
prevents the detection of it, nonspecific amplification still competes for reagents and 
can limit the extent of the signal generated by specific amplification events (4).  
In this study, we use digital single-molecule LAMP (dLAMP) to probe the 
fundamental mechanics of amplification reactions and extract real-time kinetic 
information to identify reaction conditions and data-processing parameters that 
minimize nonspecific amplification events.  Digital single-molecule methods 
compartmentalize each reaction into partitions, eliminating interference among 
individual amplification events, and enable absolute quantification and interrogation 
of individual reactions. Moreover, by separating individual amplification events into 
discrete compartments, digital experiments consist of thousands of reactions that run 
in parallel and thus provide valuable statistical information (5). In this work, we use 
real-time imaging to monitor the kinetics of tens of thousands of dLAMP reactions 
per experiment. We hypothesized that high-resolution melting analysis (HRM) could 
be used to separate specific from nonspecific amplification events and identify 
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optimal data processing  parameters to  distinguish specific and non-specific 
amplification events when assay is deployed without HRM. To test this hypothesis, 
we use a dLAMP assay with CT DNA as the target  to analyze both specific and 
nonspecific amplification under conditions that include clinically relevant 
concentrations of background human DNA.   
 
RESULTS 
Bulk LAMP studies reveal nonspecific products at high melting temperatures 
(Tm) 
  
We first wished to test whether melting temperature could be used to separate specific 
and nonspecific amplification in bulk LAMP. To find the LOD of our CT 23S 
primers in bulk LAMP, we performed half log dilutions of extracted CT genomic 
DNA. As CT concentrations approached the LOD, we began to observe nonspecific 
amplification (Fig 3.1).  At target molecule concentrations greater than 10 copies per 
µL (cp/µL), amplification using Bst 2.0 began between 10-11 min (Fig 3.1a) and had 
uniform melting temperature (Tm; Fig 3.1b). Amplification using Bst 3.0 (Fig 3. 2c), 
also yielded amplification from 10-11 min; however, we also observed a nonspecific 
amplification at 15 min, defined by having a different Tm than the specific 
amplification events (Fig 3.1d). We observed that early amplifying products 
corresponded to specific amplification events, and the later products corresponded to 
nonspecific amplification, supporting our prediction that we could use melting 
temperature as a proxy for sequence identity, as is common with PCR.     
As the concentration of the target decreased, the amount of nonspecific amplification 
increased. We reduced the concentration of specific template from 10 cp/µL in half-
log intervals. At 3.16 copies/µL (Fig 3.1e,f), only specific amplification occurred (24 
replicate wells/plate). However, once template concentrations reached 1 cp/µL (Fig 
3.1g,h), nonspecific amplification occurred with greater frequency than specific 
amplification (18 of 24 replicates produced a false amplification event). Similarly, 
for 0.316 cp/µL (Fig 3.1 I,J) 15 of 24 reactions generated false positives.  We 
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confirmed the Tm and amplification time of the nonspecific products observed 
previously, by running amplification in the absence of template (no template control, 
NTC) (Fig 3.1K,L) and observed 44 of 45 replicates produced amplifications with a 
Tm of 91°C. While it is possible the reaction generates multiple different non-specific 
amplification products, even ones with Tm matching to the specific products, we  
suspect that the single amplicon we observed at 88°C was a cross contaminant.  
The melting temperatures of specific amplification differed between the two 
polymerases tested. Specific amplification for Bst 2.0 had a Tm of 85.5°C, while 
specific amplification using Bst 3.0 had a Tm of 88°C, and demonstrated non-specific 
amplification at Tm of 91°C.  The non-specific amplification had identical Tm to 
amplification in absence of template (Fig 3.1K,L). Despite Bst 2.0 and Bst 3.0 
producing identical specific products (as confirmed by sequencing, see 3.1X) and gel 
banding patterns (Fig 3.1x), they had different Tm (Fig 3.1b,d respectively). We 
attribute the difference in Tm to Bst 3.0 having 1 mM greater Mg2+ than Bst 2.0. 
Magnesium is known to stabilize ssDNA, so we suspect this difference explains the 
higher observed melting temperature of Bst 3.0.   
In all instances in bulk, we observed a high Tm nonspecific product. This was 
surprising because PCR predicts primer dimers to occur at low Tm, however, our 
bulk amplification failed to produce a nonspecific product with low Tm. Thus, we 
investigated the sequence identity of the nonspecific product at high melting 
temperature. We ran the LAMP products on a gel and observed that the characteristic 
pattern of the specific amplification products differed substantially from the banding 
pattern seen in the high-Tm non-specific products (Fig 3.1X).  To determine the 
sequence of the high-Tm non-specific products, we performed Next Generation 
Sequencing (NGS) and identified the product as a mixture of full-length FIP, BIP, 
and their complements, as well as fragments of these primers. To confirm the 
sequence identity of the structure, we targeted the FIP region using a restriction 
endonuclease. Digestion resulted in two bands corresponding to ~40 and 100 bp and 
confirming the sequence.  
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Figure 3.1: Amplification and Melting curves of Chlamydia in a tube produces 
a high-Tm non-specific product. Plots of fluorescence as a function of time during 
a LAMP reaction (a,c,e,g,i,k) and the derivative plot of fluorescence as a function of 
temperature for the corresponding melting curves (b,d,f,h,j,i). Reactions using Bst 2.0 
at 10 cp/µL (a,b,), Bst 3.0 at 10 cp/µL (c,d), Bst 3.0 at at 3.16 cp/µL (e,f), Bst 3.0 at 
1 cp/µL (g,h), Bst 3.0 at 0.316 cp/µL (i,j), and using Bst 3.0 without template (k,l). 
Reactions of specific amplification are colored blue, while non-specific amplification 
is colored in red.  
 
Melting temperature differentiates specific and nonspecific reactions in dLAMP  
 
To study specific and nonspecific amplification events at the digital single-molecule 
level, we developed a new approach that enabled high resolution melt analysis 
(obtaining “melt-curves”) to be performed on each partition. We used a commercially 
available microfluidic chip with 20,000 partitions and a dLAMP method described 
previously. We improved this approach by incorporating an off-the-shelf 
thermoelectric unit to both heat and cool the chips, and enhanced our MATLAB 
script to allow for multicolor tracking. We used the temperature independent 
fluorophore ROX to track a partition’s location and the dsDNA intercalating 
fluorophore Syto9 to follow amplification and hybridization status. Multi-channel 
tracking thus enabled determination of the spatial location of a partition, even when 
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it did not exhibit fluorescence from the intercalating dye (Syto9). This two-channel 
approach is required to follow a partition through both amplification and the entirety 
of the melt, when fluorescence from Syto9 is lost. In these experiments, we choose 
to use a microscope, instead of the custom real-time amplification instrument we used 
previously, because the microscope, due to its smaller field of view, has superior 
optical properties (greater pixels per partition and  lower exposure time requirements) 
to access higher temporal resolution and enhanced kinetic measurements.   
We first illustrate the capabilities of using real-time digital LAMP to study the kinetic 
parameters of individual reactions and use melting temperature to classify reaction 
outcome (Fig 2). In a real-time digital LAMP experiment, we can follow individual 
partitions as they amplify as a function of time (Fig 2a) and then by temperature as 
they go through a melt (Fig 2b). Real time imaging of individual partitions enables 
us to reconstruct the standard amplification curves of intensity of each partition as a 
function of time (Fig 2c), while plotting the fluorescence intensity as a function of 
temperature yields a melt trace (Fig 2d), whose derivative plot (Fig 2e) is the standard 
melt curve. Analogous to bulk measurements, the melt curve classifies the reactions 
as specific or non-specific. We can use the classification to identify important 
patterns in the kinetics of each type of amplification (Fig2 f-h).  
We used real-time dLAMP with melting temperature to determine whether 
differences in time to positive (TTP) are due to a difference in amplification initiation 
or in rate.  We expect this information would be valuable for elucidating if the 
molecules that lead to bulk amplification are the first to initiate or those which initiate 
with the fastest rates. We found that TTP can be heterogeneous but Tm is constant, 
indicating that the same product may initiate at different times (Fig 2f). This is 
consistent with our knowledge of the stochastic initiation of LAMP. Further, we 
observed some variability in the maximum rate despite consistent melting 
temperature. This indicates the same product may amplify at different velocities. (Fig 
3.2g). In general, we observed that max rate often corresponded to the point where 
the reaction first begins to amplify. Finally, by plotting Rate as a function of TTP 
(Fig 3.2h) we observe little fluctuation in rate for very different TTP, indicating that 
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the difference in TTP is mostly delay in the initiation of amplification rather than 
rate of amplification.  
The use of real-time data revealed heterogeneity in the timing of amplification 
initiation and the amplification rate, but homogeneity in melting temperature. This 
indicates the stochasticity of initiation, but lack of heterogeneity in the composition 
of the product. In some cases, outlier data points for rate occur (Supplement S3.1). 
These outliers could have several origins, including fluctuations in fluorescence due 
to scattering of bubbles passing over a partition or random fluctuations in 
fluorescence due to shot noise. To determine whether removing these points 
impacted the distribution of enzymatic rates, we performed a non-parametric test (SI 
S3.1) and found no significant differences in enzymatic rates when these outliers 
were excluded. 
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Figure 3.2: Specific amplification in digital single-molecule experiments.  
A) Individual partitions are traced over time. For simplicity, we illustrate a subset of 
250 of 20,000 possible partitions at three time points (0, 20, and 45 min). Of the 250 
partitions in this micrograph, 30 partitions amplified. Partitions A and B are visible 
at 20 min; partition C becomes visible at 45 min.  
B) Fluorescence micrographs of individual partitions during a melting experiment. 
As the dsDNA in each partition de-hybridizes, the intercalating dye is released and 
fluorescence decreases. At 86.5 °C, partitions were uniformly bright, they began to 
decrease in fluorescence at 87.5 °C, and lost fluoresce at 90.2 °C.  
C) Plotting the fluorescence intensity as function of time generates the standard 
amplification traces of individual partitions generated during a 90-min LAMP 
experiment. Orange curves correspond to partitions A–C from panel a). 
D) Traces of fluorescence intensity as a function of temperature of individual 
partitions during melting experiments. By quantifying real time intensity of 
individual partitions as the temperature is increased, melting traces are obtained (Fig 
3.2D).  We  collected data with temperature resolution of 1 °C from 55–90 °C, and 
then at 0.5 °C resolution from 90–95 °C.  
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E) The derivative plot of panel D generates the standard melting curve. The 
temperature at which the maximum occurs corresponds to the “melting point” of the 
LAMP products in the individual partition.  
F) Summary data of the individual partitions plotting the time each well reaches a 
fluorescence intensity of 250 RFU (TTP) against temperature.   
G) Summary data of the individual partitions plotting the maximum slope against 
melting temperature.  
H) Summary data of the partition TTP against the maximum rate of individual 
partitions.  
 
 
We next asked whether we could observe in dLAMP the same pattern of high-Tm 
nonspecific amplification and low-Tm specific amplification that we observed in 
bulk. We performed dLAMP using three chips containing template, and three chips 
lacking template and observed ~55,000 partitions for each condition. (Details in SI.) 
Although 60,000 partitions are possible, not all partitions fill nor can all partitions be 
tracked for the full duration of the experiment. The Tm resolution was 1° C up to 90 
°C; and 0.5 °C from 90–95 °C. Due to slight differences in the timing between the 
heating element and the image collection, some chips were observed at slightly 
(fractional) different  temperatures.  
Our approach enabled us to differentiate specific and nonspecific amplification 
events using Tm.  When using Bst 2.0 and template (Fig 3.3a blue points), we 
observed a large band of amplification from 88.5–90.3 °C, in agreement with the Tm 
observed in Fig 3.2. In contrast, the NTC (Fig 3.3a red points) had very few 
amplification events in that temperature range. Hence, we defined 88.5–90.3°C as a 
true positive (specific amplification) event. Partitions having a Tm outside this range 
were considered to be false positives (nonspecific amplification) events and these 
appeared in both the NTC and in the presence of template. When using Bst 3.0, we 
observed a large band of amplification from 91.25–92.75 °C in the presence of 
template (Fig 3.3B, blue points) that did not correspond with amplification in the 
NTC (Fig 3.3.3D, red points) and defined these as specific amplification events. As 
with bulk measurements, we attribute the difference in Tm between specific 
amplification events between Bst 2.0 and Bst 3.0 to the difference in Mg2+ 
concentrations.  
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Comparing the performance of the two enzymes, we observed two common 
themes. First, the Tm for specific amplification events was 2–3 °C lower in digital 
compared with bulk measurements. We attribute this difference to temperature 
calibration; the thermocycler is calibrated to the liquid temperature, whereas the 
thermoelectric element measures the temperature of the heating element.. Second, 
false positives in the NTC had predominantly high Tm, which we believe 
corresponds to the nonspecific product we identified in the bulk reactions. We also 
observed differences between the enzymes. Bst 3.0 resulted in substantially more 
nonspecific amplification than Bst 2.0. After 90 min, Bst 3.0 yielded 15,200 
nonspecific events (out of 54,337 observed paritions), whereas Bst 2.0 yielded 74 
nonspecific events (out of 51,279). Occasionally, outliers occurred in the NTC and 
would be misidentified as true positives by Tm. For Bst 3.0 this occurred in 29 
partitions; for Bst 2.0, it occurred in 3.  
Next, we asked whether TTP is different for specific and nonspecific amplification. 
Because LAMP follows a “winner-takes-all” format, frequent and early nonspecific 
amplification events may dominate bulk amplification. In general, for both Bst 2.0 
and Bst 3.0, specific amplification had earlier TTP than nonspecific amplification, 
although there was some overlap, mostly at >90.5 °C (Fig 3.3a-b). We were able to 
cleanly distinguish the clustering of high-Tm nonspecific products separately from 
specific amplification (Fig 3.3c). We illustrate each partition with only partial opacity 
so that when false positives in the NTC (red) overlap with false positives in the 
template-containing sample (blue), the overlap appears purple (Fig 3.3d). Color 
intensity indicates the abundance of paritions at a given TTP and temperature. To 
further illustrate how this approach can be used to differentiate specific and 
nonspecific amplification, we next selected a region where both specific and 
nonspecific products were observed. For Bst 3.0, we were able to distinguish the 
clustering of nonspecific products separately from specific amplification at high Tm 
(Fig 3.3e) and we observed better separation of specific and nonspecific amplification 
than with Bst 2.0 (Fig 3.3f). Both enzymes had highly variable TTP, which we have 
observed previously and attribute to stochastic initiation of LAMP.  Bst 2.0 had both 
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earlier specific amplification and later nonspecific amplification than Bst 3.0. After 
removing outliers, Bst 2.0 reactions containing template started at 10 min, whereas 
nonspecific amplification began at ~40 min. In contrast, Bst 3.0 reactions containing 
template began at 11.5 min and nonspecific amplification began at ~20 min.  
Next we asked whether there is a difference between the maximum rates of specific 
and nonspecific amplification. Previously, we demonstrated that rate could be used 
to correct for some nonspecific amplification using E. coli 23S primers, so we wished 
to test whether we could use maximum rate as a way to differentiate specific and 
nonspecific amplification. Generally, specific and nonspecific amplification 
reactions did not have the same maximum rate. For Bst 2.0, nonspecific amplification 
tended to have a slower max rate than specific amplification, although there was some 
overlap (Fig 3.3g). At high Tm, the clustering of nonspecific amplification in both 
the presence of template and in the NTC were observed at > 90.5 °C and below 
approximately 50 RFU/30 sec (Fig 3.3H). For Bst 3.0, although there was substantial 
overlap, we again observed that nonspecific amplification tended to have slower 
maximum rate than specific amplification (Fig 3.3I).  Examining the high Tm 
amplification events, nonspecific amplification collects above 92.75 °C and has 
maximum rate extending out to 75 RFU/30 sec (Fig 3.3J). For both enzymes, overlap 
between specific and nonspecific amplification was similar and specific 
amplification tended to be faster. However, the maximum rate of specific 
amplification between the two enzymes differed; Bst 2.0 had a maxium rate of 150 
RFU/30 sec, whereas Bst 3.0 did not exceed 100 RFU/30 sec. Bst 2.0 performing 
faster than Bst 3.0 is consistent with our previous observations using an E Coli 23S 
primer set. Additionally, the maximum rate of non-specific amplification in Bst 2.0 
tended to be lower than nonspecific amplification in Bst 3.0 (50 and 75 RFU/30 sec, 
respectively). Consequently, the extent of overlap of specific and nonspecific 
amplification was greater for Bst 3.0 than Bst 2.0. 
During these experiments, we observed an unexpected relationship between the final 
intensity of each partition and the maximum rate of that partition. After 90 min of 
amplification, a partition should theoretically reach a fluorescence maxima whereby 
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all reagents are consumed and amplification plateaus and thus the final intensity 
would be independent of the maximum rate of amplification. However, surprisingly, 
we observed a general scaling between the maximum rate and the final intensity of 
the partition. False positives were generally dimmer and had slower maximum rates 
than most true-positive events. When examining the brightest partitions, Bst 2.0 (Fig 
3.3K) and Bst 3.0 (Fig 3.3L) exhibit a similar maximal final intensity near 3000 RFU. 
This maxima is also surprising, considering our 12-bit camera is capable of imaging 
up to 4096 RFU (the detector was not at saturation). We suspect that this maxima 
corresponds to consumption of one of the reagents. When contrasting the enzymes, 
as mentioned previously, their maximum rates differ. Further, the large increase in 
non-specific amplification for Bst 3.0, results in an increase the overlap between false 
and true positive amplification, not observed in Bst 2.0.  
We also observed a relationship between maximum rate and TTP in dLAMP. In bulk 
reactions, the first and fastest amplification event determines the reaction outcome 
by consuming all of the reagents. Thus, we hypothesized that reaction conditions that 
promote fast and early amplification in the NTC would lead to a high false-positive 
rate in bulk. In both Bst 2.0 (Fig 3.3m) and Bst 3.0 (Fig 3.3n) we observed a general 
trend of fast amplification events occurring earlier, and slow events occurring later. 
In Bst 2.0, we observed more heterogeneity in TTP and rate than in Bst 3.0. 
Additionally, nonspecific amplicons in the NTC tended to produce slower and later 
amplification events. Occasional outliers occurred at both fast and early times. 
Next, to explicitly test whether fast and early events correspond to specific 
amplification, as determined using Tm, we analyzed the relationship between a 
partition’s TTP and its maximum rate. In the first 12 min of amplification, we 
observed six nonspecific amplification events in Bst 2.0 (four in the presence of 
template; two in the NTC; Fig 3.3o), and we observed 13 nonspecific events in Bst 
3.0 (10 in the presence of template; three in the NTC; Fig 3.3p).  For both enzymes, 
we were able to distinguish the rare, fast and early nonspecific amplicons from true 
positives. For Bst 2.0, these nonspecific amplifications were slower than the fastest 
true positives, and occurred at similar times. In contrast, for Bst 3.0, the earliest 
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amplification events were false positives and tended to have similar rates to the 
true positives. We hypothesize that in bulk reactions, the fast and early nonspecific 
amplification events (as seen in Bst 3.0) lead to nonspecific measurements, whereas 
nonspecific amplification that coincides with specific amplification, but proceeds at 
a slower rate (as seen in Bst 2.0), would still produce specific amplification in bulk.  
A complex interplay exists between of TTP, Max Rate, Final Intensity, and melting 
temperature. All previous plots are merely projections of the four dimensional 
representations of these interactions. We visualize how the data are related/coupled 
across four dimensions and examine the interaction for both Bst 2.0 and Bst 3.0 
enzymes (Fig 3.3q-r). We observe clear similarities between Bst 2.0 and Bst 3.0. For 
example, all partitions, specific and non-specific alike, earlier and faster 
amplification tends to be brighter. Additionally, we observe two types of non-specific 
amplification. First, the traditional “primer-dimer” cloud composed of a low Tm, low 
final intensity, low max rate and generally late TTP. The second type of non-specific 
cloud matches only in its High Tm, and spans a variety of rates, TTP, and final 
intensities. The high Tm non-specific occurs with greater frequency than the low Tm 
non-specific. The major differences between the enzymes can also be resolved with 
this visualization. The shear number of non-specific amplification events is much 
fewer for Bst 2.0 than for Bst 3.0. Further, these non-specific events in Bst 2.0 never 
achieve same fluorescene intensity or maximum rate as with Bst 3.0. We include the 
4D representation as part of our MATLAB code, and as videos in the SI. 
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Figure 3.3: Properties of specific and non-specific amplification using real time 
kinetics and melting temperature. True positives can be sorted unequivically using 
melting temperature (approximaly 90°C using Bst 2.0 and 92°C using Bst 3.0) Blue 
amplification events in the presence of template, Red amplification in the absence of 
template. Partitions in panels a,c,d,g,h,k,n using Bst 2.0 are rendered at 20% opacity 
in the NTC and 20% opacity in the presence of template. Panels b,e,f,I,j,n using Bst 
3.0 are rendered at 5% opacity in the NTC and 20% opacitity in the presence of 
template.  
a) Plot of the melting temperature of individual amplification events as a function of 
TTP using Bst 2.0.  
b) Plot of the melting temperature of individual amplification events as a function of 
TTP using Bst 3.0.  
c) Plot of individual partitions with melting temperature between 88 and 95°C as a 
function of TTP using Bst 2.0. 
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d) Plot of individual partitions with melting temperature between 88 and 95°C and 
TTP between 60 and 70 min using Bst 2.0. 
e) Plot of individual partitions with melting temperature between 91 and 95°C as a 
function of TTP using Bst 3.0. 
f) Plot of individual partitions with melting temperature between 91 and 95°C and 
TTP between 35 and 45 min using Bst 3.0. 
g) Plot of the melting temperature of individual amplification events as a function of 
maximum rate using Bst 2.0. 
h) Plot of the melting temperature of individual amplification events between 88 and 
95°C as a function of maximum rate using Bst 2.0. 
i) Plot of the melting temperature of individual amplification events as a function of 
maximum rate using Bst 3.0. 
j) Plot of the melting temperature of individual amplification events between 88 and 
95°C as a function of maximum rate using Bst 3.0. 
k) Plot of the final intensity of individual amplification events as a function of 
maximum rate using Bst 2.0. Partitions with final intensity less than 250 RFU (dotted 
line) were excluded from analysis.  
l) Plot of the final intensity of individual amplification events as a function of 
maximum rate using Bst 3.0. Partitions with final intensity less than 250 RFU (dotted 
line) were excluded from analysis. 
m) Plot of the maximum rate of individual amplification events as a function of TTP 
using Bst 2.0. 
n) Plot of the maximum rate of individual amplification events as a function of TTP 
using Bst 3.0. 
o) Plot of maximum rate from false positive amplifications in NTC (red), false 
positives amplifications in the presence of template (blue) and true positive 
amplifications by Tm (black) using Bst 2.0 as a function of TTP. 
p) Plot of maximum rate from false positive amplifications in NTC (red), false 
positives amplifications in the presence of template (blue) and true positive 
amplifications by Tm (black) using Bst 3.0 as a function of TTP. 
q) Plot comparing maximum rate, melting temperature, TTP, and final intensity of 
individual partitions using Bst 2.0.  
r) Plot comparing maximum rate, melting temperature, TTP, and final intensity of 
individual partitions using Bst 3.0. 
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Reaction classification informs choice of optimal parameters for assay 
performance  
We next asked whether using a combination of digital real-time parameters, in 
conjunction with Tm, could be used to improve the performance (LOD) of a dLAMP 
assay. For any given assay, there is a large combination of possible parameter (e.g. 
amplification rate, TTP, fluorescence intensity). Use of these parameters and 
selection of a threshold will dictate assay performance (analytical specificity and 
sensitivity). Assay performance depends on amplification time and the combination 
of choices of parameters used to process the data impacting LOD, the probability of 
detecting a molecule (efficiency), and the CLINICAL sensitivity/specificity. Because 
of the direct relationship between melting temperature, sequence identity, and 
structure, melting temperature provides new and useful information for dLAMP to 
explicitly differentiate specific and non-specific amplification, and thus, true from 
false positive.  
We foresee two separate situations of dLAMP analysis using melting temperature. 
First, where melting temperature is not incorporated in the final assay, but is used 
during assay development. Second, the ideal situation for quantitative performance, 
where melting temperature is incorporated into the final assay. We expect the first 
group of assays to exist because collecting melting temperature data adds additional 
time to an assay and requires more advanced hardware to run. This may be unideal 
in situations requiring more rapid diagnostics or LRS/field settings where the 
hardware may be impractical. Nonetheless, melting temperature is still useful during 
assay development to select the optimal combination of parameters for end point or 
real time digital without using Tm. This method allows one to identify the correct 
combination of assay parameters, and how to analyze the data for best LOD. 
In many tests, LOD is the key parameter for clinical utility because for many 
infectious diseases the pathogen load in the sample is low (e.g. blood infections or 
asymptomatic sexually transmitted infections). We illustrate the optimization of 
parameters using improved LOD as the selection criteria. The combination of real 
time dLAMP with melting temperature can uniquely define LOD (because of the 
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combination of digital and Tm). Unlike bulk assays which require a concentration 
titration curve (and are thus dependent on integrated signal intensity and enzymatic 
turnover), digital assays only require that an event (target molecule) is or is not 
observed, and can be counted relative to the partition volume.  The minimum LOD 
for any digital assay corresponds to one target or amplification event per partition 
volume. Hence, we can define LOD from a single concentration point by: 
𝐿𝑂𝐷 =
𝐶𝑇𝑟𝑢𝑒
[𝑁𝑇𝑟𝑢𝑒 − (𝑁𝐹𝑎𝑙𝑠𝑒 + 3 × √𝑁𝐹𝑎𝑙𝑠𝑒)]/𝑁𝐸𝑀𝐶𝐼
 
Where CTrue
 is the concentration of target molecules loaded by ddPCR counts in 
copies per microliter, NTrue is the number of True Positive (specific) amplification 
events observed on a chip, and NFalse is the number of non-specific amplification 
events observed on a chip. Note that in this equation, the NTrue and NFalse are chip-
specific, and take into account the total volume of the chip, the number of partitions, 
and the volume of partitions.  Furthermore, in this equation, amplification efficiency 
is implicitly taken into account via the NTrue parameter (in other words, for a less 
efficient amplification process, a given CTrue on a given chip would lead to a lower 
value of NTrue). Finally, for simplicity, this equation makes the assumption that the 
measurements are performed at sufficiently low concentrations (as is typical for LOD 
experiments) that only a very small fraction of occupied partitions contain more than 
1 molecule and therefore there is a linear relationship between CTrue and NTrue.   
The concentration loaded, CTrue, generates N total counts of both true and false 
positive events. We can divide this concentration by the minimal number of counts 
needed to identify a specific amplification event and define this as the LOD.  
Using the Poisson equation, one can estimate the desired expected number of 
molecules that will yield at least 1 detection event/observation for a given CI.  We 
refer to this parameter as NEMCI (number of expected molecules for a confidence 
interval).  If we assume a 95% CI of observe a true positive across an entire chip, the 
minimum number is of counted events is three. (5% of the time, the expected Poisson 
loading of 3 target molecules will still measure zero events.) For a 95% confidence 
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interval, this is three molecules. For a 98% confidence interval, this value would 
be 4 counts. Hence, all true positive counts in excess of this value may be used to 
reduce the observed counts to the LOD. For example, if a concentration of 30 cp/µL 
observes 90 counts, there are 90/3 =30 fold excess counts and the LOD may be 
inferred to be 30 cp/µL lodaded/30 fold excess = 1 cp/µL.  
However, counting only true positives does not account for interference from false 
positives. In order to meet our minimum counts for detection, our equation must 
remove those counts which are false. Generally accepted procedure is to assume the 
counts arising from the background plus three standard deviations of the background. 
We approximate the variance in the background using the counting error as three 
times the square root of the number of false positive events counted and subtract 
those counts from the true positive counts to yield the equation.  
This definition of LOD has several limitations. First, this equation fails when number 
of true positive partitions amplifying (NTrue) is less than the number of false positive 
amplification events plus three times the variation in false amplification (𝑁𝐹𝑎𝑙𝑠𝑒 +
3 × √𝑁𝐹𝑎𝑙𝑠𝑒). In this case, it is not possible to conclusively observe a true positive 
amplification event, and the LOD becomes irrelevant. Second, this equation gives an 
absolute LOD. The numerator (concentration of template molecules loaded on the 
chip by PCR) is corrected for the probability of observing a molecule amplify 
(efficiency) by the True Positive counts. NFalse
 accounts for the non-specific 
amplification, and NEMCI accounts for the Poisson probability associated with 
loading a target molecule. Third, this equation is be specific to digital assays. We 
remain optimistic that digital LOD will project to bulk optimal sensitivity and 
specificity.   
We first sought to demonstrate the selection of optimal parameters for situations 
where Tm is not incorporated into the final assay. Using this process, one can pick 
any threshold and use Tm to determine the optimal trade off between true and false 
positives.  
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We first sought to determine the optimal threshold for Max Rate and Fluorescence 
Intensity using Bst 3.0. In some cases, one parameter may be more important or more 
accurate for optimizing LOD, in other cases a different parameter may exhibit better 
utility. We demonstrate optimization of all three parameters, using Tm as the arbiter, 
to illustrate the utility of our method. 
Receiver Operating Characteristic (ROC) curves more commonly used with clinical 
sensitivity and specificity, can be used to examine the analytical classification 
performance of a given parameter used for thresholding. These graphs provide a 
visual representation of the ability to distinguish between a true positive and false 
positive event, as a function of a given threshold. The graphs plot the true positive 
fraction against the false positive fraction, where the True Positive Fraction is the 
number of true positives at a given threshold out of the total number of true positives 
observed by Tm; and the False Positive Fraction is the number of false positives 
counted at the given threshold, divided by the total number of false positives observed 
by Tm. It is generally presented that a perfect classifying test will have the largest 
True Positive Fraction and smallest False Positive Fraction.  
Does the ROC curve clearly indicate the best choice for LOD? ROC curve illustrate 
tradeoffs between the fraction of true positives detected and the fraction of false 
positives detected, which are reflections of the analytical specificity and analytical 
sensitivity, but can be difficult to use for optimal selection of LOD. When plotting 
the ROC curve for Maximum Rate (Fig 3.4a), we observe that rate initially performs 
very well for eliminating false positives (False Positive Fraction is very small for 
very high rates). However, as the rate threshold decreases, a greater number of both 
false and true positive values are counted. Closer examination of this range of 
thresholds (Fig 3.4b) emphasizes the Youden Index at 34.6 True Positive Fraction 
and 4.6 False Positive Fraction as a possible choice for optimum threshold, though 
the clarity of performance is unclear.  The choice for optimal threshold is even less 
clear with the ROC curve for Final Intensity (Fig 3.4c). In this case, the ROC curves 
do not give clear indication of the optimal LOD as the curve is a gentle concave slope. 
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Even relatively high fluorescence thresholds do not give indications of the optimal 
Cut-Point (Fig 3.4d).  
In contrast, filtering using LOD reveals a clear optimum. We plot the total number 
of events for both true and false positives and LOD as a function of Maximum Rate 
(Fig 3.4e). In this scenario, the LOD curve reveals a clear minima, corresponding to 
the optimal cut-point using rate. Selecting the threshold of 49.8 RFU/30 seconds 
generates a LOD of 2.11 cp/µL. Similarly, plotting LOD against Final Intensity 
results in a clear minima, despite the cut point in histogram remaining unclear (Fig 
3.4f). Using Final Intensity a LOD of 2.14 cp/µL can be achieved at 1393 RFU.   
We next sought to determine the optimal threshold using TTP and Bst 3.0.  In this 
situation, the ROC curve presents a narrow range of choices around 50% True 
Positive Fraction and 2 % False Positive Fraction as optimum, though the precise 
choice is not obvious (Fig 3.4g). To optimize, we plot the LOD and the cumulative 
counts as a function of Time in both a linear (Fig 3.4h) and logarithmic scale (Fig 
3.4i). 
Assays employing Tm only during assay development can improve LOD by selecting 
(making an informed choice of) the optimum threshold. The LOD equation illustrates 
the optimum filter threshold. The LOD decreases (Blue Curve) as the true positives 
begin to amplify (Red Dashed). LOD begins to increase, as the false positives amplify 
(Blue dashed). The minima for this system occurs at 35 minutes and 0.89 cp/µL, 
striking a balance between allowing many true positives to amplify, and only a small 
amount of false positives to occur (54.5% True Positive Fraction and 1.7 False 
Positive Fraction) and is clearly defined using the linear scale (Fig 3.4h). Plotting of 
LOD on the logarithmic scale (Fig 3.4i) emphasizes improperly selecting a threshold 
can result in several orders of magnitude loss in assay performance (for example, 
stopping the assay too early or allowing the assay to run for too long). Though 
dLAMP is robust to perturbations, precision should still be employed.   
In contrast, assays using Tm as part of the final readout can distinguish false positives 
from the true positives and improve LOD further by removing/ignoring non-specific 
amplification term.  In some instances, a NTC may incorrectly identify partitions as 
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true positives by Tm (black dashed). We incorporate these events as non-specific 
amplification in the case Tm is used in the final readout. If non-specific amplification 
is eliminated, the assay LOD (Fig 3.4h,i, Black solid) continues to improve with time, 
and is only dependent on the stochastic probability that a true positive will initiate 
and amplify. In this scenario, there is no penalty allowing the assay to amplify for 
extended periods of time.  
Additionally, there is no limitation on the number of or which combination of 
parameters are used to select for optimal LOD. Using multiple parameters to filter 
the data may be useful for individuals not employing Tm in the final assay or in 
assays only employing endpoint measurement (No real time means rate cannot be 
measured. E.g. pick best time, pick best fluorescence). For example, we can filter 
first by optimal TTP, then filtering for the optima of a second parameter. In this case, 
we select the optimal TTP of 35 minutes, and scan for optimal fluorescence threshold. 
We plot LOD as a function of fluorescence threshold and determine that the optimal 
fluorescence threshold at 35 minutes would be 248 RFU and corresponding to a LOD 
of 0.972 cp/µL (Fig 3.4j).   
Do filter parameters exhibit the same LOD minima when using Bst 2.0, as they did 
for Bst 3.0? Bst 2.0 had much lower non-specific background than Bst 3.0, and could 
behave similarly or may behave differently.  
First, does the ROC curve for TTP display a clear optimum? Similar to the TTP ROC 
for Bst 3.0 (Fig 3.4g), the TTP ROC for Bst 2.0 has a gentle slope making choice of 
the optimum a matter of computation (Fig 3.4k). We can visually estimate the balance 
of True and False Positive Fraction in the range of 50% True and 10% False. Similar 
curves for Max Rate and Final Intensity could be generated but are not shown here. 
Second, Is there an advantage to using Tm in the final assay with Bst 2.0? To answer 
this question, we plot LOD and the cumulative counts of true and false positives as a 
function of time for Bst 2.0 (Fig 3.4L). Similarly to Bst 3.0, we observe LOD decrease 
rapidly as True Positive events are counted. However, unlike Bst 3.0, the non-specific 
amplification events are much fewer and their presence does not have an impact on 
LOD. Thus, when using Bst 2.0, the curves representing LOD with or without Tm in 
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the final assay overlay and indicate using Tm in the final assay has no additional 
benefit. Furthermore, the continuously decreasing LOD with time for either case 
indicates that use of ROC curves to determine an optimum can be misleading. While 
the ROC implies that an optimum exists, the false positive incidence is rare enough 
that a TTP optimum selected by LOD does not exist. Assay developers may select 
assay time based on requirements other than LOD.  
We next ask how does the performance of Bst 2.0 and Bst 3.0 compare with and 
without Tm? (Fig 3.4M) For both enzymes we observed a similar, rapid decrease in 
LOD in the initial moments as true positive events are detected. However, we also 
noticed several differences. Bst 2.0 has a lower LOD than Bst3 at any amplification 
time. We attribute this difference to the higher incidence of false positives when using 
Bst 3.0 compared to Bst 2.0. An additional consequence of the low false positive 
incidence using Bst 2.0, regardless of the use of Tm in the assay, is the LOD continues 
to improve with time as additional true positives are counted. In contrast, Bst 3.0 
benefits greatly from use of Tm in the final assay. If Tm is not included in the assay 
(Fig 3.4M, red dashed), a clear optimum for LOD occurs at 35 minutes and 0.89 
cp/µL at 35 min. However, if Tm is employed in the assay, the LOD more closely 
resembles the LOD curve for Bst 2.0 and improves with increased detection of true 
positive events.   
We made several overarching conclusions regarding improving the LOD of dLAMP 
using a combination of digital real time parameters and melting temperature. First, 
filter paramters can be used singly or in combination to improve the performance 
(LOD) of dLAMP. In certain assays one parameter may perform better than another 
for this selection. For this primer set, LOD for Bst 3.0 was lower when using Time 
to Positive (0.89 cp/µL) than Max Rate (2.11 cp/µL) or Final Intensity (2.14 cp/µL). 
Second, incorporation of melting temperature into the final assay readout will benefit 
some assays more than others. We observed incorporation of melting temperature as 
a filter/part of the final assay improved the perofmance of Bst 3.0 greater than the 
performance of Bst 2.0. This was especially true for long assay times.   
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Figure 3.4: Classification of amplification reactions using Tm to determine 
optimal performance of dLAMP assays.  
a) ROC curve using Bst 3.0, plotting the fraction of true positives detected versus the 
fraction of false positives detected using a threshold on Maximum Rate. 
b) ROC curve using Bst 3.0, plotting the fraction of true positives detected less than 
40% versus the fraction of false positives detected less than 20% using a threshold 
on Maximum Rate. Arrow indicates corresponding LOD. 
c) ROC curve using Bst 3.0, plotting the fraction of true positives detected versus the 
fraction of false positives detected using a threshold on Final Intensity of the 
partition. 
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d) ROC curve using Bst 3.0, plotting the fraction of true positives detected less 
than 10% versus the fraction of false positives detected less than 10% using a 
threshold on Final Intensity of the partition. Arrows indicate Final Intensity 
thresholds of >2000 RFU and >1300 RFU.  
e) Histogram of the False Positives identified by Tm within the presence of template 
(Red), true positives by Tm (blue), and false positives in the NTC (green), binned by 
Maximum Rate of the partition and a LOD curve plotted as a function of Max Rate 
using Bst 3.0.  
f) Histogram of the False Positives identified by Tm within the presence of template 
(Red), true positives by Tm (blue), and false positives in the NTC (green), binned by 
Final Intensity of the partition and a LOD curve plotted as a function of Final 
Intensity using Bst 3.0. 
g) ROC curve using Bst 3.0, plotting the fraction of true positives detected versus the 
fraction of false positives detected using a threshold on TTP. Arrow indicates LOD.  
h) LOD Curves as a function of time without using Tm in the final assay (blue) and 
using Tm in the final device (Black). Plots of cumulative counts of true positive 
amplification (Red dashed), False positive counts (blue dashed), and incorrectly 
identified partitions (black dashed). 
i) Logarithmic plot of LOD Curves as a function of time without using Tm in the 
final assay (blue) and using Tm in the final device (Black). Plots of cumulative counts 
of true positive amplification (Red dashed), False positive counts (blue dashed), and 
incorrectly identified partitions (black dashed). 
j) LOD plotted as a function of Fluorescence Intensity, when the assay is measured 
at the optimal TTP of 35 minutes.  
k) ROC curve using Bst 2.0, plotting the fraction of true positives detected versus the 
fraction of false positives detected using a threshold on TTP. 
l) Logarithmic plot of LOD curves, using Bst 2.0, as a function of time without using 
Tm in the final assay (blue) and using Tm in the final device (Black). The blue and 
black plots overlay. Plots of cumulative counts of true positive amplification (blue 
dashed), False positive counts (red dashed), and incorrectly identified partitions 
(black dashed). 
m) Plot of LOD curves as a function of time comparing Bst 2.0 (Solid Blue with Tm, 
Dotted Blue without Tm) and Bst 3.0 (Solid Red with Tm, Dotted Red without Tm). 
Curves for Bst 2.0 overlap.    
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Classification demonstrates host genomic DNA does not alter non-specific 
background in dLAMP 
LAMP assays with high clinical sensitivity and specificity are critically needed. 
Clinical samples of CT, originating from urine and swabs, pose an intrinsic challenge 
because they contain variable levels of host DNA (and DNA from other flora) [0 to 
100 HHGE/µL or 0 to 3.3E-7 mg/µL]. The analysis of these clinical samples, needs 
not only to be sensitive (good LOD), but also able to function in the presence of non-
specific, potentially amplifiable genomic secondary structures and other possible 
environmental contaminants, while remaining consistent between samples.  
We sought to investigate the impact of host gDNA on non-specific background 
amplification. We hypothesized that non-specific structures (like hairpins and 
regulatory elements), may amplify in the presence of LAMP and contribute to non-
specific background amplification. We titrated sheared buffy coat gDNA 
concentrations in 100 fold intervals from a low clinical concentration to a high 
clinical concentration and observed the impact on specific and non-specific 
amplification of CT (Fig 3.5). We measured the concentration of gDNA in Human 
Haploid Genome Equivalents (HHGE) or half the total amount of gDNA in a diploid 
cell. For each concentration of host DNA and enzyme, we ran three chips in the 
presence of CT template and three in the absence of template. In total, we observed 
862,059 different partitions.  At the highest concentration of gDNA, there was 60,600 
times more gDNA than bacterial DNA by mass.  
We first asked qualitatively how background DNA impacted TTP. We observed for 
both Bst 2.0 and Bst 3.0 enzymes, specific and non-specific amplification were 
qualitative similar independent of background DNA concentration. As with previous 
measurements, Bst 2.0 rarely produced low Tm, non-specific events; while Bst 3.0 
produced both high and low Tm non-specific amplification. Further, both high 
melting temperature and low melting temperature non-specific amplification events 
were greater for Bst 3.0 than Bst 2.0. Increasing the concentrations of gDNA 
qualitatively appear similar. The Tm of specific amplification remains constant, 
while quantities of non-specific high and low Tm are similar.  
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Figure 3.5: Impacts of host gDNA on specific and non-specific amplification. 
Plots of melting temperature as a function TTP using Bst 2.0 at (a) 0 HHGE per µL, 
(b) 0.01 HHGE per µL, c) 1 HHGE per µL and d) 100 HHGE per µL and using Bst 
3.0 at (e) 0 HHGE per µL, (g) 0.01 HHGE per µL, h) 1 HHGE per µL and i) 100 
HHGE per µL in the presence of template (blue) and NTC (red).  
 
 
We next asked quantitatively how background gDNA impacts specific and non-
specific amplification?  We categorized amplification events as specific and non-
specific based on melting temperature as previously.  
First, we asked is there a relationship between fraction of template molecules 
amplified and amplification time? We determine the total number of template copies 
loaded into a chip relative to the copies measured by ddPCR. If amplification 
initiation is stochastic, as observed in Fig2f and 3ab, does longer assay time increase 
‘efficiency’ and thereby improve LOD (as seen in Fig 3.4h,l)? We observe that for 
Bst 2.0 a large number of partitions amplify in the first 10 min, followed by a second 
phase near 20 min where additional partitions amplify with lower frequency (Fig6a). 
For Bst 3.0 (Fig7a), we observe a similar trend temporally, though Bst 3.0 
consistently had few copies detected than Bst 2.0 in all phases. This highlights the 
stochastic nature of amplification using LAMP, and importance in choice of enzyme 
on sensitivity. In theory, assays could be run until all partitions amplify as either a 
false or true positive. This would give the highest possible number of copies 
amplified and lowest possible LOD when using Tm in the final assay.  
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Second, we asked what is the impact of gDNA on efficiency as a function of time? 
For both Bst 2.0 and 3.0 (Fig6a,7a), we observed that the fraction of copies detected, 
and the moment the majority of reactions initiate, were indistinguishable regardless 
of concentration of gDNA.   
Third, we asked what is the impact of gDNA and time on non-specific amplification? 
For Bst 2.0, we observed consistent non-specific amplification at high and low Tm, 
regardless of concentration of gDNA. Single digital partition counts were observed 
at low Tm non-specific amplification in both the presence of template and the NTC 
and independent of gDNA concentration (Fig 6b,c). The fraction of wells generating 
a false positive amplification at low Tm was less infrequent through 40 minutes. For 
high Tm non-specific amplification, partition counts are in the single digits until 
around 45 minutes. After 90 minutes, the reaction finishes around 200 counts in 
20,000 partitions corresponding to a false positive fraction of 5E-4. One exception is 
the non-specific high Tm amplification in the absence template and HHGE. This 
condition appears to have lower non-specific background than other conditions. We 
collected each replicate on separate days and catch the experimental variability 
between the presence and absence of template, which might be otherwise lost when 
using a NTC alone. This experiment emphasizes the advantage of determining non-
specific amplification using Tm from the same experiment as specific amplification 
is counted. At low background rates, such as when using Bst 2.0, inherent variability 
exists in the false positive fraction and can impact LOD. Measuring non-specific 
amplification from within an experimental measurement eliminates the assumption 
that the false positive rate remains identical to the NTC or between experimental runs.   
For Bst 3.0, all concentrations of gDNA gave indistinguishable differences in non-
specific amplification. At any given time, high Tm non-specific amplification was 5-
10x more likely to occur than a low Tm non-specific product. At 40 minutes, low Tm 
non-specific amplification had a false positive fraction of 5E-4. At the completion of 
the experiment the majority of partitions have amplified; thus, indicating high rate of 
non-specific amplification with Bst 3.0 may actually suppress efficiency as you 
eventually runout of partitions.  
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For this CT primer set, both Bst 2.0 and Bst 3.0 similarly demonstrate that the 
presence or absence of template does not impact the probability of non-specific 
amplification. Furthermore, the presence of gDNA does not impact the likelihood of 
non-specific amplification occurring. In general, for this primer set and target, we 
find that Bst 2.0 performs significantly better than Bst 3.0 as a consequence of having 
higher probability of detecting a target molecule and low likelihood of generating a 
non-specific amplification event.  
Fourth, we asked is maximum rate impacted by the concentration of gDNA? We 
hypothesize that background gDNA may compete for the binding site of the 
polymerase with the target DNA or generate competing amplification events and 
thus, decrease the maximum observed velocity in a given partition. This phenomena 
would be challenging to untangle in bulk. We find that maximum rates are similar 
for a given enzyme, regardless of gDNA concentration (not shown). In general, and 
echoing the conclusions of Fig 3.3g,i, we observe that Bst 2.0 is faster than Bst 3.0, 
regardless of the gDNA concentration.  
Cumulatively, these data show background DNA neither alters the probability of 
detecting a specific molecule (analytical sensitivity), nor the false positive fraction 
(analytical specificity), nor the maximum rate of amplification. Thus, we conclude 
background gDNA does not impact LAMP for this primer set. Furthermore, these 
experiments underscore the value of quantifying non-specific amplification 
variability, using Tm, from within the same experiment as a target is quantified, 
means you don’t have to assume the false positive rate remains identical to the NTC 
or between experimental runs.    
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Figure 3.6: Quantification of the impact of gDNA on specific and non-specific 
amplification using Bst 2.0. Sampled temporally at 10,15,20, 35, 45, 60, 75, and 90 
minutes. Plot of the % copies detected (specific amplification) as a function of time. 
A) Plot of the fraction of wells with non-specific amplification with Tm less than the 
specific amplification in the NTC as a function of time. B) Plot of the fraction of 
wells with non-specific amplification with Tm less than the specific amplification in 
the presence of template as a function of time. C)Plot of the fraction of wells with 
non-specific amplification with Tm greater than the specific amplification in the NTC 
as a function of time. D) Plot of the fraction of wells with non-specific amplification 
with Tm greater than the specific amplification in the presence of template as a 
function of time. 
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Figure 3.7: Quantification of the impact of gDNA on specific and non-specific 
amplification using Bst 3.0. A) Plot of the % copies detected (specific amplification) 
as a function of time. B)Plot of the fraction of wells with non-specific amplification 
with Tm less than the specific amplification in the NTC as a function of time. C)Plot 
of the fraction of wells with non-specific amplification with Tm less than the specific 
amplification in the presence of template as a function of time. D) Plot of the fraction 
of wells with non-specific amplification with Tm greater than the specific 
amplification in the NTC as a function of time.  E) Plot of the fraction of wells with 
non-specific amplification with Tm greater than the specific amplification in the 
presence of template as a function of time. 
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CONCLUSIONS 
 
We predict that the combination of Tm to real-time dLAMP will be invaluable for 
answering many questions across a wide variety of applications, and thus our 
approach was designed to be accessible to most standard labs. We employed 
commercial chips for digitization, a commercial thermoelectric unit for heating and 
cooling, a commercial microscope for optical analyses, and we made our data-
processing script freely available. Our intention was to design an accessible system 
with readily available components to enable others to access the advantages of digital 
microfluidics and study and optimize primer sets, enzymes, and reaction conditions 
of levels of interest to them.  We predict these capabilities will be particularly 
valuable for people working with high background DNA, poorly performing primer 
sets, or poorly performing enzymes. 
We derived four major lessons from this study. First, LAMP can produce nonspecific 
amplicons with high Tm. The formation of these nonspecific amplicons is likely a 
result of the interaction of multiple primers. Primer design therefore should be 
judicious to prevent nonspecific amplification. In addition, incidence of nonspecific 
amplification differed between enzymes; nonspecific amplification occurred with 
greater frequency in Bst 3.0 than Bst 2.0. Digital enabled identification of both high-
Tm and low-Tm amplicons, which are not observable in bulk. Others have called 
these amplicons spurious or suggested the presence of primer dimers. Spurious 
amplification can also lead to full false positives: we identified these as primer-dimer 
related. 
Second, melting temperature in dLAMP is a useful method for differentiating 
specific and nonspecific amplification events. Digital experiments measure the 
fate/rate of each template, in contrast to bulk experiments that only measure early 
amplification events. Tm allows us to look at many amplification events and 
determine the nature of that amplification with high statistical probability. 
Combining these approaches, we can measure nonspecific amplification 
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experimentally, eliminating assumptions about the incidence of false positives in 
the NTC or between experimental runs. 
Third, by differentiating specific and nonspecific amplification, Tm is helpful in 
determining the combination of assay parameters that will lead to the lowest LOD in 
a digital assay.  When Tm is incorporated into a dLAMP assay, true and false positive 
amplification events can easily be separated. LOD is lowered further by elimination 
of nonspecific background and thus becomes dependent on the number of molecules 
that amplify (i.e., efficiency or % copies detected), without dependence on the 
incidence of false positives. In contrast, if Tm were employed in a bulk reaction, the 
LOD would still be limited by competition (what amplifies first) and would require 
a high number of trials to achieve sufficient statistical power. Importantly, even when 
Tm will not be used in the final assay, it can still be incorporated during the assay-
development stage to lower the assay’s LOD by determining the optimal choice of 
parameters based on rate, TTP, final intensity, or any combination of these 
parameters. 
Fourth, low-to-moderate levels of non-specific host gDNA do not impact the 
specificity or sensitivity of dLAMP. We ran our assays up to 100 HHGE per 
microliter and higher concentrations could be considered, which shows the clinical 
validity of this approach. 
Future efforts should investigate the combination of real-time dLAMP and Tm as a 
way to increase multiplexing of dLAMP when using a single reporter. In PCR, high-
resolution Tm has been used to differentiate among multiple amplification products 
by looking at differences in melting temperatures. Additionally, we see use of high-
resolution Tm for identifying specific products and mutations, such as in SNP 
detection.  
Real-time dLAMP with Tm will also enable the mechanistic optimization of primers. 
Because it reveals the incidence of nonspecific amplification at high and low Tm, 
dLAMP with Tm can also be used to investigate approaches that will eliminate 
different nonspecific products. Fast or early nonspecific events cannot be 
differentiated from specific events in experiments lacking Tm. Thus, dLAMP with 
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Tm can be used to design primers that will suppress non-specific amplification in 
bulk, by generating only nonspecific amplicons that occur at slow rates and late TTP.  
 
SUPPLEMENTAL  
 
 
Figure 3.S1 Statistical Analysis of possible outliers by Maximum Rate.  
A) We asked what caused one point (Green circle, max Rate 56 RFU) to separate 
from the majority of the data (20 to 35 RFU/30 sec), if these points were common, 
and if these points were likely to miss-represent the Max Rate data.   
B) Determined the individual trace corresponding to this amplification event. 
Observed that the maximum rate for this partition was at 52.5 minutes, corresponding 
to a fluctuation in the plateau phase of amplification (dotted line).  
C) We anticipated that the maximum rate should occur at the initial moment of 
amplification, often slightly before the TTP. To determine this, we determined the 
frame (2 per minute) where the trace reached the Fluorescence Time to Positive  of 
250 RFU. From this we subtracted the frame where Maximum Rate was calculated. 
Values greater than zero represent partitions where the maximum rate occurs before 
the TTP. Negative values occur when the Max rate occurs after the TTP. We draw a 
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vertical line separating partitions that occurring more than 15 minutes after the TTP 
(left), from all other partitions. For the case of Bst 2.0, we confirmed that the mode 
max rate occurs before the fluorescence time to positive of 250 RFU. 9099 total 
partitions measured, 821 (9.02%) were more than 15 minutes after the TTP. We 
expect these partitions to have max rate within the noise. Determined that the events 
of “late” maximum rate are rare. 
D) A similar trend was observed for Bst 3.0. 24466 positive partitions, 1113 (4.55%) 
were more than 15 minutes after TTP.  
E)We plot the Fractional cumulative distribution function of Max rate for all 
partitions (blue), and the same fractional CDF removing those points more than 15 
minutes after the Fluorescence Intensity based TTP (red). A non-parametric based 
Kolmogorov-Smirnov test indicated non-significance between the two CDFs 
(P=0.3255) 
F) We plot the Fractional cumulative distribution function of Max rate for all 
partitions (blue), and the same fractional CDF removing those points more than 15 
minutes after the Fluorescence Intensity based TTP (red).A non-parametric based 
Kolmogorov-Smirnov test indicated non-significance between the two CDFs 
(P=0.1236). This indicates that removing the partitions more than 15 minutes behind 
the TTP, does not significantly impact the overall distribution. That removing these 
points does not impact the distribution.    
I tallied up all the samples without HHGE, but containing template for Bst 2.0 and 
3.0. I ran a non-parametric test comparing the CDF of the Max Rate data with and 
without those data occurring more than 15 minutes after the TTP by fluorescence 
intensity ("Kolmogorov-Smirnov Test"). Data coming in this range could be noise in 
the plateau phase. Removing these data from the distributions did not impact the 
CDFs, and therefore does not significantly impact our data reported (previously). 
There is not statistical justification to reprocess the data or assume the max rate data 
is unrepresentative of truth.  
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Figure 3.S2: Plots of Rate v Tm, rate, final intensity, for all concentrations of 
gDNA, using Bst 2.0. NTC (red), and presence of template (blue), specific 
amplification within the presence of template (green).  
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Figure 3.S2: Plots of Rate v Tm, rate, final intensity, for all concentrations of 
gDNA, using Bst 3.0. NTC (red), and presence of template (blue), specific 
amplification within the presence of template (green).  
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Chapter IV 
 
SURFACTANT-ENHANCED DNA ACCESSIBILITY TO NUCLEASE 
ACCELERATES PHENOTYPIC Β-LACTAM ANTIBIOTIC 
SUSCEPTIBILITY TESTING OF N. GONORRHOEAE1 
 
Abstract 
 
Rapid, phenotypic antimicrobial susceptibility testing (AST) for Neisseria gonorrhoeae 
(Ng) is critically needed to counter widespread antibiotic resistance. However, rapid 
phenotypic AST for Ng is challenged by the pathogen’s slow doubling time and the lack 
of methods to quickly quantify its response to β-lactams (the largest antibiotic class used 
to treat Ng). Here, we devise an innovative approach for performing a rapid phenotypic 
AST that measures DNA accessibility to exogenous nucleases after exposure to β-lactams. 
We show that DNA in antibiotic-susceptible cells has increased accessibility, and that a 
judiciously chosen surfactant enhanced this effect. We validated our method, termed nuc-
aAST (nuclease-accessibility AST) using penicillin, cefixime, and ceftriaxone and showed 
100% categorical agreement with gold-standard AST after just 15-30 min of antibiotic 
exposure. This proof-of-concept provides a pathway toward developing a critically needed 
phenotypic AST for Ng and these innovations can be leveraged to develop ASTs for 
additional global-health threats. 
 
INTRODUCTION 
 
Gonorrhea, caused by Neisseria gonorrhoeae (Ng), is the second most common notifiable 
sexually transmitted infection (STI) in the U.S.(1) and the third most common STI globally, 
affecting 78,000,000 people each year worldwide(2). Untreated Ng infections can lead to 
pelvic inflammatory disease, infertility, ectopic pregnancy, and neonatal blindness(3), and 
                                                 
1
This chapter was submitted for publication with authorship belonging to Nathan G. Schoepp, Emily S. 
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 76 
have a significant financial burden on healthcare systems(4). Antibiotic resistance in Ng 
emerged quickly and continues to spread unchecked because there is no rapid antibiotic 
susceptibility test (AST) to guide treatment. Lacking a rapid AST, clinicians are limited to 
making empiric prescriptions as recommended by the Centers for Disease Control and 
Prevention (CDC)(5) or World Health Organization (WHO)(6). When resistance to a 
particular ABX exceeds 5%, treatment guidelines are updated and the recommended 
treatment protocol is escalated to the next line of ABX(7, 8). As a result, Ng strains 
continue to evolve resistance, including to the last-line (dual treatment with 
azithromycin/ceftriaxone)(9-11). The global prevalence and spread of resistant Ng 
infections has led the CDC to place Ng in its highest (“urgent”) category of antimicrobial-
resistant pathogen threats(12) and the WHO to label Ng as a high-priority pathogen(13). 
Despite the threat of untreatable Ng(14) and an international call for rapid diagnostics(15-
17), no phenotypic AST currently exists that can be performed rapidly enough for the point 
of care (POC). 
 
Successful and timely treatment of Ng infections while providing antibiotic stewardship 
requires two sequential steps to be performed at the POC. First, an identification (ID) test 
is run on the patient’s sample (typically urine or swab) to confirm that the patient is infected 
with Ng. Then, an AST must be run on the sample to determine whether the infecting strain 
of Ng is susceptible to the available ABX, so that the correct treatment can be prescribed. 
Substantial efforts (both academic(18-20) and commercial(21, 22)) are making great 
progress toward shortening the time required to identify Ng infections. However, there is 
no published path toward development of a rapid phenotypic AST for Ng, especially for 
beta-lactam antibiotics. Thus, even with swift diagnosis of an Ng infection, prescription of 
the correct antibiotics at the POC will remain bottlenecked by the lack of a rapid AST.  
 
AST methods are either genotypic or phenotypic. Genotypic methods predict resistance by 
screening for the presence of known resistance genes, whereas phenotypic methods 
determine susceptibly and resistance by directly measuring an organism’s response to an 
antibiotic. Rapid genotypic methods exist for select antibiotic classes such as 
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quinolones(23, 24), but the diverse mechanisms of resistance present in Ng would require 
highly multiplexed assays for most other antibiotic classes(25, 26), including β-lactams(27, 
28), which are the largest class of ABX for Ng. For example, hundreds of β-lactamase 
genes are known(29), and new resistance genes continue to emerge, making it challenging 
to design a comprehensive genotypic AST, even for a single organism. Only phenotypic 
AST methods provide the ability to directly detect resistance, and susceptibility, regardless 
of the antibiotic’s mechanism of action. The current gold-standard AST for Ng is agar 
dilution, a phenotypic method that takes many days and is only performed in a small 
number of reference laboratories(30). Efforts have been made to shorten the total assay 
time of culture-based techniques(31-33), but these methods still rely on multiple cell 
divisions and thus require many hours due to the slow doubling time (~60 min) of Ng. 
 
A phenotypic AST usable at the POC would be paradigm-shifting for Ng(34) because it 
would provide the correct timely treatment of infections, significantly reduce disease 
burden, and improve global surveillance efforts(35-37). Until a POC diagnostic is 
developed for Ng, empiric prescribing of the last-line dual antibiotic therapy of 
azithromycin/ceftriaxone will likely continue, as it has in the U.S. over the last five 
years(38). Likewise, if informed antibiotic prescriptions cannot be made, resistance will 
continue to spread, at which point no currently available ABXs will be recommended for 
treatment of Ng. Importantly, a rapid, phenotypic AST would greatly increase treatment 
options because if clinicians know which ABX will be efficacious for each infection, they 
can once again treat with ABX that are not prescribed in the current (empiric-based) system 
because of the risk of resistance. For example, even though cefixime (CFM) is no longer 
used as a first-line therapy for Ng, up to 95% of infections in the U.S. are still susceptible 
to CFM(1, 39). Similarly, up to 77% of Ng infections are susceptible to TET(1).  Therefore, 
having a POC AST would enable clinicians to once again safely prescribe CFM and other 
antibiotics(40). Several recent cases of Ng infections resistant to azithromycin(41, 42), or 
the currently recommended combination of ceftriaxone/azithromycin(9, 11) were detected 
after treatment was administered, highlighting the critical need for faster diagnostics. 
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For an Ng AST to inform treatment decisions at the POC, the total assay time to 
determine phenotypic susceptibility must be greatly decreased(43-45). Quantification of 
pathogen-specific nucleic acid (NA) concentrations has shown major promise for the rapid 
determination of susceptibility phenotype(46-49). These methods rely on comparing the 
NA concentrations of control and antibiotic-treated samples, and thus work well for rapidly 
dividing organisms and for ABX that directly affect NA replication. NA-based phenotypic 
AST methods also benefit from the high sensitivity of NA amplification, and fast 
isothermal amplification techniques have led to short total assay times(46). For example, 
by measuring the concentration of E. coli DNA, we have shown that the antibiotic-exposure 
step for phenotypic AST can be shortened to 15 min(50). We also were able to achieve a 
phenotypic AST with a 10-min antibiotic exposure time in Ng by measuring changes in 
RNA concentration after exposure to ciprofloxacin, which directly inhibits DNA 
replication and downstream translation(51). However, for ABX that do not impact DNA 
replication, such as β-lactams, these NA-based AST techniques have proven difficult; the 
fastest published method for Ng still requires four hours of beta-lactam exposure(52). 
Importantly, of the ABX prescribed for Ng, only one, ciprofloxacin(51), has been 
demonstrated to be compatible with this existing NA-based approach.  
 
Here, we describe an innovation that enables a rapid, NA-based phenotypic AST for β-
lactams, the largest class of ABX used to treat Ng. We hypothesized that cell wall damage 
caused by exposure to β-lactams could be exploited to determine phenotypic susceptibility 
faster than cell division. Our method, termed nuc-aAST (nuclease-accessibility AST), 
measures the accessibility of intracellular Ng DNA to exogenously added nucleases after a 
short antibiotic exposure. We also wished to test whether the total time of the assay could 
be further decreased by including an enhancement step, defined as a condition that would 
lead to greater differences in DNA accessibility between resistant (R) and susceptible (S) 
samples.  
 
We chose to validate this proof-of-concept nuc-aAST using three β-lactams, penicillin 
(PEN), cefixime (CFM), and ceftriaxone (CRO), that represent first-line treatments at 
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different points in the history of Ng treatment(6, 53). Additionally, CRO, in combination 
with azithromycin, is the current recommended (and last-line) treatment for Ng. 
Determining susceptibility to CRO is thus relevant not only for treatment, but for 
surveillance efforts. Urine was chosen as the matrix for contrived sample testing because 
it is one of the primary sample types used for Ng diagnosis, especially in males(5, 6). We 
chose to test only categorically S or R isolates, based on EUCAST breakpoints(54), 
because S and R isolates are more useful than intermediate isolates for gaining initial 
mechanistic insights into nuc-aAST, and because S and R are actionable calls in antibiotic-
prescribing scenarios. Lastly, keeping in mind clinical utility, we timed each assay step to 
determine whether the nuc-aAST could yield a definitive susceptibility call within the time 
period of a patient’s visit, which is usually less than an hour(44, 45). 
 
RESULTS 
 
Design and rationale of the nuc-aAST 
 
The nuc-aAST method measures differences in the accessibility of genomic DNA to an 
exogenous nuclease between control and treated samples following a short antibiotic 
(ABX) exposure. Like other NA-based AST methods, the nuc-aAST (Fig. 4.1) relies on 
measuring changes in the quantity of pathogen-specific NAs in response to a treatment 
with ABX; however, the nuc-aAST differs from existing NA-based ASTs in three aspects. 
First, in nuc-aAST, exposure of cells to β-lactams is performed in the presence of a DNase 
enzyme to degrade any DNase-accessible NAs (Fig. 4.1a). DNA is accessible to DNase if 
it is released from the cells upon cell lysis, or if the action of the antibiotic porates the cells 
and allows DNase to access the DNA. Second, in nuc-aAST, an enhancement step is 
introduced to increase accessibility of DNA in cells that have damaged or compromised 
peptidoglycan caused by β-lactams; DNase is present and active during this enhancement 
step (Fig. 4.1b). Third, in nuc-aAST, lysis of the sample is performed only after DNase has 
degraded all accessible DNA (Fig. 4.1c). This lysis step also inactivates the DNase, so that 
the enzyme does not impact downstream quantification. Following inactivation of DNase 
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and lysis, DNA remaining in the sample is quantified and the percentage of accessible 
DNA is used to determine susceptibility (Fig. 4.1d). The percentage of accessible DNA is 
quantified by subtracting the concentration of inaccessible DNA (DNA not digested) in the 
treated aliquot from the concentration of DNA in the control aliquot, and dividing this 
value by the concentration of DNA in the control. Measuring the percentage of accessible 
DNA is an NA-based metric that enables us to quantify the damage to the cellular envelope 
induced by ABX targeting cell wall biosynthesis.  
 
 
Figure 4.1. The nuc-aAST workflow shown for a sample containing an antibiotic-
susceptible pathogen. (a) A sample is split into control and treated aliquots; the treated 
aliquot is exposed to antibiotics (ABX) in the presence of DNase and any extracellular 
DNA is digested. ABX compromise peptidoglycan (PG) of cells in the treated aliquot. (b) 
Accessibility to nucleases is enhanced by the addition of an enhancer, which disrupts the 
outer membrane (OM). Genomic DNA becomes accessible and is degraded in the treated 
aliquot. Intact peptidoglycan in control samples (or in treated but resistant samples) 
prevents degradation. (c) Nucleic acids (NAs) are extracted, and DNase is inactivated. (d) 
Accessibility is quantified by measuring NA concentrations in the control and treated 
aliquots and dividing the amount of digested DNA by the amount in the control (to yield 
percentage accessibility). When the percentage accessibility is greater than the threshold 
(dashed line), the sample is categorized as susceptible. 
 
β-lactams should primarily affect peptidoglycan(55), and should not have a major impact 
on the outer membrane, which serves as a structural element in Gram-negative 
bacteria(56). Therefore, we expected the primary mechanism behind any increase in 
accessibility to be cell lysis as a result of exposure to β-lactams, leading to release of 
genomic DNA to the extracellular environment containing DNase. Additionally, we 
hypothesized that autolysis, which has been observed as an active stress response in Ng(57, 
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58), might accelerate changes in accessibility due to ABX exposure. We tested our 
hypotheses in a time-course experiment using two penicillin-susceptible (PEN-S) and two 
penicillin-resistant (PEN-R) Ng clinical isolates (Fig. 4.2). We observed a significant 
difference in the percentage accessibility between susceptible and resistant isolates after 
90 min of exposure. This is the shortest incubation time for an Ng AST with PEN to date, 
and faster than existing NA-based methods that rely on DNA replication(52). However, 
the ideal length of an exposure step for an AST used at the POC would be even shorter (15-
30 min) to keep the entire workflow within the time period of a patient visit. Thus, we were 
compelled to further accelerate changes in accessibility of DNA to nuclease as a result of 
β-lactam exposure in susceptible samples. 
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Figure 4.2. Percentage accessibility of DNA over time using the nuc-aAST without the 
addition of an enhancing step. Two penicillin-susceptible (PEN-S) and two penicillin-
resistant (PEN-R) Ng isolates were exposed to penicillin in the presence of DNase I. DNA 
from the control and PEN-treated aliquots was extracted and quantified using qPCR at 
multiple time points to calculate percentage accessibility. Error bars represent the standard 
deviation of the PCR triplicates. 
 
Enhancing changes in accessibility 
 
We next hypothesized that the differences in DNA accessibility that we observed between 
susceptible and resistant isolates exposed to β-lactams could be enhanced using conditions 
that would modify the permeability of the cell envelope. In Gram-negative organisms like 
Ng, the outer membrane (OM) presents the first, and major, permeability barrier to 
macromolecules (e.g. nucleases and other enzymes) entering or exiting the cell, typically 
allowing only small molecules with molecular weights < ~600 Da to pass through(59, 60). 
The peptidoglycan, in contrast to the OM, is a looser barrier that has been estimated to 
allow macromolecules up to 50 kDa to pass through(61-63). We thus suspected that if the 
OM could be compromised, damage to the peptidoglycan would result in immediate, 
 83 
measurable changes in accessibility of genomic DNA to DNase, both by allowing DNase 
to enter and by allowing DNA fragments to exit.  Therefore, we hypothesized that we could 
compromise the OM using an “enhancer” to decrease total assay time. 
 
The ideal enhancer would i) increase DNA accessibility to DNase in cells that have a 
compromised cell wall as a result of ABX exposure, ii) result in minimal lysis of healthy 
cells, iii) have a consistent effect on all Ng isolates and iv) have no effect on downstream 
extraction and quantification of NAs. With these parameters in mind, we chose to test 
hypo-osmotic stress, stimulated autolysis, and four classes of surfactant as potential 
enhancers.  
 
Hypo-osmotic stress was chosen as a method to enhance lysis of cells with damaged or 
compromised cell walls because osmotic stress of varying degrees is known to increase 
release of intracellular contents in Gram-negative bacteria,(64-66) although it has never 
been used to enhance accessibility in the context of AST. We exposed cells to hypo-
osmotic conditions by diluting control and treated aliquots 20-fold in water with DNase I 
and 500 µM CaCl2, resulting in a ~244 mOsm/kg shift from the ABX exposure conditions. 
Autolysis was chosen as an enhancer with the rationale of leveraging an already existing 
stress response in Ng to enhance changes in accessibility. Autolysis is a natural stress 
response in Ng, and can be accelerated by incubation in high pH conditions (e.g. Tris, pH 
8.5)(67, 68). We hypothesized that using autolysis as an enhancer might result in large 
changes in NA accessibility. Surfactants were chosen as potential enhancers as a targeted 
chemical means of disrupting the bacterial cell membrane. We chose a representative 
surfactant from each of the four major charge-based classes of surfactants to investigate 
whether surfactant charge might lead to variability in their effectiveness due to natural 
variations in the OM of Ng. We tested the anionic surfactant sodium dodecyl sulfate (SDS), 
the cationic surfactant benzalkonium chloride (BAC), the non-ionic surfactant TERGITOL 
NP (TNP), and the zwitterionic surfactant 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS). Each of these surfactant classes, with the exception of 
zwitterionic surfactants, have been well-studied for their ability to compromise the 
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integrity of the cell envelope(69), but none have been used in the context of AST, or to 
change DNA accessibility on such short time scales. We chose to include the less well-
studied zwitterionic surfactant CHAPS based on the diverse interactions of zwitterionic 
solutes with the bacterial cell envelope(70). 
 
We tested each potential enhancer with respect to i) the degree of lysis caused by incubation 
with the enhancer alone, ii) the ability to differentiate PEN-S and PEN-R isolates using an 
enhancement step after exposure to PEN, and iii) the ability to differentiate CRO-S and 
CRO-R isolates using an enhancement step after exposure to CRO. We chose to use PEN 
and CRO because we expected that the degree of change in NA accessibility as a result of 
enhancement would depend on the type of β-lactam used during exposure. CRO and PEN 
bind and inhibit a different profile of penicillin-binding proteins(40, 71) and have different 
rates of killing(72), which we expected would lead to different effects depending on the 
enhancer. Each enhancer was tested using multiple isolates susceptible or resistant to either 
PEN or CRO. All enhancers were tested using a 5-min enhancement step after 15 min of 
ABX exposure. Antibiotic-exposure and enhancement steps were performed separately to 
decouple their effects on the Ng isolates. 
 
Enhancers were first tested for the degree of lysis caused by a 5-min incubation with the 
enhancer alone (Fig. 4.3a-f). If the enhancement step lyses the majority of cells even 
without antibiotic exposure, then accessibility will increase in both control and treated 
aliquots, and any effect of the antibiotic will be diminished. We observed an average of < 
50% lysis when testing all potential enhancers except BAC (Fig. 4.3d), which showed an 
average of 94% lysis across all eight isolates tested. We next measured the percentage 
accessibility when using each enhancer after a 15 min exposure to PEN. We evaluated the 
ability to differentiate PEN-S and PEN-R isolates based on the average percentage 
accessibility in S isolates (which we want to be large), the average percentage accessibility 
in R isolates (which we want to be small), and the magnitude of separation between those 
two values. Based on these criteria, Tris (Fig. 4.3h), TNP (Fig. 4.3k), and CHAPS (Fig. 
4.3l) were the most promising enhancers for differentiating PEN-S and PEN-R isolates 
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after 15 min of exposure. However, we observed differences in accessibility in response 
to CRO compared with PEN depending on the enhancer used (Fig. 4.3m-r). Among CRO-
S isolates, enhancement with TNP or CHAPS resulted in the largest average changes in 
accessibility. We were unable to observe consistently large changes in the seven tested 
CRO-S isolates using the other two ionic surfactants, SDS (Fig. 4.3i,o) and BAC (Fig. 
4.3j,p), regardless of the ABX treatment. Following these tests, we chose CHAPS as the 
enhancer to use for validation of the nuc-aAST because it resulted in low percentage lysis, 
large increases in DNA accessibility for PEN-S and CRO-S isolates following exposure, 
and only small increases in the DNA accessibility of PEN-R and CRO-R isolates. 
 
 
Figure 4.3. Selection of enhancers. Six enhancers were tested for percentage of cell lysis 
due to enhancer alone (prior to antibiotic [ABX] exposure) (a-f), enhancement after 
exposure to penicillin (PEN) (g-l), and enhancement after exposure to ceftriaxone (CRO) 
(m-r). Each point represents the average of all biological replicates run for that condition. 
Checkmarks indicate enhancers that met our criteria for inclusion in the nuc-aAST; X’s 
indicate enhancers that did not meet our criteria. 
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Validation using clinical isolates 
 
To validate the nuc-aAST we performed 34 ASTs (with multiple biological replicates each) 
using 13 clinical isolates of Ng exposed individually to PEN, CFM, or CRO for 15 min. 
We then compared the categorical susceptibility determined using the nuc-aAST to the 
susceptibility determined using gold-standard agar dilution (Fig. 4.4a-c). Receiver 
operating characteristic (ROC) plots(73) (not shown) were created so that the area under 
the curve (AUC) could be calculated for each β-lactam tested. After 15 min of exposure 
we obtained an AUC of 1.000 (PEN), 0.955 (CFM), and 1.000 (CRO). The AUC is 
determined by scanning a threshold through the ROC plot and measuring the sensitivity 
and specificity at each theoretical threshold value. This scanning allows one to select the 
threshold that would differentiate susceptible and resistant organisms with the maximum 
sensitivity and specificity within the given dataset. For example, an AUC of 1.000 indicates 
there was a threshold value that perfectly separated susceptible (S) and resistant (R) 
categories. However, AUC measurements do not consider the experimental noise or the 
magnitude of separation between S and R samples and should be applied with care to 
datasets with limited number of measurements, such as ours.  For example, in the case of 
CFM, the difference between the two CFM-R isolates and the CFM-S isolates with the 
lowest responses (open circles in Fig. 4.4b) was small after 15 min of exposure, so setting 
the susceptibility threshold between them would be impractical. The same is true of setting 
a threshold between the single CRO-R isolate that was available to us and two CRO-S 
isolates with the lowest responses. We therefore set the thresholds for both these ABX at a 
more conservative 18% even though this threshold generates some errors (Fig. 4.4b,c; open 
circles) in the CFM and CRO measurements after 15 min of ABX exposure.  
 
We then hypothesized that the differences observed in the magnitude of the response of the 
susceptible isolates after 15 min of exposure to each antibiotic, including the errors 
observed when testing CFM and CRO (open points, Fig. 4.4b,c) could be the result of 
differences in how fast each β-lactam affects Ng(72). For example, a possible explanation 
for differences among isolates in their response to ABX could be phylogenetic 
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differences(74-76). If isolates differ in their response times, a longer exposure would 
result in larger average separation between S and R isolates and potentially better 
categorical agreement if the S isolates were less-responsive as a result of a delayed response 
to antibiotic. 
 
 
Figure 4.4. Validation of nuc‐aAST using clinical isolates. (a‐c) nuc‐aAST results after 
15 min of exposure to (a) penicillin (PEN), (b) cefixime (CFM), and (c) ceftriaxone (CRO). 
(d‐e) nuc‐aAST results after exposure to (d) CFM and (e) CRO for 30 min. All points 
represent the average percentage accessibility of single clinical isolates run in (at least) 
biological triplicate. Open points represent isolates that took longer than 15 min to respond 
to the β‐lactam being tested. The dashed line represents the susceptibility threshold, which 
was set at 18% accessibility. 
 
To test the hypothesis that there are inherent differences in isolate response time, we 
performed nuc-aAST using CFM and CRO with 30-min exposure times and, as predicted, 
we observed a larger average separation between S and R isolates and full categorical 
agreement with gold-standard agar dilution in all isolates. After 15 min of exposure to CFM 
and CRO, 73% and 83% of susceptible isolates, respectively, were classified as susceptible 
using nuc-aAST. After 30 min of exposure to CFM and CRO, 100% categorical agreement 
was obtained. 
 
Sum-of-steps total time using contrived urine samples 
 
To make a more realistic measure of total assay time, we modified the extraction and 
quantification steps of the nuc-aAST. The exposure and enhancement steps were 
performed as described above, but NA quantification was performed using a rapid, chip-
based, digital loop-mediated isothermal amplification (dLAMP) method, as described 
previously(77). Additionally, we used a faster, single-step nucleic acid extraction method 
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based on previous work(46). Both modifications made the workflow faster. Additionally, 
the high precision of digital quantification allowed us to make a susceptibility call as soon 
as there was a significant difference between the concentration of NAs in the control and 
treated aliquots. 
 
We measured total assay time based on the sum of the steps of the nuc-aAST using 
contrived urine samples. Contrived samples mimic clinical urine samples and allowed us 
to better evaluate how the assay would perform in a clinical setting than assays performed 
with isolates in media. Samples were created using two PEN-S and two PEN-R isolates; 
one of the two PEN-R isolates was positive for β-lactamase activity, which we included in 
order to have PEN-R isolates with different mechanisms of resistance. To perform the AST, 
samples were first split into control and treated aliquots, and incubated at 37 C for 15 min. 
Next the samples were transferred to the enhancement step, and incubated for 5 min in the 
presence of CHAPS. Samples were then extracted as described above and dLAMP was 
performed in commercial chips(77). Images were obtained in real time using a custom 
imaging system(78). LAMP quantification was performed using an automated data-
analysis workflow in MATLAB(77) in which images are automatically processed and 
positive wells counted based on a digitized mask created from the final image (Fig. 4.5b). 
NA concentrations were used to determine percentage accessibility as soon as the measured 
NA concentrations in the susceptible sample became significantly different between the 
control and treated chips. All samples were tested in a total time (measured as the sum-of-
steps) of 30 min and agreed with gold-standard agar dilution (Fig. 4.5c). 
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Figure 4.5. The nuc-aAST workflow with each step timed. (a) The nuc-aAST workflow 
showing the time required for each step. (b) 2x2 mm subsection of masks created from 
chips used for performing digital LAMP (dLAMP) on control and treated aliquots of 
susceptible and resistant samples; as an illustration, each mask shows ~625 wells (out of 
~20,000 total wells) after 10 min of amplification. Wells that showed amplification of Ng 
DNA appear black. (c) Percentage accessibility determined at earliest significance (<7 
minutes of amplification, see Methods) for two susceptible and two resistant samples run 
using dLAMP. Each step was timed individually and the sum-of-steps of the assay was 30 
min for PEN. 
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DISCUSSION 
 
Here we described a new approach—nuc-aAST—to enable developing a critically needed 
rapid phenotypic AST for the globally-important pathogen Neisseria gonorrhoeae. We 
show that by measuring the change in the accessibility of DNA after 15 or 30 min β-lactam 
exposure, the nuc-aAST yields a phenotypic susceptibility readout in less than 1 hour, as 
opposed to the currently available methods which require hours to days. We further show 
that the nuc-aAST breaks the current speed limits for nucleic-acid-based phenotypic ASTs 
using β-lactams (which do not directly impact NAs) by using an innovative approach: 
coupling cell wall damage to NA readout. The nuc-aAST thus provides a new approach for 
designing rapid phenotypic ASTs with NA-based readouts for ABX that impact cell 
envelope integrity. Overall, we envision that leveraging the nuc-aAST and combining it 
with other creative biological and chemical insights will result in similarly innovative 
approaches for other important antibiotic classes for Ng, such as protein-biosynthesis 
inhibitors like tetracycline and azithromycin. Existing NA-based approaches, such as those 
for ciprofloxacin(23, 51), can also be combined alongside the nuc-aAST. 
 
We found that phenotypic ASTs that use NA accessibility as a readout benefit from the use 
of a carefully chosen enhancer. Here, the enhancement step consisted of a surfactant 
(CHAPS) that enabled detection of cell wall damage faster than cell division. Without the 
enhancement step, the cell envelope remains intact longer, so measurements of 
accessibility approximate the timescale of cell division (Fig. 4.2), which, for fastidious 
organisms such as Ng, will be too slow for POC applications. The increase in DNA 
accessibility in S isolates will differ based on the combination of β-lactam used and 
enhancer, highlighting the importance of testing multiple β-lactams with the nuc-aAST. Of 
the surfactants tested as enhancers, the charge-neutral surfactants TNP and CHAPS gave 
better results than the ionic surfactants SDS and BAC, suggesting that charge may be an 
important factor when designing an effective enhancement step. We also anticipate 
organism-specific OM chemistry and general stress responses will play a role in 
determining which enhancers are optimal in other organisms. 
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We found that for PEN, susceptibility of Ng could be determined after just 15 min of 
exposure in all isolates tested (Fig. 4.4a). However, for CFM and CRO, a small number of 
S isolates did not respond after 15 min of exposure but responded after 30 min exposure 
(Fig. 4.4b-e). We hypothesize that CFM and CRO required a longer exposure than PEN 
because of their differences in binding kinetics and rates of killing(71, 72, 79). Despite 
these differences, an actionable susceptibility call (i.e. determining that an isolate is 
susceptible to a particular ABX and therefore can be treated with that ABX) could still be 
made for most isolates after 15 min of exposure (100% using PEN, 77% using CFM, and 
85% of cases using CRO). One approach to balance reducing assay time with minimizing 
errors is to perform two exposures in parallel for each ABX.  The first exposure would be 
analyzed after 15 minutes. If a response is obtained indicating that the pathogen is 
susceptible (which should be the case for the majority of patients), the second exposure 
would be discarded. If no response or if an equivocal response is obtained, then the second 
exposure (after 30 min total) would be analyzed to provide the definitive susceptibility call. 
With this approach, the test would provide the answer after 15 min of ABX exposure for 
the majority of patients, and only a few patients would be delayed by the additional 15 min 
of ABX exposure.  
 
Several limitations will need to be overcome in order to translate the nuc-aAST approach 
to an automated and distributable system. First, in this paper we used clinical isolates and 
contrived urine samples. Although contrived samples are a good proxy for clinical samples 
and are accepted by the U.S. Food and Drug Administration in certain cases(80), the nuc-
aAST should be validated with fresh clinical samples. It remains to be tested whether the 
enhancer chemistry has to be modified to account for the presence of host-derived cells 
and metabolites that might interfere with the assay.  Second, future work should test more 
Ng isolates with diverse phylogeny(74-76) as they are made available to researchers and 
characterized, as well as test isolates with intermediate resistance to PEN, CFM, and CRO. 
These efforts could also aim to establish a correlation in the magnitude of nuc-aAST 
response and minimum inhibitory concentration (MIC) of ABX, which would provide even 
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more detailed information at the POC. Third, in timing the sum-of-steps, we did not 
include handling time; future work should include optimization of handling steps and timed 
sample-to-answer experiments. Finally, the nuc-aAST method will need to be translated to 
a POC device so that larger-scale clinical evaluations can be performed.  Devices for 
multiplexed digital quantification(81-83) have been demonstrated and would be useful in 
performing nuc-aAST for multiple ABX in parallel.    
 
We envision that nuc-aAST would be deployed in combination with two complementary 
technologies:  (i) the pathogen ID technologies that are being developed by others(18, 19, 
21, 22) to identify Ng-positive samples that require an AST, and (ii) rapid genotypic and/or 
phenotypic ASTs that rely on NA readouts for other ABX used in the treatment of Ng, 
including fluoroquinolones (ciprofloxacin)(23, 46, 75) and protein synthesis inhibitors 
(tetracycline and azithromycin)(75).  Assuming these two complementary technologies are 
developed and validated, further development of nuc-aAST would provide the last—and 
we would argue the most challenging—piece needed for a complete rapid ID/AST 
workflow for Ng based on NA readout.  We chose NA readout for the nuc-aAST for two 
reasons. First, NA readouts will enable easy integration with pathogen ID and other NA-
based AST technologies. Second, NA readouts are organism-specific(46), and therefore 
should be effective even for mixed microbial populations potentially present in clinical 
samples (e.g., Ng in the presence of commensals or other pathogens).   
 
Implementation of a rapid phenotypic AST would dramatically improve the antibiotic 
stewardship of Ng infections and therefore impact the health of people who are infected 
with Ng; currently, there are an estimated 78,000,000 global cases of Ng every year(2). 
Furthermore, the nuc-aAST approach provides a framework for developing additional 
accessibility-based AST chemistries for other pathogens that pose global health threats but 
have been challenging for current phenotypic AST methods. For example, we have shown 
that quantifying NA accessibility to polymerases can be used to rapidly determine ABX 
susceptibility in Enterobacteriacea(84). Overall, this work highlights the diagnostic 
capabilities that can be attained by developing innovative NA-based assays for AST; 
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further expansion and application of these approaches is critically needed to address the 
crisis posed by antibiotic-resistant bacteria. 
 
MATERIALS AND METHODS 
 
Isolates and agar-dilution MIC testing. Isolates were provided by the University of 
Washington Neisseria Reference Laboratory. MICs were determined by agar dilution 
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines(86). 
 
Reagents and culture media. BD BBL Chocolate II Agar prepared plated media (GC II 
Agar, with Hemoglobin and BD IsoVitaleX) was purchased from VWR International LLC 
(VWR, Radnor, PA, USA). Graver-Wade Medium (GWM) was prepared as described 
previously(87). Cation-adjusted Mueller Hinton II Broth (MHB) (BD, Franklin Lakes, NJ, 
USA) was prepared according to manufacturer instructions. All sodium bicarbonate 
(NaHCO3) (Sigma, St. Louis, MO, USA) and calcium chloride (CaCl2) (Fisher Scientific, 
Hampton, NH, USA) stocks were dissolved in nuclease-free water (NF-H2O) and sterilized 
using 0.2-µm filters. DNase I (2000 U/mL) was obtained from New England Biolabs 
(NEB, Ipswich, MA, USA). Normal urine from pooled human donors was purchased from 
Lee Biosolutions (Maryland Heights, MO, USA) and filtered through 0.2-µM filters before 
use. 
 
Antibiotic stocks were prepared and stored as single-use aliquots at -80 °C. Aliquots were 
thawed once and diluted in NF-H2O before use. PEN (1 mg/mL) was prepared from 
penicillin G sodium salt (Sigma, St. Louis, MO, USA) in NF-H2O. CRO (1 mg/mL) was 
prepared from ceftriaxone disodium salt hemi(heptahydrate) (Sigma) in NF-H2O. CFM (5 
mg/mL) was prepared from cefixime trihydrate (Sigma) in DMSO. 
 
Unless otherwise noted, enhancer stock solutions were prepared in NF-H2O and stored at 
room temperature. Tris buffer (500 mM; pH 8.5 at 37 °C) was prepared according to the 
Sigma buffer reference tables(88) using 0.2-µm filter sterilized stocks of 1 M Tris-HCl 
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(Sigma) and 1 M Tris base (Fisher Scientific) prepared in milliQ H2O. TNP HLB 13.1 
(100 mM) was prepared by mixing 334 µL 100 mM Tergitol NP-9 (Sigma) + 666 µL 100 
mM Tergitol NP-10 (Sigma). CHAPS (200 mM) was prepared from CHAPS solid powder 
(Sigma). 0.1% sodium dodecyl sulfate (SDS) was prepared by diluting 10% SDS 
(Invitrogen, Carlsbad, CA, USA). BAC (10%) was prepared from benzalkonium chloride 
solid powder (MP Biomedicals, Santa Ana, CA, USA). 
 
Nucleic acid quantification. Quantitative PCR (qPCR) was performed using ssoFast 
EvaGreen Supermix (BioRad, Hercules, CA, USA) in 10 µL reactions with 500 nM 
primers targeting the Ng 16S gene(89). DNA template composed 10% of the reaction 
volume. Cycling conditions consisted of 3.0 min at 95 °C, followed by 35 cycles of 15 sec 
at 95 °C, 15 sec at 62 °C, and 20 sec at 72 °C. All qPCR was performed on either a Roche 
LightCycler 96 or BioRad CFX96 instrument. The Cq values obtained from qPCR are used 
to compute the percentage accessibility and percentage lysis as described in the equations 
below. Any negative percentages were set to 0 for all analyses. 
 
(1)  
(2)  
 
Droplet digital PCR (ddPCR) was performed using QX200 ddPCR Supermix for EvaGreen 
(BioRad, Hercules, CA, USA) with the same primers and primer concentrations used in 
qPCR. DNA template composed 10% of the reaction volume. Cycling conditions consisted 
of 5.0 min at 95 °C, followed by 40 cycles of 30 sec at 95 °C, 30 sec at 60 °C, and 30 sec 
at 72 °C, followed by a droplet stabilization step of 4 °C for 5 min, and 95 °C for 5 min. 
Calculations of percentage accessibility and percentage lysis for ddPCR are given the 
equations below, where  represents template concentration in copies/µL. The template 
concentrations are used to compute percentage accessibility and percentage lysis as 
described in the equations below. Any negative percentages were set to 0 for all analyses. 
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(3)  
(4)  
 
A dLAMP assay was performed using a previously published system(77). The dLAMP 
mix consisted of 1 µL NEB Isothermal Amplification Buffer (200 mM Tris-HCl, 20 mM 
MgSO4, 500 mM KCl, 100 mM (NH4)2SO4, 1% Tween 20, pH 8.8), 0.6 µL MgSO4, 0.5 
µL BSA (20 mg/mL), 0.4 µL Syto-9 (50 µM, prepared within two weeks of use), 1.4 µL 
dNTPs (10 mM each), 0.5 µL 20X primer mix, 0.4 µL NEB Bst 2.0 WarmStart, 0.2 µL 
Ambion RNase cocktail, 4.0 µL NF-H2O, and 1 µL of template. Primers were designed to 
target the Ng 16S gene, and screened as described previously(46). Primer sequences used 
are as follows, with the final concentration in the amplification mix in parentheses: 
GCGGTGGATGATGTGGATT (forward outer primer, 0.2 µM), 
CCGGCAGTCTCATTAGAGTG (backward outer primer, 0.2 µM), 
CTCCTCCGTCTCCGGAGGATTCaaaaCGATGCAACGCGAAGAAC (forward inner 
primer, 1.6 µM), TCGTCAGCTCGTGTCGTGAGATttttCCCAACCGAATGATGGCA 
(backward inner primer, 1.6 µM), CGCACATGTCAAAACCAGG (forward loop primer, 
0.4 µM), and GCAACGAGCGCAACCC (reverse loop primer, 0.4 µM). The following 
equation was used to compute percentage accessibility, where  represents the template NA 
concentration in copies/µL as measured by dLAMP. 
 
(5)  
 
Ng culture preparation. Isolates were streaked from glycerol stocks stored at -80 °C onto 
BD BBL Chocolate II Agar plates and incubated overnight in a 37 °C incubator with 5% 
CO2. Isolates were then passed onto fresh BD BBL Chocolate II Agar plates and grown for 
4-7 h at 37 °C with 5% CO2. In all experiments, cells from plates passed 1-3 times were 
used. Several colonies were scraped and resuspended in 37 °C GWM to generate a working 
suspension. Optical density at 600 nm (OD600) was measured, and the working suspension 
was diluted to create a 2 mL working culture of OD600 0.05 in GWM in 15 mL 
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polypropylene culture tubes. Cultures were incubated, with 500 rpm shaking, at 37 °C + 
5% CO2 for 3-5 h prior to ABX exposure. 
 
nuc-aAST time-course without enhancing step. Working cultures of Ng isolates were 
prepared as described in “Ng culture preparation.” Incubation at 37 °C was performed in 
100 µL reaction volumes in PCR tube strips on a BioRad C1000 Thermal Cycler. Treated 
samples consisted of 77.5 µL MHB, 2.5 µL NaHCO3 (200 mM), 5 µL DNase I (2 U/µL), 
5 µL PEN (20 µg/mL), and 10 µL working Ng isolate culture. PEN was replaced with NF-
H2O in control samples. A 10 µL aliquot of each sample was extracted at 15, 30, 45, 60, 
90, and 120 min and diluted 10X in QuickExtract DNA Extraction Solution 
(Lucigen, Middleton, WI, USA), then heated for 6 min at 65 °C followed by 4 min at 98 
°C on a BioRad C1000 Thermal Cycler. All sample handling following antibiotic exposure 
was performed using a multichannel pipette; qPCR and calculation of % accessibility were 
performed as described above. 
 
Enhancer use. Working cultures of Ng isolates were prepared as described in “Ng culture 
preparation.” Initial exposure was performed by incubating 100 µL control and treated 
samples at 37 °C in PCR tube strips on a BioRad C1000 Thermal Cycler. Treated samples 
consisted of 75 µL MHB, 5 µL NaHCO3 (100 mM), 5 µL DNase I (2 U/µL), 5 µL PEN or 
CRO (20 µg/mL), and 10 µL working Ng isolate culture. ABX were replaced with NF-H2O 
in control samples. After 15 min of incubation, samples were vortexed and quick-spun, and 
aliquots of all samples were transferred to the enhancement step as described below. After 
the enhancement step, 5 or 10 µL of all samples were extracted by diluting 10X in 
QuickExtract DNA Extraction Solution (Lucigen) and heating for 6 min at 65 °C followed 
by 4 min at 98 °C on a BioRad C1000 Thermal Cycler. All sample handling following 
ABX exposure was performed using a multichannel pipette; qPCR and calculation of % 
accessibility was performed as described above. 
 
Osmotic and autolytic enhancing steps were performed in 100 µL volumes. The osmotic 
enhancing step consisted of 89.75 µL NF-H2O, 4.75 µL DNase I (2 U/uL), 0.5 µL CaCl2 
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(100 mM, 0.2-µM filtered), and 5 µL initial exposure samples. The autolytic enhancing 
step consisted of 75 µL NF-H2O, 4.75 µL NaHCO3 (100 mM, 0.2-µM filtered), 10 µL Tris 
pH 8.5 (500 mM), 4.75 µL DNase I (2 U/uL), 0.5 µL CaCl2 (100 mM), and 5 µL of the 
sample exposed to antibiotic. 
 
All surfactant-enhancing steps were performed in 50 µL volumes with 25 of the 50 µL 
consisting of initial exposure samples. In the TNP enhancement step, the remaining 25 µL 
consisted of 1.25 µL DNase I (2 U/uL), 1.25 µL NaHCO3 (100 mM), 20 µL MHB, and 2.5 
µL TNP (100 mM). In the CHAPS enhancement step, the remaining 25 µL consisted of 
1.25 µL DNase I (2 U/uL), 1.25 µL NaHCO3 (100 mM), 20 µL MHB, and 2.5 µL CHAPS 
(200 mM). In the SDS and BAC enhancement steps, the remaining 25 µL consisted of 1.25 
µL DNase I (2 U/uL), 1.25 µL NaHCO3 (100 mM), 17.5 µL MHB, and either 5 µL SDS 
(1% w/v) or BAC (1% w/v) respectively. 
 
Nuclease-accessibility AST validation. Working cultures were prepared, exposed to 
ABX, and enhancing steps performed as described for the CHAPS enhancement step in the 
“enhancer selection” section above. Extraction was performed as described above. Treated 
samples in the initial exposure step had a final concentration of 1.0 µg/mL PEN, CFM, or 
CRO. Samples were excluded if the percent lysis (equation 2) due to CHAPS was > 75%. 
Three to ten biological replicates were performed for each isolate-antibiotic combination. 
Biological replicates included separate antibiotic exposure, control exposure, and no-
enhancer controls. 
 
Timed sum-of-steps. Working cultures of Ng isolates used in Fig. 4.4 were prepared as 
described in “Ng culture preparation” and 1.5 mL of the cultures were pelleted at 2500 g 
for 2.5 min and resuspended in 150 µL normal human urine (Lee Biosciences) pre-warmed 
to 37 °C. Initial exposure was performed by incubating 100 µL control and treated samples 
at 37 °C in PCR tube strips on a BioRad C1000 Thermal Cycler. Treated samples consisted 
of 65 µL MHB, 5 µL NaHCO3 (100 mM), 5 µL DNase I (2 U/µL), 5 µL PEN (20 µg/mL), 
and 20 µL Ng isolate suspension in urine. NF-H2O was used in place of PEN in control 
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samples. A CHAPS enhancing step was performed as described above. After the 
enhancement step, a 20 µL aliquot from each sample was extracted by diluting 5X in 
QuickExtract DNA Extraction Solution (Lucigen) and heated for 1 min at 65 °C followed 
by 1 min at 98 °C on a BioRad C1000 Thermal Cycler. All sample handling following 
ABX exposure was performed using a multichannel pipette. Amplification was then 
performed using qPCR, ddPCR, or dLAMP. Extractions were diluted 2.5X in NF-H2O 
before use in dLAMP. 
 
Osmolarity measurements. Osmolarity measurements were performed on a Model 3320 
Osmometer (Advanced Instruments Inc., Norwood, MA, USA). The instrument was 
calibrated with reference standards (Advanced Instruments) prior to experiments. Samples 
identical to the antibiotic-exposure condition (i.e. media, nuclease, etc.) and samples 
identical to the osmotic enhancing condition were prepared and measured. The volume that 
would normally be comprised of Ng culture was replaced with media. 
 
Statistical analysis. P-values for Fig. 4.2 were calculated using GraphPad Prism 8.0 
software from an unpaired, two-tailed t-test comparing the averages of the three replicates 
of each susceptible sample to each resistant sample. A significance value of 0.02 was used 
for statistical significance. ROC plots used for setting susceptibility thresholds in Fig. 4.4 
were created using GraphPad Prism 8.0 software. Sensitivity was defined as the proportion 
of gold-standard susceptible samples correctly identified as susceptible by the nuc-aAST. 
Specificity was defined as the proportion of gold-standard resistant samples correctly 
identified as resistant by the nuc-aAST. Statistical analyses for Fig. 4.5, (dLAMP 
measurements) were performed as published previously(46, 90). As in our previous 
publication(46), the control and treated concentrations are compared as a ratio for statistical 
analysis. 
 
(6)  
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This concentration ratio is transformed into a percentage change for visualization 
purposes, but the ratio is assessed for statistical significance. Poisson statistics were used 
to calculate the confidence interval of the NA concentration for each measurement(90). 
The error in the concentration ratio, a term used in the calculation of percentage 
accessibility, is calculated with standard-error propagation methods: 
 
(7)  
 
A one-tailed Z-test, assuming a normal distribution, is used to calculate p-values for digital 
NA concentrations. A threshold value for significance is set as a ratio of 1.22, 
corresponding to a percentage accessibility of 18%. 
 
(8)  
 
A significance value of 0.05 was used for statistical significance. The p-values to determine 
significance in dLAMP experiments were computed using Microsoft Excel’s standard 
normal cumulative distribution function and Z-value. 
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ABSTRACT 
The lumen of the small intestine (SI) is filled with particulates: microbes, therapeutic 
particles, and food granules. The structure of this particulate suspension could impact 
uptake of drugs and nutrients and the function of microorganisms; however, little is 
understood about how this suspension is re-structured as it transits the gut. Here, we 
demonstrate that particles spontaneously aggregate in SI luminal fluid ex vivo. We find 
that mucins and immunoglobulins are not required for aggregation. Instead, aggregation 
can be controlled using polymers from dietary fiber in a manner that is qualitatively 
consistent with polymer-induced depletion interactions, which do not require specific 
chemical interactions. Furthermore, we find that aggregation is tunable; by feeding mice 
dietary fibers of different molecular weights, we can control aggregation in SI luminal 
fluid. This work suggests that the molecular weight and concentration of dietary polymers 
play an underappreciated role in shaping the physicochemical environment of the gut. 
INTRODUCTION 
The small intestine (SI) contains numerous types of solid particles. Some of these particles 
include microbes, viruses, cell debris, particles for drug delivery, and food granules (1–5). 
Little is understood about the state of these particles in the small intestine; do these particles 
exist as a disperse solution or as aggregates? An understanding of how particulate matter 
is structured as it moves through the SI would contribute to fundamental knowledge on a 
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host of topics, such as how microbes, including probiotics and pathogens, function in the 
SI (6–10). Knowledge of how particle suspensions change during transit would also 
provide insight into how the uptake of drugs and nutrients are affected by the 
physiochemical properties of the SI environment (3,4). It would also give us better 
comprehension of how the SI acts to clear potential invaders and harmful debris (2,11). 
Polymers abound in the gut in the form of secretions (e.g. mucins and immunoglobulins) 
and dietary polymers (e.g. dietary fibers and synthetic polymers). It is well known that 
host-secreted polymers can cause aggregation of particles via chemical interactions; for 
example, mucins (12–16), immunoglobulins (17–25), and proteins (26) can cause bacteria 
to aggregate via an agglutination mechanism. However, non-adsorbing polymers can also 
cause aggregation via purely physical interactions that are dependent on the physical 
properties of the polymers, such as their molecular weight (MW) and concentration (27–
33). Here, we investigate whether these physical interactions play a role in structuring 
particles in the SI. For this work, we study the interactions between polystyrene particles 
densely coated with polyethylene glycol (PEG) and the luminal contents of the SI. It has 
been demonstrated previously that PEG-coated particles have little or no chemical 
interactions with biopolymers (34,35), so using PEG-coated particles allows us to isolate 
and investigate only the interactions dominated by physical effects. 
RESULTS 
PEG-coated particles aggregate in fluid from the murine small intestine 
It has been observed that both bacteria (19–21,23,25,26) and particles (3,36–38) aggregate 
in the gut. Experiments have been performed in which mice are orally co-administered 
carboxylate-coated nanoparticles, which are mucoadhesive, and PEG-coated nanoparticles, 
which are mucus-penetrating (3). The carboxylate-coated particles formed large aggregates 
in the center of the gut lumen. In contrast, PEG-coated particles were sometimes found co-
localized with carboxylate-coated particles and also penetrated mucus, distributing across 
the underlying epithelium of the SI as aggregates and single particles. 
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To evaluate the distribution of particulate suspensions in the SI, we suspended 1-µm-
diameter fluorescent PEG-coated particles (see Materials and Methods for synthesis) in 
buffers isotonic to the SI and orally administered them to mice. We chose 1 µm-diameter 
particles because of their similarity in size to bacteria. We collected luminal contents after 
3 h and confirmed using confocal fluorescence and reflectance microscopy that these 
particles aggregated with each other and co-aggregated with what appeared to be digesta 
(Figure 5.1C and D; Materials and Methods). On separate mice, fluorescent scanning was 
used to verify that particles do transit the SI after 3 h (Figure 5.1A and B; Materials and 
Methods). 
Given the rich complexity of the SI, wherein particles co-aggregate with digesta and 
bacteria, and are subjected to the mechanical forces of digestion and transit (39), and other 
phenomena, we developed an ex vivo assay to characterize the structure of particles in 
luminal fluid from the SI of mice. As a simple starting point, we sought to understand 
Figure 5.1: PEG-coated particles aggregate in the murine small intestine (SI). (A and 
B) Fluorescent scanner image of gastrointestinal tract (GIT) from a mouse orally 
administered a suspension of 1-µm diameter PEG-coated particles (green). Scale bar 
is 0.5 cm. (see Figure 2-S1 for image processing steps and how contours of gut were 
outlined). (C and D) Confocal micrographs of luminal contents from the upper (C) 
and lower (D) SI of a mouse orally gavaged with PEG-coated particles (green) 
showing scattering from luminal contents (purple). Scale bars are 10 µm. Stm = 
Stomach; USI = upper SI; LSI = lower SI; Col = colon. 
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interactions among particles of known chemistry and the luminal fluid of the SI. To 
minimize chemical interactions with the biopolymers of the SI, we again chose PEG-coated 
polystyrene particles. PEG coatings have been shown to minimize biochemical interactions 
between polystyrene particles and biopolymers in a variety of contexts (34,35), and thus 
PEG-coated particles are commonly used in drug delivery (3,38,40). 
To create PEG-coated polystyrene particles for the ex vivo experiments, we took 1-µm-
diameter carboxylate-coated polystyrene particles and conjugated PEG to the surface 
(Materials and Methods). We used NMR to verify that PEG coated the surface of the 
particles (see Materials and Methods and Table 5.S8). We found that by coating with PEG 
5 kDa and then coating again with PEG 1 kDa to backfill the remaining surface sites on 
the particle allowed us to achieve a lower zeta potential than applying a single coat of PEG 
5 kDa (Table 5.S8). We chose these particles for use in our assay. It has been suggested in 
the literature that a near-zero zeta potential minimizes the interactions particles have in 
biological environments (35). 
To collect luminal fluid from the SI of mice, we excised the SI of adult mice (8-16 weeks 
old), divided it into an upper and lower section, and gently collected the luminal contents 
on ice. To separate the liquid and solid phase, we centrifuged the contents and collected 
the supernatant. To further ensure that any remaining solid material was removed from the 
fluid phase, we filtered the supernatant through a 30-µm pore size spin column and 
collected the filtrate (see Materials and Methods for more details). We then placed the 
PEG-coated particles in the SI luminal fluid at a volume fraction of ≈0.001. A low-volume 
fraction was chosen because bacteria in the healthy SI are found at similarly low-volume 
fractions (41–43). We found that, despite the PEG coating and low-volume fraction, 
aggregates of particles formed in 5-10 min (Figure 5.2A-D), a timescale much shorter than 
the transit time for food through the SI, which can be as short as ~80 min in healthy humans 
(39) and ~60 min in mice (44). On longer timescales, peristaltic mixing could also play a 
role (39); during fasting, the migrating motor complex (MMC) cycle first consists of a 
period of quiescence for ~30-70 min, followed by a period of random contractions, then by 
5 to 10 minutes in which contractions occur at 11-12 counts per minute (cpm) in the 
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duodenum and 7-8 cpm in the ileum. After eating, MMC is substituted with intermittent 
contractions in the SI and waves can occur at a frequency of 19-24 cpm in the distal ileum 
1-4 h later. We therefore chose to focus on aggregation at short timescales (~10 min) 
because we sought to understand the initial formation of aggregates before aggregation is 
influenced by mechanical forces such as shear due to peristaltic mixing and the transit of 
food. 
To quantify the amount of aggregation in samples of luminal fluid, we developed a method 
to measure the sizes of all aggregates in solution using confocal microscopy (see Materials 
and Methods). From these datasets, we created volume-weighted empirical cumulative 
distribution functions (ECDFs) of all the aggregate sizes in a given solution. We used these 
volume-weighted ECDFs to compare the extent of aggregation in a given sample (Figure 
5.2F and H). To test the variability of aggregation in samples collected from groups of 
mice treated under the same conditions, we compared the extent of aggregation in pooled 
samples taken from three groups, each consisting of three male mice on a standard chow 
diet. We plotted the volume-weighted ECDFs of each sample (Figure 5.2F and H) and 
observed that the variation among the groups under the same conditions appeared to be 
small compared with the differences between the samples and the control. 
To quantify the variability of aggregation among groups using an additional method, we 
bootstrapped our datasets to create 95% bootstrap confidence intervals (CI) of the volume-
weighted average aggregate size of each of the three groups and the control in Hank’s 
balanced salt solution (HBSS) (Figure 5.2G and I; see Materials and Methods for complete 
details of the bootstrapping procedure). All 95% bootstrap CI either overlapped or came 
close to overlapping, again suggesting there was little variability among pooled samples 
treated under the same conditions (male mice on a standard chow diet). 
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Figure 5.2: PEG-coated particles aggregate in fluid from the murine small intestine (SI) ex 
vivo. The 1-µm-diameter PEG-coated particles form aggregates in fluid collected from the 
upper (A-C) and lower (D) SI in ~10 min. (A and D) Maximum z-projections of 10 optical 
slices taken on a confocal microscope. (B and C) 3D renderings of aggregates found in 
panel A. (E) Maximum z-projection of the same particles in HBSS. Scale bars are 10 µm 
in 2D images and 2 µm in 3D images. (F and H) Volume-weighted empirical cumulative 
distribution functions (ECDFs) comparing aggregation of the particles in pooled samples 
from the upper (F) and lower (H) SI of three separate groups of male chow-fed mice (each 
group consisted of three mice) and a control (particles suspended in HBSS). The vertical 
axis is the cumulative volume fraction of the total number of particles in solution in an 
aggregate of a given size. The horizontal axis (aggregate size) is given as the number of 
particles per aggregate (N). (G and I) Box plots depicting the 95% empirical bootstrap CI 
of the volume-weighted average aggregate size (given in number of particles per aggregate, 
N) in samples from the upper (G) and lower (I) SI (the samples are the same as those from 
panels F and H). The line bisecting the box is the 50th percentile, the upper and lower edges 
of the box are the 25th and 75th percentile respectively, and the whiskers are the 2.5th and 
97.5th percentiles. USI = upper SI; LSI = lower SI. See Materials and Methods for 
bootstrapping procedure.  
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Fractionation of SI fluids suggests polymers play a role in aggregation of PEG-coated 
particles 
Given that polymers can aggregate particles and bacteria via several mechanisms (12–33), 
we hypothesized that biopolymers in SI luminal fluid are involved in the aggregation of 
our PEG-coated particles. We therefore sought to first quantify the physical properties of 
the polymers in the luminal fluid of the SI. To do this, we used a 0.45-µm filter to remove 
additional debris and ran samples from a group of three chow-fed mice on a gel permeation 
chromatography (GPC) instrument coupled to a refractometer, a dual-angle light scattering 
(LS) detector, and a viscometer (details in Materials and Methods). Chromatography 
confirmed that polymers were indeed present in the SI fluid (Figure 5.3A and D). Because 
we do not know the refractive index increment (dn/dc) of the polymers present in these 
samples and the polymers are extremely polydisperse, we cannot make exact calculations 
of the physical parameters of these polymers. We can, however, calculate estimated values 
by assuming the range of the dn/dc values to be about 0.147 for polysaccharides and about 
0.185 for proteins and then dividing the sample into different fractions based on retention 
volume (estimates of concentration and MW of polymers are displayed on Figure 5.3A 
and D). The estimates suggest that the SI is abundant in polymers with a range of MWs. 
To qualitatively test our hypothesis that biopolymers in the SI were involved in the 
aggregation of our PEG-coated particles, we collected SI luminal fluid from a different 
group of three male, chow-fed mice. We performed an additional filtration step (0.45-µm) 
to further ensure the removal of any solid materials. This filtrate was then separated into 
aliquots and each aliquot was run through a different MW cut-off (MWCO) filter (see 
Materials and Methods). We then collected the eluent of each aliquot and compared the 
aggregation of our PEG-coated particles in each (Figure 5.3B, C, E, and F). We generally 
found less aggregation in the fractionated samples compared with the 30- and 0.45-µm 
filtered samples. When the MWCO was decreased to 3 kDa, the observed aggregation in 
the eluent matched the extent of aggregation observed for particles in HBSS. Overall, these 
data supported our hypothesis that polymers were involved in the aggregation of these 
particles. 
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Interestingly, in the lower SI, we observed more aggregation in the 0.45-µm filtered sample 
compared with the 30-µm filtered sample. From handling the samples, we observed that 
the 30-µm filtered samples appeared to be more viscous than the 0.45-µm filtered samples. 
We postulate that this increase in viscosity was due to the formation of self-associating 
polymeric structures, although we did not test this assumption. We attribute this decrease 
in aggregation in the 30-µm filtered samples to slower aggregation kinetics due to 
decreased diffusivity of particles in this viscous medium. This decrease in aggregation at 
high polymer concentrations or viscosities is also observed in solutions of model polymers, 
as discussed in the next section. 
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Figure 5.3: Gel permeation chromatography (GPC) of fluid from the small intestine (SI) 
and aggregation of PEG-coated particles in fractionated fluid from SI. (A and D) 
Chromatograms of samples from the upper (A) and lower (D) SI from a group of three 
chow-fed mice. Dashed lines indicate the three retention volumes the chromatograms were 
divided into for analysis: 11-16 mL, 16-20 mL, and >20 mL. Estimated concentrations and 
molecular weight (MW) are reported in green on the chromatograms for each retention 
volume. (B and E) Volume-weighted empirical cumulative distribution functions (ECDFs) 
of aggregate sizes in the upper (B) and lower (E) SI liquid fractions of chow-fed mice 
which have been run through MW cut-off (MWCO) filters with different MWCOs. As a 
control, aggregate sizes were also measured for particles placed in HBSS. The vertical axis 
is the cumulative volume fraction of the total number of particles in solution in an aggregate 
of a given size. The horizontal axis is aggregate size (number of particles per aggregate, 
N). (C and F) Box plots depict the 95% empirical bootstrap CI of the volume-weighted 
average aggregate size (given in number of particles per aggregate, N) in the samples from 
panels B and E, respectively (see Materials and Methods for bootstrapping procedure). The 
line bisecting the box is the 50th percentile, the upper and lower edges of the box are the 
25th and 75th percentile respectively, and the whiskers are the 2.5th and 97.5th percentiles. 
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Aggregation of PEG-coated particles in model polymer solutions shows complex 
dependence on the concentration and MW of polymers. 
Before exploring the complex environment of the SI further, we sought to first understand 
how our PEG-coated particles behaved in simple, well-characterized polymer solutions 
with similar MW and concentrations to those polymers we found in the SI in the previous 
experiments (Figure 5.3A and D). It has been demonstrated that the aggregation of colloids 
and bacteria can be controlled by altering the concentration and size of the non-adsorbing 
polymers to which particles are exposed (27–33). In these controlled settings, particles 
aggregate due to what are known as depletion interactions (27–29). Many groups have 
focused on depletion interactions with hard-sphere-like colloids; they often use 
polymethylmethacrylate particles sterically stabilized with polyhydroxystearic acid, 
because these particles closely approximate hard-sphere-like behavior (45,46). In these 
scenarios, depletion interactions are often described as forces that arise when particles get 
close enough to exclude polymers from the space between them, resulting in a difference 
in osmotic pressure between the solution and the exclusion region, leading to a net 
attractive force (27–31). Others have instead chosen to describe the phase behavior of the 
colloid/polymer mixture in terms of the free energy of the entire system (33,47). Short-
range attractions (polymer radius is ten-fold less than particle radius) between hard-sphere 
colloids induced by polymers have been described successfully in the language of 
equilibrium liquid–gas phase separation (48,49). 
Some groups have explicitly accounted for the effects of the grafted polymer layer used to 
sterically stabilize colloids when studying interactions between polymer solutions and 
colloids (50–58); this includes groups studying mixtures of polystyrene particles sterically 
stabilized with grafted layers of PEG (MWs of 750 Da and 2 kDa) and aqueous solutions 
of free PEG polymer (MW from 200 Da to 300 kDa) (51,52). It has been found 
experimentally that in mixtures of polymers and sterically stabilized colloids, the colloids 
form aggregates above a threshold polymer concentration. At even higher concentrations, 
as the characteristic polymer size shrinks, the colloids cease to aggregate, a phenomenon 
referred to as “depletion stabilization.” 
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To test whether our PEG-coated particles behave similarly to what has been previously 
found in mixtures of polymers and sterically stabilized particles, we created polymer 
solutions with PEG at a range of polymer concentrations and MWs and measured the extent 
of aggregation in these polymer/particle mixtures (Figure 5.4A-D). We chose PEGs that 
have MWs similar to the MW of polymers we found naturally occurring in the SI (Figure 
2.3A, D): 1 MDa, 100 kDa, and 3350 Da. Using PEGs with similar physical properties (i.e. 
MW, concentration) as a simple model of polymers found in the SI allows us to focus solely 
on physical interactions between the particles and polymers. We created PEG solutions in 
HBSS at mass concentrations similar to those measured for polymers in the SI (Figure 
2.3A and D) and imaged the polymer/particle mixtures after ~10 min. HBSS was chosen 
because it has a similar pH and ionic strength to that of the SI (59,60). At the high ionic 
strengths of these buffered aqueous solutions (~170 mM), any electrostatic repulsions that 
can occur between particles should be screened to length scales of order the Debye 
screening length ~0.7 nm (61,62), nearly an order of magnitude smaller than the estimated 
length of the surface PEG brush (~6.4 nm; see Materials and Methods for more details). 
We again chose to look at aggregation on short timescales (after ~10 min) because we 
sought to understand the initial formation of aggregates; in the SI, on longer timescales, 
aggregation will likely also be influenced by mechanical forces such as shear due to 
peristaltic mixing and the transit of food. 
For PEG 1 MDa and 100 kDa solutions we found aggregates of similar sizes to those 
observed in the SI luminal fluid (Figure 5.4A-D). We did not detect any aggregation for 
the PEG 3350 Da solutions (Figure 5.4D). Because the pH is known to vary across 
different sections of the gastrointestinal tract and this could affect the observed aggregation 
behavior, we measured the pH in luminal fluid from the upper and lower small intestine 
(see Figure 2-S2 and Materials and Methods). We found that the upper small intestine 
(USI) luminal fluid was 𝑝𝐻 = 6.0 ± 0.1 and for the lower small intestine (LSI) 𝑝𝐻 =
7.5 ± 0.3. For the HBSS used, 𝑝𝐻 = 7.6 ± 0.1 (See Materials and Methods), which 
matches that of the LSI but not the USI. We therefore conducted the same in vitro 
experiment for PEG 1 MDa in phosphate buffered saline with 𝑝𝐻 = 6.0 ± 0.1 (Materials 
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and Methods and Figure 5.4 – Figure supplement 1). We found some differences in the 
aggregation, but the overall trends were similar to before. 
Overall, though our system is not at equilibrium at these short timescales, we found trends 
consistent with what has been observed in the literature for depletion interactions with 
sterically stabilized particles (50–58). At dilute polymer concentrations, the extent of 
aggregation increased with concentration. At higher polymer concentrations, the extent of 
aggregation began to decrease as the solutions begin to “re-stabilize.” Additionally, the 
extent of aggregation was greater for longer polymers. Interestingly, we found that the 
curves for the long polymers in Figure 5.4D could be collapsed by normalizing the 
polymer concentration by the overlap concentration (which denotes the transition between 
the dilute to semi-dilute polymer concentration regimes) for each respective polymer 
solution (Figure 5.4 – Figure supplement 2). We next sought to describe the inter-particle 
potential using theory that combines depletion interactions with steric interactions. 
We applied previously established theoretical frameworks that combine depletion 
interactions with steric interactions to better understand our system (50,54,58). To account 
for the depletion attractions between colloids we used the Asakura–Oosawa (AO) potential 
(Udep) (27–29): 
𝑈𝑑𝑒𝑝(𝑟) =  {
+∞ 𝑓𝑜𝑟 𝑟 ≤ 0
−2𝜋Π𝑃𝑎 (𝑅𝑃 −
𝑟
2
)
2
𝑓𝑜𝑟 0 < 𝑟 < 2𝑅𝑃
0 𝑓𝑜𝑟 𝑟 > 2𝑅𝑃
(𝐸𝑞. 2.1) 
Where Udep is given in joules, ΠP is the polymer osmotic pressure (in Pa), a is the radius of 
the colloid (in m), RP is the characteristic polymer size (in m), and r is the separation 
distance between bare particle surfaces (in m). This form of the depletion potential equation 
assumes that a >> RP, a condition satisfied for 1 µm particles we used. For the polymer 
osmotic pressure, we used the following crossover equation for a polymer in a good solvent 
(63,64): 
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Π𝑃 =  
𝑁𝐴𝑣𝑜𝑘𝑇
𝑀𝑊
𝑐𝑃 (1 + (
𝑐𝑃
𝑐𝑃
∗ )
1.3
) (𝐸𝑞. 5.2) 
Where ΠP  is given in pascals, NAvo is Avogadro’s number, k is the Boltzmann constant, T 
is the temperature (in kelvins), MW is the molecular weight of the polymer (in Da), 𝑐𝑃 is 
the polymer mass concentration (in kg/m3), and 𝑐𝑃
∗
 is the polymer overlap concentration (in 
kg/m3). This equation describes the polymer osmotic pressure well in both the dilute and 
semi-dilute regime. 
For the characteristic polymer size, we used the concentration-dependent radius of gyration 
(31,65). This can be written as: 
𝑅𝑃(𝑐𝑃) =  𝑅𝑔(0) (
𝑀𝑤
𝑁𝐴𝑣𝑜𝑘𝑇
𝑑Π𝑃
𝑑𝑐𝑃
 )
−
1
2
(𝐸𝑞. 5.3) 
Where 𝑅𝑃(𝑐𝑃) is the concentration-dependent radius of gyration or the characteristic 
polymer size given in meters, Rg(0) is the radius of gyration (in m) at dilute concentrations 
and ΠP is given by equation 5.2. The characteristic polymer size is given by the dilute 
radius of gyration at low concentration and is close to the correlation length of the polymer 
solution, or the average distance between monomers, in the semi-dilute regime. Therefore, 
using equations 5.2 and 5.3, we acquire the correct limits for the depletion potential; the 
Asakura–Oosawa potential in the dilute regime and the depletion potential described by 
Joanny, Liebler, and de Gennes in the semi-dilute regime (66). Similar crossover equations 
have been found to adequately describe experimentally observed depletion aggregation in 
polymer-colloid mixtures where the polymer concentration spans the dilute and semi-dilute 
regimes  (67). Using literature values for the hydrodynamic radii of the PEGs (68) and the 
Kirkwood-Riseman relation, which relates the hydrodynamic radius to the radius of 
gyration (68–70), we estimated Rg(0) for each polymer. We estimated Rg(0) ≈ 62.6, 16.7, 
2.9 nm for PEG 1 MDa, 100 kDa, and 3350 Da, respectively. Using both the estimates of 
Rg(0) and the MW of each polymer, we then estimated 𝑐𝑝
∗  for each polymer (63,71). We 
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estimated cp
* = 1.6, 8.6, and 52.6 mg/mL for PEG 1 MDa, 100 kDa, and 3350 Da, 
respectively. 
To account for steric interactions between the two grafted layers upon close inter-particle 
separations, we used equation 5.4 (50,52). For inter-particle separation distances between 
L and 2L, where L is the length of the grafted layer, the steric interactions between the two 
grafted layers can be described using the Flory–Huggins free energy of mixing: 
𝑈𝑠,𝑚𝑖𝑥(𝑟) =  
4𝜋𝑎𝑘𝑇
𝜐1
(𝜙2
𝑎̅̅ ̅̅ )
2
(
1
2
− 𝜒) (𝐿 −
𝑟
2
)
2
(𝐸𝑞. 5.4) 
Where 𝑈𝑠,𝑚𝑖𝑥 is the steric interaction energy due to mixing (given in joules), a is the particle 
radius (in m), 𝜐1 is the volume of a water molecule (in m
3), 𝜙2
𝑎̅̅ ̅̅
 is the average volume 
fraction of the grafted polymer (unitless), 𝜒 is the Flory–Huggins interaction parameter for 
the grafted polymer and the solvent (unitless), and L is the length of the grafted layer (in 
m). For PEG in aqueous solvents, 𝜒 = 0.45 (72). Our NMR measurements (see Materials 
and Methods for details) suggest that the grafting density of PEG is within the brush 
regime. We therefore use the Alexander–de Gennes approximation (63) and our NMR 
measurements to estimate the length of the grafted layer (L) as L ~ 6.4 nm and the average 
volume fraction to be 𝜙2
𝑎̅̅ ̅̅  ~ 0.43. 
For inter-particle separations closer than L, one needs to account for elastic deformations 
of the grafted layers (50,57). This is far greater in magnitude than Udep, so one can simply 
assume that at this point the potential is extremely repulsive. For inter-particle separations 
greater than L: 
𝑈(𝑟) =  {
𝑈𝑠,𝑚𝑖𝑥 + 𝑈𝑑𝑒𝑝 𝑓𝑜𝑟 𝐿 < 𝑟 < 2𝐿
𝑈𝑑𝑒𝑝 𝑓𝑜𝑟 𝑟 ≥ 2𝐿
(𝐸𝑞. 5.5)  
Using this theoretical framework, we can build a physical intuition for the system (Figure 
5.4E-G). Long polymers have depletion layers that extend out past the brush layer and 
overlap, inducing attractions between the particles (Figure 5.4E). For short polymers (RP 
< L), the depletion attractions are buried within the steric repulsions induced by the brush 
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and there are effectively no attractions among the particles (Figure 5.4F). We can use this 
crossover to estimate the magnitudes of the minima in the inter-particle potentials for the 
three PEG solutions (Figure 5.4H). It should be noted that we have made several 
simplifications; for example, we do not consider interactions between free polymers and 
the grafted layer, which could lead to partial penetration of free polymers into the grafted 
layer or possible compression of the grafted layer by the free polymers (50,56,57). Despite 
such simplifications, we find that the calculated minima display similar concentration 
trends to the trends seen in the average aggregate sizes (Figure 5.4D). These calculations 
offer an explanation for why there is no aggregation of PEG-coated particles in solutions 
of PEG 3350. 
 Another factor that needs to be considered at the short timescales and low-volume 
fractions we are working at is aggregation kinetics (73–75). The probability that particles 
collide in solution is directly related to the diffusion coefficient and the volume fraction of 
the particles. As we increase the polymer concentration we increase the viscosity of the 
solution and decrease the diffusivity of the particles. In Figure 5.4I, we plot theoretical 
estimates of the diffusion coefficients of the particles against the concentrations of the PEG 
solutions. These diffusion coefficients were estimated using literature measurements, the 
Stokes–Einstein–Sutherland equation, and the Huggins equation for viscosity (63,68). 
Because our system has not reached equilibrium, in this case the non-monotonic 
dependence of aggregation on polymer concentration for long polymers is due to a complex 
interplay between thermodynamics and kinetics (which we have not untangled). However, 
both the dependence of diffusivity (Figure 5.4I) and the equilibrium prediction of inter-
particle minima (Figure 5.4H) on polymer concentration suggest that we should expect a 
decrease in aggregation at high polymer concentrations. The inter-particle minima also 
suggests that we should not expect short polymers to induce aggregation. Both trends are 
consistent with what we observe. Understanding how our PEG-coated particles behave in 
these so-called “simple” polymer solutions with similar physical properties to the intestinal 
polymers we detected (Figure 5.3A and D) informs the interpretation of the results of the 
next sections. 
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Figure 5.4: Aggregation of PEG-coated particles in model polymer solutions shows 
complex dependence on molecular weight (MW) and concentration of PEG. (A) 
Aggregates of 1 µm diameter PEG-coated particles in a 1 MDa PEG solution with a 
polymer concentration (c) of 1.6 mg/mL. Image is a maximum z-projection of 10 optical 
slices taken on a confocal microscope. Scale bar is 10 µm. (B and C) 3D renders of 
aggregates found in panel A. Scale bars are 2 µm. (D) Volume-weighted average sizes for 
serial dilutions of PEG solutions of three MW (1 MDa, 100 kDa, and 3350 Da). Volume-
weighted average sizes are plotted on the vertical axis in terms of number of particles per 
aggregate (N) against polymer mass concentration (cp) in mg/mL. The vertical error bars 
are 95% empirical bootstrap CI (see Materials and Methods for bootstrapping procedure). 
Shaded regions indicate the concentration ranges of detected intestinal polymers of similar 
MW. (E) Schematic depicting depletion interactions induced by “long polymers” (polymer 
radius (RP) > length of the brush, L). Free polymers are depicted as purple spheres. Colloids 
are depicted in green with the grafted brush layer in purple. The depletion layer around 
each colloid is depicted by dotted lines. The overlap region between the two depletion 
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layers is indicated in grey. (F) Schematic depicting depletion interactions induced by “short 
polymers” (Rp < L). The depletion zone does not extend past the length of the brush and 
there is effectively no overlap in the depletion layers; the depletion attractions are “buried” 
within the steric layer. (G) Schematic depicting the different contributions to the inter-
particle potential (U(r)) against inter-particle separation distance (r). The hard surfaces of 
the particles are in contact at r = 0. Udep depicts the depletion potential for a short polymer 
(RP,short) and a long polymer (RP,long). Us,mix shows the contribution to the steric potential 
due to mixing. Us,el + Us,mix shows the contribution due to elastic deformations and mixing 
at close inter-particle separations. (H) The magnitude of the minima of the inter-particle 
potential (Umin/kT) plotted against polymer concentration for the three PEG solutions in 
(D). (I) Diffusion coefficients estimated from the Stokes–Einstein–Sutherland equation for 
1 µm particles in the PEG solutions used in (D). Diffusion coefficients of particles in 
polymer solutions (DP) are normalized by the diffusion coefficients in water (DW) and 
plotted against polymer concentration. Figure supplement 1 shows the dilution series for 
PEG 1 MDa at pH = 6.0 compared to pH = 7.6. Figure supplement 2 shows the dilution 
series displayed in Figure 5.4D where the polymer concentration has been normalized by 
the overlap concentration of each polymer solution. 
 
 
Figure 5.4 – Figure supplement 1: Aggregation of PEG-coated particles in model 
polymer solutions with different pH. (A) Volume-weighted average sizes for serial 
dilutions of 1 MDa PEG solutions in a phosphate buffered saline solution with 𝑝𝐻 = 6.0 ±
0.1 (labeled pH = 6.0) and in Hank’s balanced salt solution (HBSS) with 𝑝𝐻 = 7.6 ± 0.1 
(same data from Figure 5.4D). Volume-weighted average sizes are plotted on the vertical 
axis in terms of number of particles per aggregate (N) against polymer mass concentration 
(cp) in mg/mL. The vertical error bars are 95% empirical bootstrap CI (see Materials and 
Methods for bootstrapping procedure). 
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Figure 5.4 – Figure supplement 2: Aggregation of PEG-coated particles in model polymer 
solutions from Figure 4D normalized by polymer overlap concentration. Volume-
weighted average sizes for serial dilutions of 1 MDa PEG solutions in Hank’s balanced salt 
solution (HBSS). Volume-weighted average sizes are plotted on the vertical axis in units 
of number of particles per aggregate (N) against the “normalized polymer concentration.” 
The normalized polymer concentration is the polymer mass concentration (cp) in mg/mL 
divided by the overlap concentration of each polymer solution (cp
*) in mg/mL. The overlap 
concentrations for PEG 1 MDa, 100 kDa, and 3350 Da are cp
* = 1.6, 8.6, and 52.6 mg/mL, 
respectively. The vertical error bars are 95% empirical bootstrap CI (see Materials and 
Methods for bootstrapping procedure). 
 
 
 
MUC2 may play a role in the aggregation of PEG-coated particles, but is not required for 
aggregation to occur 
It has been demonstrated that mucins can aggregate and bind to bacteria in vitro (12–16); 
thus, we wanted to test whether mucins, such as Mucin 2 (MUC2), which is the primary 
mucin secreted in the SI (76,77), drive the aggregation of PEG-coated particles in SI fluid. 
It is known that in the presence of Ca2+ and at 𝑝𝐻 ≤ 6.2, MUC2 can form aggregates or 
precipitate out, but it is soluble without Ca2+ or at higher pH (78). Our measurements of 
the pH throughout the SI suggest that it is possible that MUC2 precipitates out in the upper 
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small intestine; however, because it is unclear how much Ca2+ is in the lumen of the upper 
small intestine, there could be soluble MUC2 in the upper small intestine. Additionally, the 
literature suggests that, based on the pH, there should be soluble MUC2 in the lower small 
intestine. We therefore tested if MUC2 drives aggregation in both the upper and lower 
small intestine. To do this, we compared the aggregation of our PEG-coated particles in 
samples from MUC2 knockout (MUC2KO) mice to samples from wild-type (WT) mice. 
To carefully preserve the native composition of the SI fluid, we used a protease-inhibitor 
cocktail when collecting the samples (see Materials and Methods). We confirmed mouse 
MUC2KO status via genotyping and Western blot (Figure 5.5E; Materials and Methods). 
The Western blot detected MUC2 in the colons of WT mice and not MUC2KO mice, as 
expected, however it did not detect a signal for MUC2 in the SI of either the WT or 
MUC2KO mice. We speculate that the lack of MUC2 signal in the SI of WT mice may be 
due to low levels of MUC2 present in the luminal contents of the SI. 
We observed aggregation in samples from both the MUC2KO and WT mice (Figure 5.5A-
B). To test the strength of the aggregation effect in the different samples, we serially diluted 
the samples and measured the average aggregate size to see when the effect disappeared 
(Figure 5.5C-D). As explained in the previous section, we do not necessarily expect to see 
a linear decrease in aggregation with dilution. For simplicity, we will refer to the dilution 
factor at which aggregation begins to disappear as the “aggregation threshold.” We found 
differences in the aggregation threshold in the samples from MUC2KO and WT mice 
(Figure 5.5C-D), suggesting that although MUC2 is not required for aggregation to occur, 
it could play a role in the aggregation of PEG-coated particles. 
We wanted to test differences in the MW distribution of the polymers found in these 
samples, so we 0.45-µm-filtered our samples and analyzed them by GPC (see Materials 
and Methods). The chromatograms from the refractometer (Figure 5.5F-G) suggest that 
the polymer composition of MUC2KO and WT samples were qualitatively similar. 
Following the same methods in Figure 5.3, we made estimates of the physical parameters 
of the detected polymers. These estimates are summarized in Tables 5.S1–S2 for both the 
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upper and lower SI of MUC2KO and WT mice. We find that these estimates suggest there 
are some differences in the polymeric composition of the SI of these two groups. 
 To test whether these measured differences in polymeric composition are reflected in 
differences in aggregation, we looked at aggregation in the 0.45-µm-filtered samples. We 
found that the undiluted samples from both groups displayed aggregation (Figure 5.S3A-
B). We then created serial dilutions of the samples and found different aggregation 
thresholds for the samples (Figure 5.S3C-D). These results further confirm our conclusion 
that although MUC2 may play a role in particle aggregation, it is not required for 
aggregation to occur. 
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Figure 5.5: Quantification of the aggregation of particles in the small intestine (SI) in 
MUC2 knockout (MUC2KO) and wild-type (WT) mice. (A and B) Volume-weighted 
empirical cumulative distribution functions (ECDFs) comparing aggregation of the 
particles in undiluted, 30-µm filtered samples from the upper (A) and lower (B ) SI of two 
separate groups of wild-type (WT) and MUC2-knockout (MUC2KO) mice to the control 
(particles suspended in HBSS). The vertical axis is the cumulative volume fraction of the 
total number of particles in solution in an aggregate of a given size; the horizontal axis is 
aggregate size in number of particles per aggregate (N). (C and D). Volume-weighted 
average aggregate sizes (Vol Wt Avg Size) for serial dilutions of 30-µm-filtered samples 
from the upper (C) and lower (D) SI of two separate groups of WT and MUC2KO mice. 
The dilution factor is plotted on the horizontal axis; a dilution factor of 1 is undiluted, ½ is 
a two-fold dilution. The vertical error bars are 95% empirical bootstrap CI (see Materials 
and Methods). (E) Western blots of 30-µm filtered samples from the SI and the colon of 
WT and MUC2KO mice. WT USI = WT upper SI; KO USI = KO lower SI; WT LSI = WT 
lower SI; KO USI = KO upper SI; WT Col = WT colon; KO Col = KO colon (F and G). 
Chromatograms of samples from the upper (F) and lower (G) SI of groups of WT and 
MUC2KO mice.  
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Immunoglobulins may play a role in aggregation, but are not required for aggregation to 
occur 
It has also been demonstrated that immunoglobulins can bind to bacteria and induce them 
to aggregate (17–25). We therefore wanted to test the hypothesis that immunoglobulins 
drive the aggregation of PEG-coated particles in the SI. To do this, we compared the 
aggregation of our PEG-coated particles in samples from groups of mutant mice that do 
not produce immunoglobulins (Rag1KO), to samples from groups of WT mice. Again, to 
carefully preserve the native composition of the SI fluid, we used a protease-inhibitor 
cocktail when collecting the samples (see Materials and Methods). Because Rag1KO mice 
are immunocompromised, they need be fed an autoclaved chow diet. To control any 
potential differences in diet, both the Rag1KO and WT mice were fed an autoclaved chow 
diet for 48 h before samples were collected. 
The mice were confirmed to be Rag1KO via genotyping and Western blot (Figure 5.6E). 
According to the literature, IgA is abundant in the SI (79). As expected, we saw a signal 
for IgA in the upper and lower SI of WT mice. We also tested for less abundant 
immunoglobulins such as IgG and IgM (Figure 5.S4 and Figure 5.S5, respectively), but 
did not detect their presence in the luminal contents of either WT or KO mice. 
We observed aggregation in 30-µm-filtered samples from Rag1KO and WT mice (Figure 
5.6A and B). To test the strength of the aggregation effect in the different samples, we 
serially diluted the samples and compared the volume-weighted average aggregate sizes at 
each dilution (Figure 5.6C and D). We found differences in the amount of aggregation 
between the Rag1KO and WT samples at different dilutions, suggesting that although 
immunoglobulins are not required for aggregation to occur, they could play a role in the 
aggregation of PEG-coated particles. 
We wanted to test differences in the MW distribution of the polymers found in these 
samples, so we 0.45-µm-filtered our samples and analyzed them by GPC (see Materials 
and Methods). The chromatograms from the refractometer (Figure 5.6F and G) suggested 
that the Rag1KO and WT samples were visually similar. We again made estimates of the 
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physical parameters of the polymers in these samples (summarized in Tables 5.S3–S4). 
These estimates suggest that there are some differences in the polymeric composition of 
the SI of these two groups of mice. 
To test whether these measured differences in polymeric composition correspond with 
differences in aggregation, we quantified aggregation in the 0.45-µm-filtered samples. We 
found that the undiluted samples for both groups displayed aggregation (Figure 5.S6A and 
B). When we created serial dilutions of the samples we found that the levels of aggregation 
were similar (Figure 5.S6C and D). Taken together, the results suggest that 
immunoglobulins may play some role in aggregation, but the presence of immunoglobulins 
are not required for aggregation to occur. 
Interestingly, there are some differences in the levels of aggregation in WT mice fed the 
autoclaved diet compared with the standard chow diet. The two diets are nutritionally the 
same, only the processing is different. When samples from the WT mice in the MUC2KO 
experiments are compared with samples from the WT mice in the Rag1KO experiments 
are compared, it is apparent that, compared with WT mice fed the normal chow diet, 
samples from WT mice fed the autoclaved diet had (i) a lower average concentration of 
polymers and (ii) polymers of lower overall MW (see “WT” samples in Tables 5.S1–S4). 
These observations suggested two hypotheses: (1) dietary polymers may play a role in 
aggregation and (2) aggregation may be controlled by changing the polymer composition 
of the diet. We tested these hypotheses next. 
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Figure 5.6: Quantification of the aggregation of particles in the small intestine (SI) in 
Immunoglobulin-deficient (Rag1KO) and wild-type (WT) mice. (A and B) Volume-
weighted empirical cumulative distribution functions (ECDFs) comparing aggregation of 
the particles in undiluted, 30-µm filtered samples from the upper (A) and lower (B ) SI of 
two separate groups of wild-type (WT) and immunoglobulin-deficient (Rag1KO) mice to 
the control (particles suspended in HBSS). Plotted on the vertical axis is the cumulative 
volume fraction of the total number of particles in solution in an aggregate of a given size. 
Plotted on the horizontal axis are aggregate sizes in number of particles. (C and D). 
Volume-weighted average aggregate sizes (Vol Wt Avg Size) for serial dilutions of 30-µm 
filtered samples from the upper (C) and lower (D) SI of two separate groups of WT and 
Rag1KO mice. The dilution factor is plotted on the horizontal axis, where a dilution factor 
of 1 is undiluted, ½ is a two-fold dilution, and so on. The vertical error bars are 95% 
empirical bootstrap CI using the bootstrapping procedure described in Materials and 
Methods. (E ) Western blots of 30-µm filtered samples from the SI of WT and Rag1KO 
mice. WT USI = WT upper SI; KO USI = KO lower SI; WT LSI = WT lower SI; KO USI 
= KO upper SI. (F and G) Chromatograms of samples from the upper (F) and lower (G) SI 
of groups of WT and Rag1KO mice. 
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Polymers in the diet control aggregation of PEG-coated particles in a manner consistent 
with depletion-type interactions 
As described in Figure 5.4, the extent of aggregation can be controlled by altering the 
polymer size and concentration of the polymer solution. Furthermore, as pointed out above, 
SI fluid from mice fed autoclaved and non-autoclaved diets induced different levels of 
aggregation. We hypothesized that aggregation behavior would differ between mice fed 
polymers of different sizes—even if the polymers were composed of similar chemical 
monomers and were present at the same polymer mass concentration. We hypothesized 
that mice fed short polymers would exhibit less aggregation in the SI (i.e. short polymers 
reduce the strength of the effect because depletion attractions are reduced). We predicted 
that the converse would be true for long polymers (i.e. long polymers increase the strength 
of the effect because depletion attractions are increased). 
We first identified two candidate dietary carbohydrate polymers; Fibersol-2, a “resistant 
maltodextrin” composed of D-glucose monomers (80,81), with a MW of ~3500 Da (see 
Table 5.S5) and apple pectin, composed of D-galacturonic acid and D-galacturonic acid 
methyl ester monomers (82,83), with a MW of ~230 kDa (Table 5.S5). Before feeding 
mice these polymers, we first tested their effects on aggregation in vitro at various 
concentrations in buffer (Figure 5.7A). We found similar trends to the PEG solutions in 
Figure 5.4. Pectin at low (~0.05 to ~1 mg/mL) and very high mass concentrations showed 
little aggregation (~7 mg/mL) and showed the most aggregation at an intermediate 
concentration (~1.5 to ~3 mg/mL). Fibersol-2 did not induce much aggregation up to a 
mass concentration of ~240 mg/mL. 
To test our hypothesis that we could use polymer size to control aggregation, we devised a 
simple experiment. One group of mice was fed a solution of Fibersol-2 and a second group 
was fed a solution of apple pectin for 24 h. The mass concentrations of the fibers in the two 
solutions were matched at 2% w/v and 5% w/v sucrose was added to each to ensure the 
mice consumed the solutions. Mesh-bottom cages were used to ensure that the mice did 
not re-ingest polymers from fecal matter via coprophagy. According to the literature, 
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neither of these two polymers should be broken down in the SI (81,84,85). As before, all 
samples were collected with a protease-inhibitor cocktail. 
As before, we created serial dilutions of the small intestinal luminal fluid and looked at the 
extent of aggregation in each sample. In the 30-µm-filtered samples from the upper SI we 
observed more aggregation in the pectin-fed mice compared with the Fibersol-2 fed mice 
(Figure 5.7E). For the undiluted 30-µm-filtered lower SI sample, the pectin-fed mice 
samples formed a gel-like material which we were unable to pipette and therefore could 
not use for aggregation experiments. This gelation is not too surprising considering that 
pectin can form a gel in certain contexts (83,86). We were able to dilute this gel four-fold 
and then compare the aggregation in serial dilutions of the pectin-fed LSI to the Fibersol-
2-fed LSI. We found, again, more aggregation in the pectin-fed mice than the Fibersol-2-
fed mice (Figure 5.7G). 
We again 0.45-µm-filtered these samples and ran them on GPC to test differences in the 
MW and size distributions of the polymers in these samples. The chromatograms from the 
refractometer (Figure 5.7C and D) suggest that there are differences in the polymeric 
distribution in the two groups of mice. Figure 7B shows chromatograms of just Fibersol-2 
and pectin in buffer. We see that pectin elutes between 14-18 min, which is where we see 
an enhancement of the concentration of high-MW polymers in the samples from the SIs of 
the group fed pectin. We also see that Fibersol-2 elutes between 18-22 min, which is where 
we see an enhancement in the concentration of low-MW polymers in the samples from the 
SI of the group fed Fibersol-2. We again made estimates of the physical parameters of the 
polymers in these samples which are summarized in Tables 5.S6 and 5.S7. The estimates 
also suggest that there are differences in the polymeric composition of the SI of the two 
groups. Overall, the data from GPC suggests that the pectin-fed mice have more high-MW 
polymers than the Fibersol-2-fed mice. Low-MW polymers appear to be more abundant in 
Fibersol-2 fed mice compared with pectin-fed mice. We observed visually that the SI 
contents of the pectin-fed mice formed a gel and pectin is also known to self-associate to 
form a gel or aggregates in solution (83,86). We note, therefore that by 0.45-µm-filtering 
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these samples we may be removing these structures and decreasing the concentration of 
pectin in our samples. 
To test that these measured differences in polymeric composition are reflected in 
differences in aggregation, we tested aggregation in the 0.45-µm-filtered samples. We 
found that in both the upper and lower SI samples, the samples from the pectin-fed group 
showed more aggregation than the samples from the group fed Fibersol-2 (Figure 5.7F 
and H). When we created serial dilutions of these samples, we found that the samples from 
the mice fed Fibersol-2 showed almost no aggregation at any concentration whereas the 
samples from pectin-fed mice showed aggregation. We also observed that we needed to 
dilute the 30-µm-filtered samples more to achieve the greatest extent of aggregation 
(Figure 5.7E and G). We speculate that this shift in the aggregation behavior between the 
30-µm-filtered and 0.45-µm-filtered samples is due to some of the polymers being lost 
when 0.45-µm-filtering the samples as a result of the aforementioned self-association of 
pectin.  
These data taken together lead us to conclude that polymers in the diet can be used to 
control the aggregation of PEG-coated particles. This data further suggests that feeding 
higher MW polymers at the same mass concentration as lower MW polymers leads to an 
enhancement in aggregation. Due to the high polydispersity and complex chemical 
composition of SI luminal fluid as measured by GPC, it is unfeasible to apply the same 
theoretical analysis as was done in Figure 5.4 to these data. We can, however, note that 
visually the behavior is qualitatively consistent with the depletion-type interactions found 
in simple PEG solutions in Figure 5.4.  
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Figure 5.7: Quantification of aggregation of PEG-coated particles in the small intestine 
(SI) of mice fed different polymers from dietary fiber. (A) Volume-weighted average 
aggregate sizes (Vol Wt Avg Size) for serial dilutions of apple pectin and Fibersol-2. 
Volume-weighted average sizes are plotted on the vertical axis in terms of number of 
particles per aggregate (N) against polymer concentration (mg/mL). The vertical error bars 
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are 95% empirical bootstrap CI using the bootstrapping procedure described in Materials 
and Methods. (B) Chromatograms of apple pectin and Fibersol-2 in buffer. (C and D) 
Chromatograms of samples from the upper (E) and lower (F) SI of two separate groups of 
mice (fed pectin or Fibersol-2). (E-H) Volume-weighted average aggregate sizes (Vol Wt 
Avg Size) for serial dilutions of 30-µm-filtered samples from the upper (E) and lower (G) 
SI of two separate groups of mice (fed pectin or Fibersol-2) to the control (particles 
suspended in HBSS). (F and H) Serial dilutions of 0.45-µm-filtered samples from the same 
groups. The dilution factor is plotted on the horizontal axis, where a dilution factor of 1 is 
undiluted, and ½ is a two-fold dilution. The vertical error bars are 95% empirical bootstrap 
CI using the bootstrapping procedure described in Materials and Methods. 
 
DISCUSSION 
This work shows that even PEG-coated particles, which have minimal biochemical 
interactions, form aggregates in the luminal fluid of the SI. It reveals a previously unknown 
way in which dietary polymers can impact, and be used to control, the structure of particles 
in the SI. We speculate that this phenomenon may play a role in the aggregation of other 
particles in the SI such as microbes, viruses, nanoparticles for drug delivery, and food 
granules. In these systems, other factors will also inevitably affect the formation of these 
aggregates (e.g. interactions with mucins and immunoglobulins); thus, it will be important 
to explore the interplay among all these factors. Another important next step is to 
investigate how mixing in the SI and the co-aggregation of different types of particles may 
affect aggregation. We speculate that the aggregation of particles in the SI could also have 
functional consequences, such as promoting colonization by microbes, affecting infection 
by pathogens, and altering clearance of microbes (2,6–8,10,11). Aggregation will also need 
to be considered when designing nanoparticles for drug delivery (3,4). 
We found that MUC2 and immunoglobulins, which have been found to aggregate microbes 
both in vivo and in vitro (12–25), are not required for the aggregation of PEG-coated 
particles. Instead, we found that by feeding mice dietary polymers with similar chemistry 
but very different sizes we could tune the extent of aggregation in the SI. These polymers 
(pectin and Fibersol-2) are forms of fiber commonly found in the human diet. We found 
that feeding long polymers induced aggregation, whereas short polymers did not. More 
work needs to be done to understand the underlying mechanism, but surprisingly the 
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observed aggregation behavior in the SI luminal fluid from mice fed dietary polymers of 
different sizes is qualitatively consistent with the aggregation behavior in simple PEG 
solutions, where aggregation is driven by depletion interactions. Overall, this suggests a 
simple dietary method for controlling aggregation in the gut. It will be important to extend 
this work to microbes and other particles commonly found in the gut and to measure the 
relative contributions of polymer-driven aggregation and chemical-driven aggregation. We 
note that mucins and immunoglobulins are polymers that can also self-associate into 
structures of very high MW (78,87,88), suggesting that they could cause aggregation via 
both physical and chemical mechanisms. Interestingly, during the review of this 
manuscript, a study was published with in vitro work done using model buffer solutions of 
mucins, DNA, and other biopolymers further implying that aggregation of bacteria by host-
polymers can be depletion-mediated (89). In vivo, it will also be important to consider the 
effects of flow, as it has been shown that flow in non-Newtonian fluids can induce particle 
aggregation (90–92). In particular, studies have suggested that the combination of flow and 
polymer elasticity can lead to aggregation (93) and that shear thinning viscosity can 
influence aggregation as well (94). In our work, we neglected flow effects for simplicity 
and thus our findings are most applicable to the initial formation of aggregates before 
aggregation is influenced by mechanical forces due to peristaltic mixing and the transit of 
food. A rudimentary estimate of the Weissenberg number (see Materials and Methods), 
which weighs the contributions of elastic and viscous forces, yields Wi ~ 0.3 to 10, 
suggesting that elasticity-induced effects may play a role in the SI and will be an important 
direction to pursue in follow-up studies. If flow-induced clustering does occur in vivo, the 
literature suggests it would aid in the process, perhaps enhancing particle aggregation. 
We note that current dietary guidelines do not differentiate between fibers of low and high 
MW (95,96). Our work implies that the MW of fiber, and the subsequent degradation of a 
high-MW fiber into a low-MW component (97), which we have discussed previously in 
the context of mucus compression, is important in defining the physicochemical 
environment of the gut. Further studies will be required to understand the effects of 
industrial food processing on MW of the dietary polymers present in foods, and which 
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processing methods preserve or produce high-MW polymers that impact mucus 
compression (97) and particle aggregation in the gut.   
 
MATERIALS AND METHODS 
Table 5.1: Key Resources Table 
Reagent type 
(species) or 
resource 
Designation Source or 
reference 
Identifiers Additional 
information 
MUC2KO, 
C57BL/6 
mice (female) 
MUC2KO Eugene Chang Lab 
provided initial 
breeding pairs 
which were 
provided to them 
from Leonard H. 
Augenlicht at the 
Department of 
Oncology of 
Albert Einstein 
Cancer Center 
  Genotyping 
was performed 
by Transnetyx 
Inc.; Western 
blot was done 
to confirm lack 
of MUC2 (See 
Fig. 5.5E) 
Rag1KO, 
C57BL/6 
mice (male) 
Rag1KO Provided by 
Mazmanian Lab at 
Caltech 
  Western blot 
was done to 
confirm lack of 
IgA as 
explained in the 
text (See Fig. 
5.6E) 
C57BL/6 
mice (all 
male except 
for WT 
controls in 
MUC2KO 
experiments 
in Figure 5 
and S3) 
WT The Jackson 
Laboratory 
    
antibody MUC2 
polyclonal 
antibody 
(rabbit 
host) 
Biomatik Cat No: 
CAU27315 
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antibody Li-Cor 
IRDye 
800CW 
Goat Anti-
Rabbit IgG  
Li-Cor P/N 925-
32211 
  
antibody Li-Cor 
IRDye 800 
CW Goat 
Anti-Mouse 
IgG 
Li-Cor P/N 925-
32210 
  
antibody Li-Cor 
IRDye 800 
CW Goat 
Anti-Mouse 
IgM 
Li-Cor P/N 925-
32280 
  
antibody Goat Anti-
Mouse IgA-
unlabeled 
SouthernBiotech Cat No: 1040-
01 
  
antibody Li-Cor 
IRDye 800 
CW 
Donkey 
Anti-Goat 
IgG 
Li-Cor P/N 925-
32214 
  
chemical 
compound, 
drug 
apple pectin Solgar Inc. "Apple pectin 
powder"; 
SOLGB70120 
00B 
  
chemical 
compound, 
drug 
Fibersol-2 Archer Daniels 
Midland/Matsutani 
LLC 
Product code: 
013100, Lot 
#: 
CY4P28540 
  
chemical 
compound, 
drug 
USP grade 
sucrose 
Sigma-Aldrich     
chemical 
compound, 
drug 
Protease 
inhibitor 
cocktail 
Roche cOmplete, 
Mini, EDTA-free 
Protease-Inhibitor 
cocktail, Roche 
    
chemical 
compound, 
drug 
PEG 
100kDa 
Dow POLYOX 
WSR N-10 
  
chemical 
compound, 
drug 
PEG 1 
MDa 
Dow POLYOX 
WSR N-12K 
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chemical 
compound, 
drug 
PEG 3350 Bayer MiraLAX   
chemical 
compound, 
drug 
Hanks' 
Balanced 
Salt 
Solution 
(without 
calcium, 
magnesium, 
phenol red) 
GE Healthcare 
Life Sciences 
Product code: 
SH30588.02 
  
software, 
algorithm 
3D 
aggregate 
analysis 
pipeline 
This paper; source 
code available 
through Dryad 
  Description in 
Materials and 
Methods; 
source code 
provided on 
Dryad 
other mesh-
bottom (or 
wire-
bottom) 
floors 
 Lab Products, Inc. P/N: 75016   
other 1-μm 
diameter 
PEG 5kDa-
coated 
polysytrene 
beads 
This paper   Description of 
synthesis in 
Materials and 
Methods 
other 1-μm 
diameter 
PEG 5kDa-
coated 
polysytrene 
beads with 
PEG 1 kDa 
"back-
filling" 
This paper   Description of 
synthesis in 
Materials and 
Methods 
other standard 
chow diet 
PicoLab PicoLab 
Rodent Diet 
20; Product 
#5053 
  
other autoclaved 
chow diet 
PicoLab Laboratory 
Autoclavable 
Rodent Diet 
5010 
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Details of animals used  
All mice were male or female specific pathogen free (SPF) C57BL/6 mice between 8-16 
weeks old. Mice on a standard, solid chow diet were given food and water ad libitum. 
Immunoglobulin-deficient (Rag1KO) mice were maintained on an autoclaved chow diet 
due to their immunocompromised status. The control group of WT mice used as a 
comparison to this group was maintained on the same autoclaved chow diet for 48 h before 
euthanasia. Genotyping of MUC2 deficient (MUC2KO) and Rag1KO mice was done by 
Transnetyx (Transnetyx, Inc., Cordova, TN, USA). Mice given only apple pectin (Solgar, 
Inc., Leonia, NJ, USA) with sucrose (USP grade, Sigma-Aldrich, St. Louis, MO, USA) or 
Fibersol-2 (Archer Daniels Midland/Matsutani LLC, Chicago, IL, USA) with sucrose were 
first raised on a standard chow diet and given water ad libitum, then were maintained on a 
restricted diet consisting of only 2% apple pectin + 5% sucrose or 2% Fibersol-2 + 5% 
sucrose for 24 h. For those 24 h, these mice were kept on mesh-bottom cages to prevent 
the re-ingestion of polymers from the standard chow diet via coprophagy. The MUC2KO 
colony was raised and maintained by the Ismagilov Lab. The Rag1KO mice were provided 
by the Mazmanian lab (Caltech). All other mice were from Jackson Labs (The Jackson 
Laboratory, Bar Harbor, ME, USA). All animal experiments were approved by the 
California Institute of Technology (Caltech) Institutional Animal Care and Use Committee 
(IACUC) and the U.S. Army’s Animal Care and Use Review Office (ACURO). Mice were 
euthanized via CO2 inhalation as approved by the Caltech IACUC in accordance with the 
American Veterinary Medical Association Guidelines on Euthanasia (98). 
Oral administration of particles  
Particles were gavaged at a concentration of 0.1–2% w/v in either 1x HBSS or 1x PBS. We 
used small fluid volumes (50 µL) to minimize volume-related artifacts (3). We chose 
buffers isotonic to the SI because it has been shown that the isotonicity of the delivery 
medium can greatly affect the in vivo particle distribution (38). In some experiments, 
animals were food-restricted for 4 h prior to administration of particles. It has been 
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previously demonstrated though that food-restriction has minimal effects on the in vivo 
distribution of PEG-coated particles (3). In all experiments animals were euthanized 3 h 
after administration of particles. 
Fluorescent scanner experiments  
Gastrointestinal tracts (GIT) were excised and laid out flat on petri dishes on ice. Drops of 
saline were then placed around the GIT and the petri dishes were sealed with parafilm. 
Samples were then immediately brought to the fluorescent laser scanner (Typhoon FLA 
9000) for imaging. Samples were scanned with an excitation wavelength of 473 nm and a 
530 nm bandpass filter. 
Imaging of luminal contents from mice orally administered particles  
Immediately after euthanization the small intestines of the mice were excised and divided 
into an upper and lower section. The luminal contents were collected by gently squeezing 
the intestines with tweezers. They were placed directly onto a glass slide and encircled by 
a ring of vacuum grease that did not touch the contents. A coverslip was then immediately 
placed on top to create an air-tight chamber. Samples were kept on ice during the collection 
process. The samples were then immediately taken for imaging. All imaging was 
performed using a Zeiss LSM 800 or a Leica DMI6000, using either bright-field 
microscopy, epifluorescence microscopy (GFP, L5 Nomarski prism), confocal 
fluorescence microscopy (488 nm excitation and 490-540 nm detection), or confocal 
reflectance microscopy (561 nm excitation and 540-700 nm detection). 
Collection of intestinal luminal fluid 
Immediately after euthanasia, the SI of each mouse was excised and divided into an upper 
and lower section. If luminal fluid was collected from the colon, then the colon was also 
excised. The luminal contents were then collected from each section in separate tubes and 
kept on ice. The luminal contents from an individual mouse was insufficient in volume to 
perform all the required analyses (i.e. ex vivo aggregation, GPC, and sometimes Western 
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blot), so contents were pooled from a group of three mice of the same age that were co-
housed. These pooled samples, kept divided by section, were then spun down at 17 kG at 
4 °C for 1 h to separate the liquid and solid portions of the contents. The supernatant of 
each sample was collected and then placed on 30 µm filters (Pierce Spin Columns – Snap 
Cap, Thermo Fisher Scientific, Waltham, MA, USA) and spun down at 17 kG at 4 °C for 
1 h. Part of the filtrates of each sample were then collected, divided into aliquots, and frozen 
at -20 °C for future experiments. The remaining portion of the filtrates was then taken and 
placed on 0.45 µm centrifugal filters (Corning Costar Spin-X centrifuge tube filters; 
cellulose acetate membrane, pore size 0.45 µm, sterile) and spun down at 5 kG at 4 °C for 
1 h. For experiments in which a protease-inhibitor cocktail (Roche cOmplete, Mini, EDTA-
free Protease-Inhibitor Cocktail, Roche, Indianapolis, IN, USA) was used, a 100x 
concentrated stock solution was prepared in HBSS (without calcium, magnesium, and 
phenol red; GE Healthcare Life Sciences, Marlborough, MA, USA). The same procedure 
as detailed above was followed for the collection of luminal fluid, except immediately after 
the luminal contents were brought back from the animal facility on ice, 10 µL of the 100x 
protease-inhibitor cocktail was added to each tube. The mixtures were then vortexed briefly 
to mix. The contents were then spun down at 17kG at 4 °C as described above to separate 
the solid from liquid contents. The liquid fraction collected from each group before 30 and 
0.45 µm filtration was usually ~200–300 mL, so the additional 10 µL of protease-inhibitor 
cocktail only diluted the samples by ~5% at most. 
Ex vivo and in vitro aggregation assays 
We took 1-µm diameter PEG 5 kDa-coated polystyrene beads (with PEG 1 kDa “back-
filling”) and suspended them at 10 mg/mL in deionized water. Before use, they were 
vortexed to re-suspend in solution and then sonicated for 1 min. The particle solution was 
then added to the polymer solution or small intestinal luminal fluid at a ratio of 1:10. After 
addition of particles, the mixture was vortexed for 10 seconds. Then, 2 µL of the mixture 
was then immediately pipetted into an imaging chamber created with a SecureSeal imaging 
spacer (0.12 mm depth and 9 mm diameter, Electron Microscopy Sciences, Hatfield, PA, 
USA) and a glass slide. The top of the imaging chamber was immediately sealed with a 
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#1.5 coverslip. The samples were then imaged approximately 10 min later. In PEG solution 
experiments and serial dilution experiments, HBSS (without calcium, magnesium, phenol 
red; GE Healthcare Life Sciences) was used to dilute.  
In the 1 MDa PEG experiments conducted in phosphate buffered saline (PBS) with pH = 
6 (Figure 4 – Figure supplement 1) the PBS solution was initially prepared with 138 mM 
sodium chloride, 7.5 mM monosodium phosphate dihydrate, 1.1 mM disodium phosphate 
heptahydrate, and deionized (DI) water (Milli-Q). The sodium chloride was added to 
ensure that the ionic strength matched that of Hank’s balanced salt solution. The pH was 
then measured using an Orion 2-Star Benchtop pH Meter (Thermo Scientific) with an 
Orion 9110DJWP Double Junction pH electrode (Thermo Fisher Scientific) after first 
calibrating the instrument using the following reference standard buffers: pH = 10 (VWR 
BDH5078-500 mL), pH = 7 (VWR BDH5046-500 mL), and pH = 4 (VWR BDH5024-500 
mL). The pH of the solution was then adjusted to pH = 6 using 1 M NaOH in DI water. 
Microscopy for ex vitro and in vitro aggregation assays 
All imaging was performed using a Zeiss LSM 800, using confocal fluorescence 
microscopy (488 nm excitation, detection at 490-540 nm). We collected 3D stacks which 
were 200 x 200 x 40 µm in volume. 3D renders of aggregates were created using Imaris 
software from Bitplane, an Oxford Instruments Company. 
Imaging analysis 
All image analysis was done in FIJI (ImageJ 2.0.0) using an ImageJ macro written using 
the ImageJ macro scripting language. These macros are available in Dryad. Z-stacks were 
saved as 16 bit .czi files and were subsequently loaded into FIJI. Each z-stack extended 
~40 µm deep into each sample in the z-direction and was composed of 113 slices. As a 
result of the depth of the stacks in the z-direction, we observed a significant drop-off in 
measured aggregate fluorescence between the first slice and the last slice, likely due to 
scattering from the intestinal fluid and the particles themselves. To ensure that aggregates 
throughout a given stack had a similar brightness, which is important for the 3D Object 
 148 
Counter plugin, the median pixel intensity for aggregates in every slice was set as the 
maximum pixel intensity value for every slice. To achieve this, first the 10th slice and the 
10th to last slice of the z-stack were selected and thresholded using the Otsu method (99), 
creating a binary image of the aggregates in the two slices. The binary images were used 
as masks to measure the median pixel intensity of each aggregate in the two slices as well 
as the mean and max pixel intensity values for the background of both images. The drop-
off in intensity was assumed to be approximately linear, so the median pixel intensity for 
aggregates in each slice was determined by interpolating between the median aggregate 
pixel intensity values from the 10th slice and 10th to last slice. The minimum pixel intensity 
value for each slice was determined by adding 1/3 of the mean background pixel intensity 
to 2/3 of the maximum background pixel intensity for the 10th and 10th to last slices (this 
was necessary to deal with the challenge determining background pixel intensities) and 
then interpolating to calculate the minimum for all other slices. The process of intentionally 
introducing image clipping in the z-stacks was justified by the manner in which aggregates 
were identified; aggregates were first measured by total volume instead of by particle 
count, thus being able to discern individual particles inside of each aggregate was 
unnecessary. 
The 3D Objects Counter plugin in FIJI was used to measure various parameters, including 
the volume of each aggregate. The plugin initially thresholds all slices in a stack using a 
single thresholding value, which requires objects in every slice of a stack to be roughly the 
same intensity (hence, the thresholding procedure described previously). The plugin takes 
the resulting now-binary z-stack and determines the number of voxels occupied by each 
aggregate and converts voxel volume to metric volume using metadata in each .czi file. A 
second macro was used to determine the average size of a singlet (single particle) for each 
z-stack. In this macro, we identified 10 singlets by visually inspecting the sample to 
determine the average size of a singlet. This was then used to normalize differences in 
measured aggregate volume between samples by converting to a particle count per 
aggregate. This normalization step was necessary due to variations in the average 
measured singlet size between samples. It also helped account for any differences in the 
thresholding procedure from sample to sample. 
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The accuracy of this method for determining aggregate sizes was validated by comparing 
empirical cumulative distribution functions (ECDFs) of the cross-sectional area of the 
aggregates in a given z-stack determined by the ImageJ macro to ECDFs generated by 
visually inspecting the samples to measure the cross-sectional areas of aggregates. This 
comparison was done for at least three separate z-stacks. ImageJ macros will be made 
available upon request. 
Quantification of aggregate sizes 
The sizes of aggregates in solution were quantified in two ways. One was by comparing 
the volume-weighted empirical cumulative distribution functions (ECDFs) of the 
aggregate sizes of each sample to each other. The volume-weighted ECDF, ?̂?, as follows 
(100): 
?̂?(𝑁) =
1
∑ 𝑁𝑖
∑ 𝐼(𝑁𝑖
𝑛
𝑖=1
≤ 𝑁) (𝐸𝑞. 5.6) 
𝐼(𝑁𝑖 ≤ 𝑁) =  {
𝑁𝑖  𝑖𝑓 𝑁𝑖 ≤ 𝑁
0 𝑖𝑓 𝑁𝑖 > 𝑁
(𝐸𝑞. 5. 7) 
Where Ni is the number of particles per aggregate and n is the total number of aggregates 
in solutions (where single particles also count as aggregates). 
The other way in which the extent of aggregation was quantified was by creating bootstrap 
replicates of the ECDFs of the aggregate distributions of each sample and computing the 
volume-weighted average aggregate size (〈𝑁〉; given in number of particles per aggregate) 
for each bootstrap replicate. The volume-weighted average aggregate size is given by the 
following equation in units of “number of particles per aggregate”: 
〈𝑁〉 =  
∑ 𝑁𝑖
2𝑛
𝑖=1
∑ 𝑁𝑖
𝑛
𝑖=1
 (𝐸𝑞. 5.8) 
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This allowed us to calculate 95% empirical bootstrap CI on the volume-weighted average 
aggregate size. We generated 10,000 bootstrap replicates from the original ECDF of each 
sample to generate these. The advantage of this approach is that we do not need to assume 
anything about the underlying probability distribution; it is non-parametric (100). The 
original ECDFs, from which the replicates were generated, each contained at least 300 
aggregates, in many cases containing ~1000 or more aggregates. The codes used for the 
analyses (volume-weighted ECDFs and 95% empirical bootstrap CIs) were written in 
Python 3.6.4 and are available on Dryad. 
Filtration with MW cut-off filters 
Small intestinal luminal fluid was collected and 0.45 µm-filtered as described in 
“Collection of Luminal Fluid”. It was then divided up and placed on MWCO filters (Pierce 
Protein Concentrators, Thermo Fisher Scientific) of with the following MWCOs: 100 kDa, 
30 kDa, and 3 kDa. The samples were then centrifuged at 15 kG at 4 °C for 2 h, checking 
every 15 min for the first hour if additional volume had flowed through. After the eluent 
from each was collected, they were diluted back to their original volumes with HBSS. 
pH measurements of luminal fluid 
Pooled samples of luminal fluid were collected from each section (stomach, upper small 
intestine, lower small intestine, cecum, and colon) and 30 µm-filtered as described in 
“Collection of Luminal fluid” (with use of the same protease inhibitor cocktail). Samples 
were collected from two separate groups of 2-month old B6 male mice on a standard chow 
diet. Each group had three mice. Because there was only ~25 µL of luminal fluid from the 
colons of each group we did not 30 µm-filter the colonic fluid as there was concern all the 
fluid would be retained by the filter. The colonic contents were simply spun down at 17 
kG at 4 °C for 1 h to separate the liquid and solid portions of the contents. Then the 
supernatant (luminal fluid) was collected. Measurements were done using an Orion 2-Star 
Benchtop pH Meter. The instrument was first calibrated with three reference standard 
buffers: pH = 10 (VWR BDH5078-500 mL), pH = 7 (VWR BDH5046-500 mL), and pH 
= 4 (VWR BDH5024-500 mL). Measurements were conducted at T = 25 °C. There was at 
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least 100 µL of sample from each section except for the stomach sample from one group 
of mice and from colon samples from both groups. Measurements were conducted with 
both a standard pH electrode (Orion 9110DJWP Double Junction pH Electrode) and a 
micro pH electrode (Orion 9810BN Micro pH Electrode, Thermo Fisher Scientific). This 
was done because the standard electrode is only accurate for samples with volumes of 200 
µL whereas the micro electrode is accurate for samples as small as 0.5 µL in volume. The 
results are consistent with other results for rodents (101,102) with the exception of a study 
conducted with mice of a different gender, strain, and fed an 18% protein diet (103). 
 For the pH measurement of HBSS, the pH was measured with both the standard and micro 
pH electrodes, and three technical replicates were done with each probe. The value for the 
pH reported in the main text is the average of all six measurements. 
Estimation of coverage and length of grafted PEG layer 
Based on our NMR measurements (see section NMR of PEG-coated particles with 
“backfill”) the grafting density (Γ) of the PEG polymer on our PEG 5 kDa-coated particles 
with PEG 1 kDa backfill should be approximately: Γ = 0.48 chains/nm2 (to estimate this 
we assume that all of the PEG on the surface is PEG 5 kDa). One can estimate the grafting 
density at which the grafted chains transition from separate coils to overlapping coils or 
the brush regime by calculating the grafting density at which coils would just begin to 
overlap (104). This can be estimated as: 
Γ∗ ∼
1
𝜋𝑅𝑔2
(𝐸𝑞. 5.9) 
Where 𝑅𝑔 is the radius of gyration of the grafted polymer. Using literature measurements 
of the hydrodynamic radius of PEG 5 kDa and the Kirkwood-Riseman relation, this can be 
estimated as 𝑅𝑔~ 3.45 nm. We therefore estimate that 
Γ
Γ∗
 ~ 5, meaning that the grafting 
density is such that the polymer coils on the surface should be overlapping and within the 
brush regime. To estimate the length and average volume fraction of the layer, we therefore 
made the assumption that the grafted polymer layer behaved as a brush and used the 
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Alexander-deGennes brush approximation (63,105). This theory was originally developed 
for high-MW polymer coils, but has also been found, surprisingly, to quantitatively capture 
forces for grafted layers only a few segments long (105). We estimated the length (L) of 
the brush as (63):(62,95). This theory was originally developed for high-MW polymer 
coils, but has also been found, surprisingly, to quantitatively capture forces for grafted 
layers only a few segments long . We estimated the length (L) of the brush as : 
𝐿 ~ 𝑁Γ
1−𝜈
2𝜈 𝑏
1
𝜈 (𝐸𝑞. 5.10) 
Where N is the number of monomers per grafted chain, 𝜈 is the Flory exponent, and b is 
the Kuhn length of the grafted polymer. We used b = 0.76 nm based on literature 
measurements (106) and took 𝜈 ≅ 0.588, because aqueous salt solutions are good solvents 
for PEG (107). Lastly, we estimated the number of monomers per chain by assuming the 
number of monomers is approximately equation to the number of Kuhn segments and the 
relationship between the radius of gyration, the Kuhn length and the number of Kuhn 
segments (63): 𝑁 ~ (
𝑅𝑔
𝑏
)
1
0.588
~ 13. We therefore estimate that 𝐿 ~ 6.4 𝑛𝑚. 
 The Alexander–de Gennes approximation assumes a step profile for the volume fraction 
of the grafted polymer (𝜙). We can estimate this using the following equation (63): 
𝜙 ≈  {(Γ𝑏
2)
3𝜈−1
2𝜈  𝑓𝑜𝑟 𝑧 < 𝐿
0 𝑓𝑜𝑟 𝑧 > 𝐿
(𝐸𝑞. 5.11) 
Where z is the distance from the bare particle surface. Using the same approximations as 
above we find 𝜙 ≈ 0.43. 
Western blot of luminal contents 
 30-µm filtered small intestinal luminal fluid was reduced in sample buffer with 100 mM 
dithiotreitol DTT at 95 °C for 5 min (the luminal fluid was diluted 10-fold in the sample 
buffer). Gel electrophoresis was then run on 4–15% SDS/PAGE gels. The transfer was 
performed using wet electroblotting to a nitrocellulose membrane. For detection of MUC2, 
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the primary antibody was diluted 1:1,000 (MUC2 polyclonal antibody, rabbit host, 
Biomatik, Wilmington, DE, USA) as a 1:10,000 in Odyssey blocking buffer (Li-Cor, 
Lincoln, NE, USA) with 0.2% Tween 20. The secondary antibody (Li-Cor IRDye 800CW 
Goat Anti-Rabbit IgG, Li-Cor) was diluted 1:10,000. For the detection of IgG and IgM, 
1:10,000 dilutions of Li-Cor IRDye 800 CW Goat Anti-Mouse IgG and Li-Cor IRDye 
800CW Goat Anti-Mouse IgM were used respectively. For detection of IgA, a 1:10,000 
dilution of SouthernBiotech Goat Anti-Mouse IgA-unlabeled was used as the primary and 
a 1:10,000 dilution of Li-Cor IRDye 800CW Donkey Anti-Goat IgG was used as the 
secondary. All membranes were visualized using a Li-Cor Odyssey scanner. 
Gel permeation chromatography 
We used a Malvern OMNISEC RESOLVE connected to two Malvern A6000M columns 
(Malvern, Westborough, MA, USA) equilibrated with 1x PBS with 0.02% sodium azide, 
flow rate: 0.75 mL/min. For detection of the polymers, the OMNISEC REVEAL was used 
with a refractometer, UV detector, dual-angle light scattering detector, and a capillary 
viscometer. Luminal contents were 0.45-µm filtered as described above, then diluted 10-
fold in the running buffer (1x PBS with 0.02% sodium azide) before injection into the 
system. Prior to injection, samples were kept on the autosampler at 4 °C. 
Synthesis of PEG-coated particles 
We amended a previously published protocol (3) to synthesize PEG-coated particles; 
briefly, 2 mL of 1-µm fluorescent carboxylic-acid-terminated polystyrene beads 
(FluoroSpheres, Invitrogen, Thermo Fisher Scientific) at 2% v/v with 2 mM NaN3 
were rinsed at 3900g for 40 min using a centrifugal filter (Millipore Amicon Ultra-4 mL 
100 K MWCO). Particles were removed from the filter using 4 mL of a solution of 15 
mg/mL 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, Sigma-Aldrich) and 15 
mg/mL N-hydrosuccinimide (NHS, Aldrich), an excess concentration of NH2-PEG-OMe 
(5 kDa, Creative PEGworks, Chapel Hill, NC, USA) in 1 mL increments using 100 mM 
borate buffer, pH 8.4. By an excess concentration of NH2-PEG-OMe we mean ten-fold the 
concentration of PEG required to enter the polymer brush regime (see “Estimation of 
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coverage and length of grafted PEG layer” section for details of calculation). This solution 
was tumbled on a rotary tumbler for 4 h at room temperature in a 15 mL falcon 
tube. Particles were washed three times to remove starting materials with 4 mL Milli-Q 
water in a centrifugal filter and re-suspended in 2 mL in Milli-Q water. 
Synthesis of PEG-coated particles with “backfill.”  
12 mL of 1-µm fluorescent carboxylic-acid-terminated polystyrene beads at 2% v/v with 2 
mM NaN3 (FluoroSpheres 1-µm; 505/515, Invitrogen) were centrifuged to a pellet at 
12,000g for 10 min. Beads were pelleted and rinsed three times with Milli-Q water. To the 
final pellet of particles, 12 mL of a solution of 6 mM EDC (10 mg/mL; Sigma-Aldrich) 
and 5 mM Sulfo-NHS (1.08 mg/mL, ThermoFisher), with 50x excess of the number of 
chains needed to enter the brush regime (see “Estimation of coverage and length of grafted 
PEG layer” for details of calculation) of NH2-PEG-OMe (mPEG-Amine 2kDa; mPEG-
Amine 5kDa; Creative PEGWorks) in 10x PBS, pH 7.4 (100 mM), was added. This 
solution was tumbled on a rotary tumbler for 4 h at room temperature. Tubes were vented 
every 30 min to release gas produced by the reaction. Particles were then pelleted and 
rinsed three times with Milli-Q water. The 12 mL sample was divided into four 3 mL 
aliquots for the remaining conditions. For condition without backfill, beads were quenched 
with 50 mM Tris pH 7.4 overnight at room temperature with slow tilt rotation prepared 
from 10x Tris-buffered saline with Tween 20, pH 7.5 (Sigma-Aldrich). For particles with 
backfill, the 3-mL aliquot was re-suspended in with 50x excess of the number of chains 
needed to enter the brush regime (see “Estimation of coverage and length of grafted PEG 
layer” for details of calculation) of NH2-PEG-OMe (mPEG-Amine 350; mPEG-Amine 1 
kDa; mPEG-Amine 5kDa, Creative PEGWorks) in 100 mM PBS, pH 7.4 containing 6 mM 
EDC and 5 mM Sulfo-NHS for 4 h before quenching overnight with 50 mM TRIS buffered 
Saline with Tween 20, pH 7.5. All beads were washed three times with Milli-Q water 
before suspending in 3 mL sterile filtered PBS, pH7.4 with 1% BSA for storage. 
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NMR of PEG-coated particles with “backfill.”  
We took 400 µl of 2% w/v samples and lyophilized (~8 mg), then dissolved in deuterated 
chloroform (Cambridge Isotope Laboratories, Tewksbury, MA, USA) with 0.01% 
tetramethylsilane (Aldrich) immediately before measurement. Data were collected on a 
Varian Innova 600 MHz spectrometer without spinning, using a 45o pulse width and 1 sec 
relaxation delay between scans. The concentration of PEG in each sample was determined 
by integrating the singlet at 3.64 pm and normalizing the integral to TMS internal standard 
at 0.0 ppm. 
Zeta potential measurements on PEG-coated particles with “backfill.” 
Each particle solution was 0.1 mg/mL of particles in 1 mM KCl. Measurements were done 
on a Brookhaven NanoBrook ZetaPALS Potential Analyzer (Brookhaven Instruments 
Corporation, Holtsville, NY, USA). Three trials were done where each trial was 10 runs 
each and each run was 10 cycles. Values reported are the average zeta potential for the 30 
runs. 
Estimate of Weissenberg number for small intestine  
The Weissenberg number (Wi), which weighs the relative contributions of elastic and 
viscous forces, can be written as (108): 
𝑊𝑖 =  ?̇?𝜆 (𝐸𝑞. 5.12) 
Where ?̇? is the shear rate (in 𝑠−1) and λ is the fluid relaxation time (in s). The shear rate in 
the human small intestine during peristaltic contractions has been estimated as ?̇? ~ 29 𝑠−1 
(109). For dilute aqueous polymeric solutions of polyacrylamide with MWs ranging from 
104 to 107 Da, it has been found that 𝜆 = 0.009 to 0.45 s, with the relaxation time increasing 
with MW as 𝜆 𝛼 𝑀𝑊2/3(110). Using these values, we can estimate the Weissenberg 
number to be Wi ~ 0.3 to 10. 
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Supplementary Information 
Supplemental Figures 
 
Figure 5.S1: Overview of image processing for fluorescent scanner images in Figure 5.1. 
(A) Unmodified fluorescent scanner images of the gastrointestinal tract of a mouse gavaged 
with 1 µm-diameter PEG-coated particles (prior to the contrast and color-adjustments 
shown in Figure 5.S1A–B). Scale bar is 0.5 cm. Boxes indicate the regions that are shown 
in panels C and D. (B) Unmodified fluorescent scanner image of the gut of a mouse that 
has not been gavaged with particles. Scale bar is 0.5 cm. (C and D). The contrast and color-
adjusted images that appear in Figure 5.S1A–B. (E) Contrast-adjusted image of Figures 
5.S1A-B that was used to trace the outline of the gut shown in Figure 5.S1A–B (and panel 
C and D of this Figure). Outline of gut is shown in grey on both C, D, and E.  
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Figure 5.S2: pH measurements of luminal fluid from different sections of the 
gastrointestinal tract. Measurements were conducted on pooled samples of luminal fluid 
collected from two groups of mice. Each measurement was repeated three times, and the 
error bars are the standard deviation across the six trials (three trials per group). Micro 
(blue) indicates measurements that were conducted using a micro pH electrode. Standard 
(orange) indicates measurements that were conducted using a standard pH electrode. For 
the stomach and colon samples there was insufficient luminal fluid from both groups to 
submerge the tip of the standard pH electrode, so measurements were only taken with the 
micro pH electrode. Stm = stomach, USI = upper small intestine. LSI = lower small 
intestine, Cec = cecum, and Col = colon. 
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Figure 5.S3: Ex vivo aggregation in 0.45 µm-filtered luminal fluid from the small intestines 
(SI) of wild-type (WT) and MUC2 knockout (MUC2KO) mice. (A and B) Volume-
weighted empirical cumulative distribution functions (ECDFs) comparing aggregation of 
the particles in undiluted, 0.45-µm-filtered samples from the upper (A) and lower (B ) SI 
of two separate groups of WT and MUC2KO mice to the control (particles suspended in 
HBSS). The vertical axis is the cumulative volume fraction of the total number of particles 
in solution in an aggregate of a given size. The horizontal axis is aggregate size in number 
of particles per aggregate (N). (C and D) Volume-weighted average aggregate sizes (Vol 
Wt Avg Size) for serial dilutions of 0.45 µm-filtered samples from the upper (C) and lower 
(D) SI of two separate groups of WT and MUC2KO mice. Volume-weighted average sizes 
are plotted on the vertical axis in terms of number of particles per aggregate (N). The 
dilution factor is plotted on the horizontal axis, where a dilution factor of 1 is undiluted and 
½ is a two-fold dilution. The control (particles suspended in HBSS) is plotted as a dilution 
factor of 0. The vertical error bars are 95% empirical bootstrap CI using the bootstrapping 
procedure described in Materials and Methods. 
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Figure 5.S4: Western blots of 30 µm-filtered samples from the small intestine (SI) of wild-
type (WT) and Rag1 knockout (Rag1KO) mice. WT USI = WT upper SI; KO USI = KO 
lower SI; WT LSI = WT lower SI; KO USI = KO upper SI. For the detection of IgG, 
1:10,000 dilutions of Li-Cor IRDye 800 CW Goat Anti-Mouse IgG was used. Because the 
Anti-IgG antibody appears to be binding to just the light chains (around 25 kDa), we 
suspect that it is mostly binding to IgA. Li-Cor’s published validation 
(https://www.licor.com/bio/products/reagents/secondary_antibodies/irdye_800cw.html) 
found that the antibody binds to the heavy and light chains of IgG and just the light chains 
of IgA. Because we see binding of the antibody to both the heavy and light chains in the 
IgG standard, but only binding to a light chain in the SI samples and the IgA control, this 
suggests that we are detecting the light chains of IgA in the SI samples. 
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Figure 5.S5: Western blots of 30 µm-filtered samples from the small intestine (SI) of wild-
type (WT) and Rag1 knockout (Rag1KO) mice. WT USI = WT upper SI; KO USI = KO 
lower SI; WT LSI = WT lower SI; KO USI = KO upper SI. For detection of IgM, 1:10,000 
dilution of Li-Cor IRDye 800CW Goat Anti-Mouse IgM was used. We do not detect IgM 
in any of the SI samples.  
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Figure 5.S6: Ex vivo aggregation in 0.45-µm-filtered luminal fluid from the small 
intestines (SI) of wild-type (WT) and Rag1 knockout (Rag1KO) mice. (A and B) Volume-
weighted empirical cumulative distribution functions (ECDFs) comparing aggregation of 
the particles in undiluted, 0.45-µm-filtered samples from the upper (A) and lower (B ) SI 
of two separate groups of WT and immunoglobulin-deficient (Rag1KO) mice to the control 
(particles suspended in HBSS). Plotted on the vertical axis is the cumulative volume 
fraction of the total number of particles in solution in an aggregate of a given size. Plotted 
on the horizontal axis are aggregate sizes in number of particles per aggregate (N). (C and 
D). Volume-weighted average aggregate sizes (Vol Wt Avg Size) for serial dilutions of 
0.45-µm-filtered samples from the upper (C) and lower (D) SI of two separate groups of 
WT and Rag1KO mice. Volume-weighted average sizes are plotted on the vertical axis in 
terms of number of particles per aggregate (N). The dilution factor is plotted on the 
horizontal axis, where a dilution factor of 1 is undiluted and ½ is a two-fold dilution. The 
control (particles suspended in HBSS) is plotted as a dilution factor of 0. The vertical error 
bars are 95% empirical bootstrap CI using the bootstrapping procedure described in  
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Materials and Methods. 
 
Supplemental Tables 
Table 5.S1: Estimates of physical parameters of polymers from gel permeation 
chromatography for liquid fractions from the upper small intestine of MUC2 
knockout (MUC2KO) and wild-type (WT) mice. 
 
Retention 
volume (mL) 
11 to 16 16 to 20 >20 
Mouse type WT MUC2KO WT MUC2
KO 
WT MUC2
KO 
Mw (kDa) 3,560±410 5,420±620 162±20 147±17 4.05±0.4
6 
2.96±0
.34 
Mw/Mn 1.36 1.59 2.16 2.43 3.59 10.9 
Rh (nm) 49.1 45.5 6.31 5.95 1.18 1.02 
Fract. Conc. 
(mg/mL) 
2.52±0.29 1.18±0.13 24.6±2.8 21.9±2.
5 
88.7±10.
1 
86.0±9
.8 
We calculated values with both dn/dc = 0.185 (for proteins) and dn/dc = 0.147 (pullulan). 
When the value varied with dn/dc, it is reported in the table as the mid-range values ± the 
absolute deviation between the two calculated values. Mw = the weight-average molecular 
weight; Mw/Mn = the dispersity; Rh = hydrodynamic radius; Fract. Conc. = Concentration 
of a given molecular weight fraction. 
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Table 5.S2: Estimates of physical parameters of polymers from gel permeation 
chromatography for liquid fractions from the lower small intestine of MUC2 
knockout (MUC2KO) and wild-type (WT) mice 
 
Retention 
volume 
(mL) 
 
11 to 16 
 
16 to 20 
 
>20 
Mouse 
type 
WT MUC2KO WT MUC2KO WT MUC2KO 
Mw (kDa) 4,730±540 5,180±590 219±25 155±18 13.7±1.6 5.93±0.6
8 
Mw/Mn 1.24 1.80 1.91 1.84 1.88 2.03 
Rh (nm) 57.0 49.2 8.45 7.58 1.89 1.35 
Fract. 
Conc. 
(mg/mL) 
3.42±0.39 2.36±0.27 23.0±2.6 22.8±2.6 54.8±6.3 63.3±7.2 
We calculated values with both dn/dc = 0.185 (for proteins) and dn/dc = 0.147 (pullulan). 
When the value varied with dn/dc, it is reported in the table as the mid-range values +/- the 
absolute deviation between the two calculated values. Mw = the weight-average molecular 
weight; Mw/Mn = the dispersity; Rh = hydrodynamic radius; Fract. Conc. = Concentration 
of a given molecular weight fraction. 
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Table 5.S3: Estimates of physical parameters of polymers from gel permeation 
chromatography for liquid fractions from the upper small intestine of 
immunoglobulin-deficient (Rag1KO) and wild-type WT mice. 
 
Retention 
volume 
(mL) 
11 to 16 16 to 20 >20 
Mouse 
type 
WT Rag1KO WT Rag1KO WT Rag1KO 
Mw (kDa) 1,480±170 2,140±250 108±12 74.2±8.5 2.84±0.3
2 
1.91±0.2
2 
Mw/Mn 1.09 1.14 2.62 2.42 1.59 1.54 
Rh (nm) 31.8 39.8 4.77 2.51 1.078 0.936 
Fract. 
Conc. 
(mg/mL) 
1.07±0.12 1.13±0.13 14.3±1.6 13.9±1.6 66.1±7.6 70.5±8.1 
We calculated values with both dn/dc = 0.185 (for proteins) and dn/dc = 0.147 (pullulan). 
When the value varied with dn/dc, it is reported in the table as the mid-range value +/- the 
absolute deviation between the two calculated values. Mw = the weight-average molecular 
weight; Mw/Mn = the dispersity; Rh = hydrodynamic radius; Fract. Conc. = Concentration 
of a given molecular weight fraction. 
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Table 5.S4: Estimates of physical parameters of polymers from gel permeation 
chromatography for liquid fractions from the lower small intestine of 
immunoglobulin-deficient (Rag1KO) and wild-type WT mice. 
 
Retention 
volume 
(mL) 
11 to 16 16 to 20 >20 
Mouse type WT Rag1KO WT Rag1KO WT Rag1KO 
Mw (kDa) 1,080±120 2,490±290 66.9±
7.7 
91.6±10.5 3.64±0.42 3.72±0.4
3 
Mw/Mn 1.18 1.05 1.71 1.98 2.09 1.98 
Rh (nm) 34.6 47.1 4.67 4.85 1.116 1.09 
Fract. Conc. 
(mg/mL) 
1.52±0.17 1.89±0.22 15.8±
1.8 
14.1±1.6 49.5±5.7 55.1±6.3 
We calculated values with both dn/dc = 0.185 (for proteins) and dn/dc = 0.147 (pullulan). 
When the value varied with dn/dc, it is reported in the table as the mid-range values +/- the 
absolute deviation between the two calculated values. Mw = the weight-average molecular 
weight; Mw/Mn = the dispersity; Rh = hydrodynamic radius; Fract. Conc. = Concentration 
of a given molecular weight fraction. 
 
Table 5.S5: Gel permeation chromatography of 
Fibersol-2 and pectin in phosphate-buffered saline 
Sample Fibersol-
2 
Pectin 
Mw (kDa) 3.48 232 
Mw/Mn 10.5 1.97 
Rh (nm) 1.24 25.4 
Both fiber types were analyzed with dn/dc = 0.147 for polysaccharides. Mw = weight-
average molecular weight; Mw/Mn = the dispersity; Rh = hydrodynamic radius 
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Table 5.S6: Estimates of physical parameters of polymers from gel permeation 
chromatography for liquid fractions from upper small intestine of pectin and 
Fibersol-2 fed mice 
 
Retention 
volume 
(mL) 
11 to 16 16 to 20 >20 
Mouse 
type 
Pectin Fibersol-2 Pectin Fibersol-
2 
Pectin Fibersol-
2 
Mw (kDa) 267±31 686±79 40.0±4.5 35.3±4.0 1.39±0.1
6 
1.67±0.1
9 
Mw/Mn 1.50 1.08 2.15 2.64 2.45 1.48 
Rh (nm) 31.8 N/C** 5.52 2.88 0.819 N/C** 
Fract. 
Conc. 
(mg/mL) 
1.62±0.19 0.516±0.059 9.00±1.03 23.3±2.7 53.7±6.1 77.0±8.8 
 
We calculated values with both dn/dc = 0.185 (for proteins) and dn/dc = 0.147 (pullulan). 
When the value varied with dn/dc, it is reported in the table as the mid-range values +/- the 
absolute deviation between the two calculated values. Mw = the weight-average molecular 
weight; Mw/Mn = the dispersity; Rh = hydrodynamic radius; Fract. Conc. = Concentration 
of a given molecular weight fraction. N/C** denotes values for which the concentration 
was too low to calculate. 
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Table 5.S7: Estimates of physical parameters of polymers from gel permeation 
chromatography for liquid fractions from lower small intestine of pectin and 
Fibersol-2-fed mice 
Retention 
volume 
(mL) 
11 to 16 16 to 20 >20 
Mouse 
type 
Pectin Fibersol-2 Pectin Fibersol-
2 
Pectin Fibersol-
2 
Mw (kDa) 282±32 1680±190 30.2±3.5 18.8±2.2 1.12±0.1
3 
2.32±0.2
7 
Mw/Mn 7.37 1.64 1.70 2.78 2.89 1.14 
Rh (nm) 29.0 26.4 5.28 2.16 0.724 1.06 
Fract. 
Conc. 
(mg/mL) 
2.48±0.28 0.839±0.096 9.43±1.1 53.6±6.1 42.7±4.9 88.3 
±10.1 
 
We calculated values with both dn/dc = 0.185 (for proteins) and dn/dc = 0.147 (pullulan). 
When the value varied with dn/dc, it is reported in the table as the mid-range values +/- the 
absolute deviation between the two calculated values. Mw = the weight-average molecular 
weight; Mw/Mn = the dispersity; Rh = hydrodynamic radius; Fract. Conc. = concentration 
of a given molecular weight fraction. 
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Table 5.S8: Zeta potential and NMR measurements of PEG-coated particles 
Surface Modification of PS 
particles 
Zeta 
potential 
(mV) 
Nanomoles PEG/mg particles 
mPEG 5 kDa -18.87 
±1.78 
5.5 
mPEG 5 kDa w/ mPEG 1 kDa 
backfill 
-7.66 
±2.12 
4.6 
mPEG 5 kDa w/ mPEG 350 Da 
backfill 
-9.99 ± 
1.65 
4.3 
mPEG 5 kDa w/ mPEG 5 kDa 
backfill 
-14.56 ± 
1.78 
4.0 
mPEG 2 kDa -39.59 ± 
2.41 
9.4 
Carboxylate-coated (no PEG) -61.36 ± 
12.40 
0.0 
For the zeta potential measurements, each particle solution was 0.1 mg/ml of particles in 1 
mM KCl. Measurements were done on a Brookhaven NanoBrook ZetaPALS Potential 
Analyzer. Three trials were done where each trial was 10 runs each and each run was 10 
cycles. Values reported are the average zeta potential for the 30 runs. NMR measurements 
were performed as described in Materials and Methods. Values are estimates of the 
nanomoles of polyethylene glycol (PEG) per milligrams of particles. To calculate this, we 
have to assume all the PEG on the surface is a single MW. It is therefore assumed all the 
PEG on the surface is PEG 5 kDa. 
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approach to extract liquid fraction of murine intestinal contents; co-organized transfer and 
initial set up of MUC2KO colony; setup genotyping of MUC2KO mice; helped supervise 
animal husbandry of MUC2KO colony; helped with interpretation of results; co-wrote the 
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C h a p t e r  6  
QUANTITATIVE AND QUALITATIVE CHANGES IN THE UPPER 
GASTROINTESTINAL MICROBIOME CONTROLLED BY SELF-
REINOCULATION IN MICE INFLUENCE BILE-ACID METABOLISM 
AND HOST PHYSIOLOGY 
Said Bogatyrev, Justin C. Rolando, and Rustem F. Ismagilov 
 
ABSTRACT 
The composition and functional roles of the small-intestine microbiome in humans remains 
obscure primarily because it is difficult to access the upper gastrointestinal system in humans 
for sampling. Rodent models are used extensively in microbiome research and enable the 
spatial, compositional, and functional evaluation interrogation of the gastrointestinal 
microbiome and its effects on the host physiology and disease phenotype. However, 
important differences in rodent physiology can affect the relevance of these models to 
humans. Specifically, fecal microbial reinoculation (via coprophagy) in mice and rats is 
believed to transmit microbes among co-housed animals and is known to affect the 
composition and abundance of microbes in their upper gastrointestinal tracts. Coprophagy 
thus complicates investigations of the unique structure and function of the upper 
gastrointestinal microbiome, alterations of which are believed to be implicated in the disease 
pathogenesis (e.g., small intestinal bacterial overgrowth (SIBO) in non-alcoholic and 
alcoholic steatohepatitis (NASH) or inflammatory bowel conditions). Here, we evaluated the 
dependence of the structure and function of the small-intestine microbiome on repeated fecal 
microbial self-reinoculation in conventional specific pathogen-free laboratory mice using 
two methods: housing on wire floors and fitting mice with tail cups. We confirmed that only 
tail cups were truly effective at preventing self-reinoculation. When not completely 
prevented, the continuous self-exposure to the fecal microbiota in mice had substantial 
quantitative and qualitative effects on the upper gastrointestinal microbiome in these animals. 
These differences in microbial abundance and community composition resulted in altered 
microbial functions in the small intestine, specifically in relation to bile acid metabolism, 
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with detectable changes on host physiology. Our work highlights the importance of 
evaluating the structure and function of the upper gastrointestinal microbiome in relation to 
the effects of the gut microbiome on host physiology and disease phenotype and emphasizes 
the important role of microbial exposure on its structure and function. 
 
INTRODUCTION 
The small intestine is the primary site for nutrient uptake and immune sampling in the human 
gastrointestinal system. Its large surface area vastly exceeding that of the large intestine [1] 
and represents a broad interface for the host interaction with the microbial players in the 
external environment. 
Normal microbial levels in the small intestine in healthy humans are orders of magnitude 
lower than those in the large intestine and generally the physiological role of the small-
intestinal microbial colonization remains obscure. 
Rodents (mice and rats) remain the predominant mammalian animal model organisms in the 
field of human microbiome research despite some well-recognized limitations of these model 
organisms associated with their anatomical and physiological differences with humans [2], 
[3]. Among these limitations is the persistent tendency of rodents to practice gastrointestinal 
auto- and allo-reinoculaiton with large-intestinal microbiota (via fecal ingestion, or 
coprophagy) in laboratory settings. 
We hypothesized that this behavioral variable may have dramatic effects on the structure and 
function of the upper gastrointestinal microbiome (and the gastrointestinal microbiome in 
general), which in turn could have detectable effects on the model host organism physiology 
and disease modeling. Moreover, self-reinoculation in model mammalian organisms may 
have dramatic effects not only on their native complex microbiota (e.g., in SPF mice) but 
also on the individual microbial colonizers (e.g., gnotobiotic animals) and the 
xenomicrobiota (e.g., human microbiota-associated mice). By understanding and controlling 
these effects, the field will be able to refine mouse models of gastrointestinal microbial 
colonization and improve analyses of the related host physiological states and diseases.  
In the past several decades, multiple studies have evaluated the effects of self-reinoculation 
on the structure of the upper gut microbiome [4]–[7] and the persistence of its selected 
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members [8] in rodents using classical microbiological techniques. Others suggested self-
reinoculation has augmenting effects on establishing a stable microbial colonization in the 
mouse gut by Pseudomonas spp. [9] and other species via repeated self-exposure. However, 
the field is lacking precise and comprehensive evaluations of the effects of self-reinoculation 
on the spatial, structural and functional state of the gut microbiome and its effects on the 
mammalian host physiology and microbiome-associated disease modeling. 
We evaluated two methods for preventing fecal microbial self-reinoculation in conventional 
specific pathogen-free (SPF) laboratory mice: housing on wire floors and fitting mice with 
“tail cups”.  We looked at the quantitative and compositional changes in the microbiome 
along the entire length of mouse gastrointestinal tract, evaluated the bile acid profile in the 
corresponding segments of the gut and other elements of the enterohepatic circulation system 
(bile, liver tissues, and plasma), and measured host blood cytokine response and 
gastrointestinal mucosal and liver gene expression. 
 
METHODS 
Reagents 
 
TαMCA, TβMCA, TωMCA, THCA, αMCA, βMCA, ωMCA, HCA, HDCA, MCA, 
GCDCA, GDCA, and GCA were obtained from Steraloids (Newport, Rhode Island, USA). 
 
TCA, CA, DCA, TCDCA, TDCA, TUDCA, TLCA, CDCA, UDCA, LCA, D4-TCA, D4-
DCA, D4-CA, D4-TDCA, D4-GLCA, D4-GUDCA, D4-GCDCA, D4-GCA, and D4-GDCA  
were obtained from Isosciences (Ambler, PA, USA). 
 
Acetonitrile (Optima grade), Water (Optima grade) and Formic Acid were obtained from 
Fisher Scientific.  
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Fig. 6.1: Study layout, timeline, and logistics. A: Two cohorts of mice C57BL/J6 were 
used, 3 and 7 months of age. During the acclimation phase, mice were housed in groups of 
four animals per cage and then split into four different experimental groups. During the study, 
all animals were singly housed. Each experimental group consisted of six animals. The 
following groups of animals have been set up: RF: SPF reference animals maintained in 
standard conditions; WF: SPF animals maintained on wire floors; TC: mice fitted with 
functional “tail cups” to prevent self-reinoculation; CT: mice fitted with mock “tail cups” 
allowing self-reinoculation to control for the handling procedures and potentially higher 
stress levels in TC mice. B: Body weight and food intake were recorded during the 
“exposure” phase of the study. After the terminal sample collection, microbial loads and 
profiles were analyzed in gastrointestinal contents and mucosal samples along the 
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gastrointestinal tract. Metabolomic bile acids profiling was performed on gastrointestinal 
contents along the gastrointestinal tract, bile, liver tissues, blood plasma, and urine. 
 
Sample preparation  
To overcome sample buffering (pH  issues), samples were extracted in 9x volumes of ethanol 
with 0.5% formic acid and nine different heavy isotope (D4) internal standards at 5 µM. D4 
internal standards were Taurocholic acid (TCA), Cholic Acid (CA), Deoxycholic Acid 
(DCA), Taurodeoxycholic Acid (TDCA), Glycocholic acid (GCA), Glycolithocholic acid 
(GLCA), Glycoursodeoxycholic acid (GUDCA), Glycochenodeoxycholic acid (GCDCA), 
and Glycodeoxycholic acid (GDCA). Samples were heated for one hour at 70°C with gentle 
shaking (250 rpm). Solids were precipitated at 17,000 RCF for 15 minutes at 4°C. 10% of 
the original sample (e.g. 100 µL of a 1 mL extraction sample) was decanted and evaporated 
at approximately 100 mTorr without heating. The solids were reconsistuted at 100x dilution 
from the original sample (e.g. 100 µL decanted solution is resuspended at 1 mL) in 20% 
Acetonitrile, 80% water with 0.1% formic acid. Gall bladder samples were diluted 100x in 
water prior to extraction.  
 
10 µL extracted and reconsistuted sample injections were analyzed on a Waters Acquity 
UPLC coupled to a Xevo-qTOF Mass Spectrometer (Waters, Manchester, UK) using an 
Acquity UPLC HSS T3 1.8 micron, 2.1 x 100 mm column (Part No 186003539) and Acquity 
UPLC HSS T3 1.8 micron Guard Column (Part No 186003976). Needle wash was two parts 
isopropanol, one part water, and one part acetonitrile. Purge solvent was 5% acetonitrile in 
water.  A pooled quality control sample was run every 8 injections to correct for drift in 
response.  
 
Mass spectrometer instrument parameters were as follows: 2.4 kV, Collision Energy 6.0 eV, 
Sampling Cone 90V, Source Offset 40, Source 120°C, desolvation 550°C, Cone Gas 50 
L/Hr, and desolvation Gas 900 L/Hr. 
 
A seven point external calibration curve was collected three times within the run from 0.05 
to 30 µM of the bile acid standards [0.05, 0.1, 0.5, 1, 5, 10, 30 µM]. External standards were 
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Taurocholic acid (TCA), Tauro-alpha-Muricholic acid (TαMCA), Tauro-beta-Muricholic 
acid (TβMCA), Tauro-omega-Muricholic acid (TωMCA), Tauro-hyocholic acid (THCA), 
Tauro-Deoxycholic acid (TDCA), TauroUrsodeoxycholic acid (TUDCA), Tauro-
Chenodeoxycholic acid (TCDCA), Taurolithocholic acid (TLCA), Glyco-Cholic acid 
(GCA), Glyco-Hyocholic acid (GHCA), Glyco-deoxycholic acid (GDCA), Glyco-
hyodeoxycholic acid (GHDCA), Cholic acid (CA),  alpha-muricholic acid (αMCA), beta-
muricholic acid (βMCA), omega-muricholic acid (ωMCA), Hyocholic acid (HCA, also 
known as γ-Muricholic acid), Deoxy-cholic acid (DCA), ChenoDeoxycholic acid (CDCA), 
Ursodeoxycholic acid (UDCA), Hyodeoxycholic acid (HDCA), Murocholic acid 
(Murideoxycholic acid, MDCA), lithocholic acid (LCA), Glycolithocholic acid (GLCA), 
Glycourosodeoxycholic acid (GUDCA), and Glycochenodeoxycholic acid (GCDCA). It was 
not possible to resolve UDCA and HDCA and report the sum.  
 
Elution Gradient  
Samples were eluted using the following gradient of water with 0.1% formic acid (“A”) and 
balance of acetonitrile with 0.1% formic acid: 
1. 0 min, 0.55 mL/min at 68% A 
2. 2 min, 0.55 mL/min at 60% A, 10 curve 
3. 5 min, 0.55 mL/min at 40% A, 5 curve 
4. 6 min, 1.1 mL/min at 0% A, 10 curve,  
5. 6.2 min, 1.2 mL/min at 0% A, 6 curve; 
6. 6.5 min, 1.47 mL/min at 0% A, 6 curve; 
7. 8.9 min, 1.5 mL/min at 0% A, 6 curve; 
8. 9.0 min, 0.9 mL/min at 68% A, 6 curve; 
9. 10 min, 0.55 mL/min at 68% A, 6 curve; 
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RESULTS 
 Self-reinoculation dramatically increases the microbial load in the upper gut in mice, 
but does not affect its levels in the large intestine. 
 Self-reinoculation profoundly affects the microbial composition in the mouse upper 
gut and changes the absolute abundance of selected taxa in the large-intestine. 
 Shifts in microbial loads and composition in the upper gastrointestinal tract in mice 
translate into differential microbial function resulting in the distinctive bile acid 
profile. 
 Self-reinoculation exerts subtle effects on secondary bile acid metabolism. 
 We hypothesize similar total levels of secondary bile acids are likely to have similar 
“dose-dependent” effects on the host. 
 Reduced deconjugation of bile acids is known to increase reuptake by the host from 
the small intestine and reduce their availability for the large-intestinal microbiota to 
metabolize. This could be one of the explanations for the non-coprophagic mice to 
have a lower fraction of the secondary bile acids in the entire bile acid pool. 
Alternatively, eliminated re-ingestion of secondary bile acids in tail cup mice may be 
a reason for their lower fraction in the entire bile acid pool in these animals. 
 Secondary bile acid metabolism is generally believed to be occurring in the large 
intestine of mammals. Based on the presence of some microbial secondary bile acid 
metabolism genes in the small intestine of non-“TC” mice the possibility of the 
secondary bile acid metabolism occurring in the small intestine of coprophagic mice 
rich in the deconjugated primary bile acid substrates cannot be ruled out. 
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Fig. 6.2: Shifts in microbial loads and composition in the upper gastrointestinal tract in 
mice translate into differential microbial function resulting in the distinctive bile acid 
profile. A: Total bile acid (primary + secondary, conjugated + deconjugated) levels 
throughout the gastrointestinal tract or in bile are not affected by fecal ingestion and 
microbial self-reinoculation. B: Depletion of the small-intestinal microbiota in non-
coprophagic mice results in a dramatically reduced rate of bile acid deconjugation: almost 
100% of total bile acids remain in a conjugated form in the small intestine of TC mice, while 
in all other groups the fraction of deconjugated bile acids increases towards the distal small 
intestine. Additionally, TC mice carry a larger fraction of conjugated bile acids in the large 
intestine (CEC + COL) compared to all other groups of animals. 
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Fig. 6.3: Self-reinoculation exerts subtle effects on secondary bile acid metabolism.  A: 
Plot of total levels of secondary bile acids (conjugated + deconjugated) in all parts of the 
gastrointestinal tract and in bile are similar among all groups. B: Plot of the fraction of total 
secondary bile acids (conjugated + deconjugated) in the entire bile acid pool in bile, small 
intestine, and cecum is few % lower in “TC” mice, suggesting a somewhat lower microbial 
contribution to the total bile acid pool in these animals 
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CONCLUSION 
Consistent with a previous studies [10], we confirmed that only “tail cups” were truly 
effective for preventing self-reinoculation. Continuous self-exposure to the fecal microbiome 
in mice has dramatic quantitative and qualitative effects on the upper gastrointestinal 
microbiome in these animals. Such changes result in a differential microbial function in the 
small intestine in relation to the bile acid metabolism, which in turn leads to detectable 
changes in the host physiology (liver gene expression via FXR signaling/sterol metabolism; 
and mucosal gene expression – FXR signaling/FGF15-19/AMPs/etc.). 
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